

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

15966-562NATL

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

10/069626

INTERNATIONAL APPLICATION NO.  
PCT/US00/24220INTERNATIONAL FILING DATE  
31 August 2000 (31.08.00)PRIORITY DATE CLAIMED  
03 September 1999 (03.09.99)

## TITLE OF INVENTION

POLYNUCLEOTIDES ENCODING MEMBERS OF THE HUMAN B LYMPHOCYTE ACTIVATION ANTIGEN B7  
FAMILY AND POLYPEPTIDES ENCODED THEREBY

## APPLICANT(S) FOR DO/EO/US

GREEN, Cynthia; KOTELIANSKI, Victor; FOUGEROLLES, Antonin; CARULLI, John; HESSION; Catherine

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a. ☒ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ has been communicated by the International Bureau.
  - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☐ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

## Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☒ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

Express Mail Label Number: EL918131139US

Filed On: 26 February 2002 (26.02.02)



30623

PATENT TRADEMARK OFFICE

10/069626 20 FEB 2002

U.S. APPLICATION NO. **10/069626** INTERNATIONAL APPLICATION NO. **PCT/US00/24220** ATTORNEY'S DOCKET NUMBER **15966-562NATL**

24. The following fees are submitted:

**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :**

☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. .... **\$1040.00**

☒ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... **\$890.00**

☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... **\$740.00**

☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... **\$710.00**

☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... **\$100.00**

**ENTER APPROPRIATE BASIC FEE AMOUNT =** **\$890.00**

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☒ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)). **\$130.00**

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	32 - 20 =	12	x \$18.00	<b>\$216.00</b>
Independent claims	4 - 3 =	1	x \$84.00	<b>\$84.00</b>
Multiple Dependent Claims (check if applicable). <input checked="" type="checkbox"/>				<b>\$280.00</b>
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$1,600.00</b>
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27). The fees indicated above are reduced by 1/2.				<b>\$0.00</b>
<b>SUBTOTAL =</b>				<b>\$1,600.00</b>
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				<b>\$0.00</b>
<b>TOTAL NATIONAL FEE =</b>				<b>\$1,600.00</b>
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				<b>\$0.00</b>
<b>TOTAL FEES ENCLOSED =</b>				<b>\$1,600.00</b>
				Amount to be: refunded \$
				charged \$

- a. ☒ A check in the amount of **\$1,600.00** to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **50-0311**. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

ELRIF1, Ivor R.  
Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
United States of America

SIGNATURE

TRIANO, Nicholas P. III

NAME

36,397

REGISTRATION NUMBER

26 February 2002 (26.02.02)

DATE

Express Mail Label No.: EV058280658US  
Date of Deposit: July 25, 2002

25 JUL 2002

10069626 072502

15966-562 NATL (CURA-62 NATL)

#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Green, et al.  
SERIAL NUMBER: 10/069,626 EXAMINER: Not Yet Assigned  
FILING DATE: February 26, 2002 ART UNIT: Not Yet Assigned  
FOR: POLYNUCLEOTIDES ENCODING MEMBERS OF THE HUMAN B  
LYMPHOCYTE ACTIVATION ANTIGEN B-7 FAMILY AND  
POLYPEPTIDES ENCODED THEREBY

July 25, 2002  
Boston, Massachusetts

U. S. Patent and Trademark Office  
Box Sequence  
P. O. Box 2327  
Arlington, VA 22202

PRELIMINARY AMENDMENT

Prior to examination of the above-identified patent application, please amend the application as set forth below and consider the following remarks.

In the Specification:

Please insert the Sequence Listing, pages 1-73, at the end of the specification.

REMARKS


Applicants submit a Sequence Listing for the nucleotide sequences disclosed in the specification, in compliance with the requirements for patent applications containing nucleotide sequences and/or amino acid sequence disclosures. 37 C.F.R. §§ 1.821-1.825.

Applicants: Green, et al.  
USSN: 10/069,626

### CONCLUSION

Applicants respectfully submit that the present application complies with 37 C.F.R. §§.1.821-1.825. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 69,519  
Christina V. Karnakis, Reg. No. 45,899  
Attorneys for Applicants  
c/o MINTZ, LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

TRA 1694321v1



PTO/PCT Rec'd 25 JUL 2002 065626 .072302

Express Mail Label No. EV058280658US  
Date of Deposit: July 25, 2002

Attorney Docket 15966-562 NATL (CURA-62 NATL)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Green, *et al*  
SERIAL NUMBER: 10/069,626  
FILING DATE: February 26, 2002  
FOR: POLYNUCLEOTIDES ENCODING MEMBERS OF THE HUMAN B  
LYMPHOCYTE ACTIVATION ANTIGEN B-7 FAMILY AND POLYPEPTIDES  
ENCODED THEREBY


July 25, 2002  
Boston, Massachusetts

U. S. Patent and Trademark Office  
Box Sequence  
P. O. Box 2327  
Arlington, VA 22202

STATEMENT IN SUPPORT OF COMPUTER READABLE  
FORM SUBMISSION UNDER 37 C.F.R. § 1.821(f)

I hereby state that the content of the paper and computer readable forms of the Sequence Listing, submitted in the above-identified application in accordance with 37 C.F.R. § 1.821(c) and 1.821(e), respectively, are the same. No new matter has been added.

Respectfully submitted,

  
Gregory J. Sieczkiewicz, Reg. No. 48,223  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

TRA 1694161v1

13/PRTS

10/069626  
JC19 Rec'd PCT/PTO 26 FEB 2002

WO 01/18204

PCT/US00/24220

**POLYNUCLEOTIDES ENCODING MEMBERS OF THE  
HUMAN B LYMPHOCYTE ACTIVATION ANTIGEN B7  
FAMILY AND POLYPEPTIDES ENCODED THEREBY**

**FIELD OF THE INVENTION**

5       The invention relates generally to polynucleotides and polypeptides encoded thereby, as well as vectors, antibodies and recombinant methods for producing the polypeptides and polynucleotides.

**BACKGROUND OF THE INVENTION**

10       The immune system of vertebrates is characterized by its ability to discriminate "self" from "non-self" and to mount an appropriate, selective response to pathogens and other potentially harmful agents. Cell types involved in immune responses include lymphocytes known as B cells and T cells. Interactions between B cells and T cells are important for the propagation of full immune responses.

15       T cells must be activated in order to effect an immune response. T cell activation is thought to require two signals: an antigen-specific signal and a signal that is not antigen-specific. T cells can become activated by binding to B cells, particularly B cells which are themselves activated.

20       B cell-mediated activation of T cells is thought to be mediated, at least in part, by B7 proteins, which are expressed on the surface of B cells. B7 proteins are members of the immunoglobulin superfamily. They bind to activated T lymphocytes and provide regulatory signals for T lymphocyte cell growth and activation. (See, e.g., "Immunobiology - The Immune System in Health and Disease", 1997, Third edition, chapter 7, Janeway, C.A. et al., eds., Garland Publishing Inc., New York.) Cell surface molecules on T cells which bind to B7 molecules include CTLA4 and CD28.

# SUMMARY OF THE INVENTION

The present invention is based, in part, upon the discovery of BLAA polynucleotide sequences encoding novel members of the human B Lymphocyte Activation Antigen B7 family (henceforth "BLAA").

5 In one aspect, the present invention involves an isolated nucleic acid molecule encoding a BLAA. This nucleic acid molecule may be a nucleotide that encodes a polypeptide having a sequence that is at least 95% identical to SEQ ID NO:2 or SEQ ID NO:6. Alternatively, it may be the complement of such a nucleic acid molecule.

10 In another aspect, this invention involves an oligonucleotide that is less than 100 nucleotides in length and contains at least 6 contiguous nucleotides of SEQ ID NO:1, 3, 5, 7, 8, 9, 10, 11, or 12. This oligonucleotide contains at least 6 contiguous nucleotides of a complement of SEQ ID NO:1, 3, 5, 7, 8, 9, 10, 11, or 12.

15 Another aspect of this invention relates to a vector containing an isolated nucleic acid molecule encoding a BLAA, as described above. In one embodiment, this vector is an expression vector. In another embodiment, this vector contains a regulatory element that is operably linked to the isolated nucleic acid molecule.

A further aspect of this invention involves an isolated polypeptide that is at least 80% identical to a polypeptide having an amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6. In another embodiment of this aspect of the invention, the isolated polypeptide is at least 80% homologous to a fragment of a polypeptide having an amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6. In this embodiment, the fragment contains at least 6 contiguous amino acids of SEQ ID NO:2, SEQ IDNO:4, or SEQ ID NO:6. Other embodiments of this aspect of the invention require that the isolated polypeptides of the invention be at least 80% homologous to a derivative, analog, or homolog of a polypeptide having an amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6. Yet another embodiment involves an isolated polypeptide that is at least 80% identical to a naturally occurring allelic variant of a polypeptide having an amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6. This embodiment requires that the polypeptide be encoded by a nucleic acid molecule capable of hybridizing to a nucleic acid molecule of SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5, under stringent conditions.

20

25

30

WO 01/18204

PCT/US00/24220

Another embodiment of this invention involves an antibody that selectively binds to the polypeptide(s) described above. Further embodiments of this invention provide methods for (a) producing such polypeptide(s) by culturing a host cell under conditions in which the nucleic acid molecule is expressed; (b) detecting the presence of the polypeptide(s) in a sample  
5 by contacting the sample with a compound that selectively binds to the polypeptide(s) of the invention; and (c) modulating the activity of such polypeptide(s) by contacting a cell sample containing the polypeptide(s) of the instant invention with a compound that binds to the polypeptide(s) to modulate its activity.

10 Additionally, a method of detecting the presence of one of the nucleic acid molecules of this invention is also provided. This method involves contacting a sample with a compound that selectively binds to the polypeptide(s) of this invention and determining whether the compound bound to the polypeptide(s) is present in the sample.

Other embodiments of this invention include methods of treating or preventing immune response-associated disorders and therapeutic or prophylactic pharmaceutical  
15 compositions. Additionally, another aspect of this invention involves a kit containing therapeutically or prophylactically effective amounts of the pharmaceutical compositions provided for in the instant invention.

Another aspect of this invention involves the use of a therapeutic in the manufacture of a medicament for treating diseases associated with immune-response disorders. Another  
20 embodiment of this invention involves a method for screening for a modulator of activity, latency or predisposition to an immune response-associated disorder. In this embodiment, a test compound is administered to an animal at an increased risk for an immune response-associated disorder, measuring the expression of the polypeptide of the invention in the test animal, measuring polypeptide expression in a control animal, and comparing the expression  
25 in both animals.

Other embodiments of this invention include methods for determining the presence of or predisposition to a disease associate with altered levels of a BLAA polypeptide or a BLAA nucleic acid by measuring the amount of BLAA polypeptide or nucleic acid in a sample and comparing it to the amount present in a control sample. Yet other embodiments of this  
30 invention involve methods of treating a pathological state in a mammal by administering a

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a representation of a 2691 nucleotide human cDNA sequence (SEQ ID NO: 1), and  
15 an amino acid sequence of the encoded polypeptide (SEQ ID NO:2).

Figure 2 is a representation of a 2885 nucleotide human cDNA sequence (SEQ ID NO: 3), and an amino acid sequence of the encoded polypeptide (SEQ ID NO:4).

Figure 3 is a representation of a 2229 nucleotide human cDNA sequence (SEQ ID NO: 5), and an amino acid sequence of the encoded polypeptide (SEQ ID NO:6).

25 Figure 4 shows the ClustalW Alignment of the BLAA polypeptide of SEQ ID NO: 6 as compared to several homologous B7 proteins and indicates the conserved regions by dark highlighting and conservative amino acid substitutions by lighter highlighting.

Figure 5 depicts the hydrophobicity plot for the polypeptide of SEQ ID NO: 6.

WO 01/18204

PCT/US00/24220

# DETAILED DESCRIPTION OF THE INVENTION

The invention provides novel polynucleotides encoding polypeptides bearing sequence similarity to the B7 family of B lymphocyte antigens (BLAA). These cDNA sequences according to the invention, along with their encoded BLAA polypeptides are shown in Figures 1, 2 and 3.

The BLAA polypeptides are 20-25% identical and 40-45% similar to previously described members of the B7 family (*i.e.*, B7-1 and B7-2). As discussed in detail below, several motifs of the BLAA polypeptides are highly conserved with B7 polypeptides. Additionally, comparable similarity to human, mouse, and bovine butyrophilin as well as human myelin oligodendrocyte glycoprotein (MOG) has been observed.

The polypeptides of this invention have two (SEQ ID NO: 2), three (SEQ ID NO: 4), or four (SEQ ID NO: 6) Ig-like domains, followed by a transmembrane domain and a 44 amino acid cytoplasmic domain. This is consistent with previously described members of the B7 protein family, which are known to be localized on the cell surface (see, e.g., Selvakumar et al., Immunogenetics 36:175-181 (1992) and Linsley et al., Protein Sci 3:1341-1343 (1994)).

As used herein, the term "human B lymphocyte activation antigen B7-like activity" encompasses binding to activated T lymphocytes and providing regulatory signals for T lymphocyte cell growth and activation.

Accordingly, the polypeptides of the instant invention are novel members of the B7 protein family. The nucleic acid molecules and polypeptides of the present invention can be used to modulate immune responses. As such, they are useful in potential therapeutic applications implicated in the treatment of infectious diseases, cancers, autoimmune disorders and complications associated with graft vs. host disease in organ transplantation, and/or in similar immune system pathologies and disorders. For example, a cDNA encoding a polypeptide of the instant invention may be useful in gene therapy. Alternatively, a BLAA polypeptide can be administered directly to treat immune disorders. The nucleic acids, polypeptides and antibodies of the instant invention may be further useful in diagnostic and therapeutic applications.

The BLAA polypeptides contain numerous regions and/or single amino acids that are conserved at corresponding position in other homologous B7 proteins. For example, Figure 4 depicts the ClustalW alignment of the polypeptide of SEQ ID NO: 6. Conserved regions

WO 01/18204

PCT/US00/24220

include, *e.g.*, amino acids 16, 42, 46, 48, 50, 52, 59, 60, 63, 67-68, 75, 82, 89, 92-93, 107-109, 116, 118, 122, 134, 136, 138, 140, 143, 145, 152, 164-167, 170, 172-173, 187, 191, 194, 198, 210, 217, 223, 242 and 310. In addition, there are also regions with conservative amino acid substitutions as defined in the section "Conservative Mutations". By "conservative amino acid  
5 substitutions" is meant amino acids having similar side chains. Such substitutions are found, *e.g.*, at amino acids 14, 25, 38, 65, 71, 79, 84, 106, 112, 114, 119, 123-124, 127-128, 142, 148-149, 161, 163, 171, 202, 212, 217, 221-223, 264, 266, 278, 283-284, 291, 305 and 335.

The BLAA polypeptides include hydrophilic and hydrophobic regions. As shown in Figure 5, the polypeptide of SEQ ID NO: 6 contains both hydrophilic and hydrophobic  
10 portions. Hydrophobic regions include from about amino acid 1 to about amino acid 75; from about amino acid 110 to about amino acid 150; from about amino acid 200 to about amino acid 225; from about amino acid 250 to about amino acid 290; from about amino acid 310 to about amino acid 380; from about amino acid 420 to about amino acid 440; and from about amino acid 460 to about amino acid 500. Conversely, the hydrophilic regions include from  
15 about amino acid 75 to about amino acid 110; from about amino acid 150 to about amino acid 200; from about amino acid 225 to about amino acid 250; from about amino acid 290 to about amino acid 310; from about amino acid 380 to about amino acid 420; from about amino acid 440 to about amino acid 534. Accordingly, these regions are useful for designing epitopes or selecting antigens.

20 For ease of reference, the novel polynucleotide and polypeptide sequences of the present invention shall be referred to collectively as BLAA (for B Lymphocyte Activation Antigen). A summary of the BLAA nucleic acid and polypeptide sequences of the present invention is provided in Table 1.

WO 01/18204

PCT/US00/24220

Table 1: Sequences and Corresponding SEQ ID Numbers

Sequence Identifier Number	Description
SEQ ID NO: 1	2691 nucleotide human cDNA sequence
SEQ ID NO: 2	340 amino acid polypeptide encoded by nucleotides 111-1130 (SEQ ID NO: 7) of SEQ ID NO: 1
SEQ ID NO: 3	2885 nucleotide human cDNA sequence
SEQ ID NO: 4	441 amino acid polypeptide encoded by nucleotides 2-1324 (SEQ ID NO: 9) of SEQ ID NO: 3
SEQ ID NO: 5	2229 nucleotide human cDNA sequence
SEQ ID NO: 6	534 amino acid polypeptide encoded by nucleotides 60-1661 (SEQ ID NO: 11) of SEQ ID NO: 5
SEQ ID NO: 7	Open reading frame extending from nucleotide 110 to 1130 of SEQ ID NO: 1
SEQ ID NO: 8	3' non-translated region ("NTR") extending from nucleotide 1130 to 2691 of SEQ ID NO: 1
SEQ ID NO: 9	Open reading frame extending from nucleotide 2 to 1324 of SEQ ID NO: 3
SEQ ID NO: 10	3' NTR extending from nucleotide 1325 to 2885 of SEQ ID NO: 3
SEQ ID NO: 11	Open reading frame extending from nucleotide 60 to 1661 of SEQ ID NO: 5
SEQ ID NO: 12	3' NTR extending from nucleotide 1662 to 2229 of SEQ ID NO: 7



As used herein, "identical" residues correspond to those residues in a comparison between two sequences where the equivalent nucleotide base or amino acid residue in an alignment of two sequences is the same residue. Residues are "similar" when the comparisons between two sequences in an alignment show that residues in an equivalent position in a comparison are either the same amino acid or a conservatively substituted amino acid as defined below in the section "Conservative Mutations".

### Nucleic Acids

One aspect of the invention pertains to isolated BLAA nucleic acid molecules that encode BLAA polypeptides or biologically active portions thereof. BLAA nucleic acid molecules also include nucleic acid fragments sufficient for use as hybridization probes to identify BLAA-encoding nucleic acids (*e.g.*, BLAA mRNA) and fragments for use as PCR primers for the amplification or mutation of BLAA nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (*e.g.*, cDNA or genomic DNA), RNA molecules (*e.g.*, mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.

"Probes" refer to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), 100 nt, or as many as about, *e.g.*, 6,000 nt, depending on use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are usually obtained from a natural or recombinant source and are highly specific and much slower to hybridize than oligomers. Probes may be single- or double-stranded and designed to have specificity in PCR, membrane-based hybridization technologies, or ELISA-like technologies.

An "isolated" nucleic acid molecule is one that is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (*i.e.*, sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated BLAA nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from

which the nucleic acid is derived. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material or culture medium when produced by recombinant techniques, or of chemical precursors or other chemicals when chemically synthesized.

5 A nucleic acid molecule of the present invention, *e.g.*, a nucleic acid molecule having a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12, or a complement of any of these nucleotide sequences, can be isolated using standard molecular biology techniques and the sequence information provided  
10 herein. Using all or a portion of the nucleic acid sequences of SEQ ID NO: 1, 3, 5, 7, 8, 9, 10, 11, or 12 as a hybridization probe, BLAA molecules can be isolated using standard hybridization and cloning techniques (*e.g.*, as described in Sambrook *et al.*, (eds.), MOLECULAR CLONING: A LABORATORY MANUAL 2<sup>nd</sup> Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; and Ausubel, *et al.*, (eds.), CURRENT PROTOCOLS IN  
15 MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993.)

A nucleic acid of the invention can be amplified using cDNA, mRNA or, alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore,  
20 oligonucleotides corresponding to BLAA nucleotide sequences can be prepared by standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

As used herein, the term "oligonucleotide" refers to a series of linked nucleotide residues, which oligonucleotide has a sufficient number of nucleotide bases to be used in a PCR reaction. A short oligonucleotide sequence may be based on, or designed from, a  
25 genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise portions of a nucleic acid sequence having about 10 nt, 50 nt, or 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment, an oligonucleotide comprising a nucleic acid molecule less than 100 nt in length would further  
30 comprise at least 6 contiguous nucleotides of SEQ ID NO: 1, 3, 5, 7, 8, 9, 10, 11, or 12 or a

complement thereof. Oligonucleotides may be chemically synthesized and may be used as probes.

In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in SEQ ID NO: 1, 3, 5, 7, 8, 9, 10, 11, or 12. A nucleic acid molecule that is complementary to the nucleotide sequence shown in SEQ ID NO: 1, 3, 5, 7, 8, 9, 10, 11, or 12 is one that is sufficiently complementary to the nucleotide sequence shown in SEQ ID NO: 1, 3, 5, 7, 8, 9, 10, 11, or 12, that it can hydrogen bond with little or no mismatches to the nucleotide sequence shown in SEQ ID NO: 1, 3, 5, 7, 8, 9, 10, 11, or 12, thereby forming a stable duplex.

As used herein, the term "complementary" refers to Watson-Crick or Hoogsteen base pairing between nucleotides units of a nucleic acid molecule. and the term "binding" means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof. Binding includes ionic, non-ionic, Van der Waals, hydrophobic interactions, etc. A physical interaction can be either direct or indirect. Indirect interactions may be through or due to the effects of another polypeptide or compound. Direct binding refers to interactions that do not take place through, or due to, the effect of another polypeptide or compound, but instead are without other substantial chemical intermediates.

Moreover, the nucleic acid molecule of the invention can comprise only a portion of the nucleic acid sequence of SEQ ID NO: 1, 3, 5, 7, 8, 9, 10, 11, or 12, *e.g.*, a fragment that can be used as a probe or primer or a fragment encoding a biologically active portion of BLAA.

Fragments provided herein are defined as sequences of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of amino acids. respectively, and are at most some portion less than a full length sequence. Fragments may be derived from any contiguous portion of a nucleic acid or amino acid sequence of choice. Derivatives are nucleic acid sequences or amino acid sequences formed from the native compounds either directly or by modification or partial substitution. Analogs are nucleic acid sequences or amino acid sequences that have a structure similar to, but not

identical to, the native compound but differs from it in respect to certain components or side chains. Analogs may be synthetic or from a different evolutionary origin and may have a similar or opposite metabolic activity compared to wild type. Homologs are nucleic acid sequences or amino acid sequences of a particular gene that are derived from different species.

5 Derivatives and analogs may be full length or other than full length, if the derivative or analog contains a modified nucleic acid or amino acid, as described below. Derivatives or analogs of the nucleic acids or proteins of the invention include, but are not limited to, molecules comprising regions that are substantially homologous to the nucleic acids or proteins of the invention, in various embodiments, by at least about 30%, 50%, 70%, 80%, or  
10 95% identity (with a preferred identity of 80-95%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to the complement of a sequence encoding the aforementioned proteins under stringent, moderately stringent, or low stringent conditions. See *e.g.* Ausubel, *et al.*, CURRENT  
15 PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993, and below.

A "homologous nucleic acid sequence" or "homologous amino acid sequence," or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level as discussed above. Homologous nucleotide sequences encode those sequences coding for isoforms of a BLAA polypeptide. Isoforms can be expressed in different  
20 tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. In the present invention, homologous nucleotide sequences include nucleotide sequences encoding for a BLAA polypeptide of species other than humans, including, but not limited to, mammals, and thus can include, *e.g.*, mouse, rat, rabbit, dog, cat, cow, horse, and other organisms. Homologous  
25 nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence does not, however, include a nucleotide sequence encoding a human BLAA polypeptide. Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see below) in SEQ ID NO: 2, SEQ ID NO: 4, or  
30 SEQ ID NO: 6, as well as a polypeptide having BLAA activity. Biological activities of the

BLAA proteins are described below. A homologous amino acid sequence does not encode the amino acid sequence of a human BLAA polypeptide.

A BLAA polypeptide can be encoded by an open reading frame ("ORF") of a BLAA nucleic acid, as described herein. For example, the invention includes a nucleic acid sequence comprising the stretch of nucleic acid sequences of SEQ ID NO: 7, SEQ ID NO: 9, and SEQ ID NO: 11 that comprise the ORFs of the instant invention and encode a polypeptide of SEQ ID NO: 2, SEQ ID NO: 4, and SEQ ID NO: 6, respectively.

An "open reading frame" ("ORF") corresponds to a nucleotide sequence that can potentially be translated into a polypeptide. A stretch of nucleic acids comprising an ORF is uninterrupted by a stop codon. An ORF that represents the coding sequence for a full protein begins with an ATG "start" codon and terminates with one of the three "stop" codons, namely, TAA, TAG, or TGA. For the purposes of this invention, an ORF may be any part of a coding sequence, with or without a start codon, a stop codon, or both. For an ORF to be considered as a good candidate for coding for a bona fide cellular protein, a minimum size requirement is often set, for example, a stretch of DNA that would encode a protein of 50 amino acids or more.

In one embodiment, a 1020 base pair (bp) ORF (SEQ ID NO: 7) includes nucleotide 111 to nucleotide 1130 of SEQ ID NO: 1. This ORF can be translated into a 340 amino acid polypeptide according to SEQ ID NO: 2. In another embodiment, a 1323 bp ORF (SEQ ID NO: 9) includes nucleotide 2 to nucleotide 1324 of SEQ ID NO: 3. This ORF can be translated into a 441 amino acid polypeptide according to SEQ ID NO: 4. In another embodiment, a 1601 bp ORF (SEQ ID NO: 11) includes nucleotide 60 to nucleotide 1661 of SEQ ID NO: 5. This ORF could be translated into a 534 amino acid polypeptide according to SEQ ID NO: 6.

The nucleotide sequence determined from the cloning of the human BLAA gene allows for the generation of probes and primers designed for use in identifying and/or cloning BLAA homologues in other cell types, *e.g.* from other tissues, as well as BLAA homologues from other mammals. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 200, 250, 300, 350 or 400

consecutive sense strand nucleotide sequence of SEQ ID NO: 1, 3, 5, 7, 8, 9, 10, 11, or 12; or an anti-sense strand nucleotide sequence of SEQ ID NO: 1, 3, 5, 7, 8, 9, 10, 11, or 12; or of a naturally occurring mutant of SEQ ID NO: 1, 3, 5, 7, 8, 9, 10, 11, or 12.

Probes based on a human BLAA nucleotide sequence can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In various embodiments, the probe further comprises a label group attached thereto, *e.g.* the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissue which misexpress a BLAA protein, such as by measuring a level of a BLAA-encoding nucleic acid in a sample of cells from a subject *e.g.*, detecting BLAA mRNA levels or determining whether a genomic BLAA gene has been mutated or deleted.

"A polypeptide having a biologically active portion of BLAA" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encoding a "biologically active portion of BLAA" can be prepared by isolating a portion of SEQ ID NO: 1, 3, 5, 7, 9, or 11, that encodes a polypeptide having a BLAA biological activity (the biological activities of the BLAA proteins are described below), expressing the encoded portion of BLAA polypeptide (*e.g.*, by recombinant expression *in vitro*) and assessing the activity of the encoded portion of BLAA.

#### BLAA variants

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequence shown in SEQ ID NO: 1, 3, 5, 7, 9, or 11, due to degeneracy of the genetic code and thus encode the same BLAA protein as that encoded by the nucleotide sequence shown in SEQ ID NO: 1, 3, 5, 7, 9, or 11. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6.

In addition to the human BLAA nucleotide sequence shown in SEQ ID NO: 1, 3, 5, 7, 9, or 11, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of BLAA may exist within a population (*e.g.*, the human population). Such genetic polymorphism in the BLAA gene may exist among

individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding a BLAA polypeptide, preferably a mammalian BLAA polypeptide. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the BLAA gene. Any and all such nucleotide variations and resulting amino acid polymorphisms in BLAA that are the result of natural allelic variation and that do not alter the functional activity of BLAA are intended to be within the scope of the invention.

Moreover, nucleic acid molecules encoding BLAA polypeptides from other species, and thus that have a nucleotide sequence that differs from the human sequence of SEQ ID NO: 1, 3, 5, 7, 9, or 11, are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the BLAA cDNAs of the invention can be isolated based on their homology to the human BLAA nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. For example, a soluble human BLAA cDNA can be isolated based on its homology to human membrane-bound BLAA. Likewise, a membrane-bound human BLAA cDNA can be isolated based on its homology to soluble human BLAA.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1, 3, 5, 7, 8, 9, 10, 11, or 12. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250, 500, 1000, 1500, 2000, or more nucleotides in length. In another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region, for example SEQ ID NO: 1, 3, 5, 7, 9, or 11. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other.

Homologs (*i.e.*, nucleic acids encoding BLAA polypeptides derived from species other than human) or other related sequences (*e.g.*, paralogs) can be obtained by low, moderate or high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.

As used herein, the phrase "stringent hybridization conditions" refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T<sub>m</sub>) for the specific sequence at a defined ionic strength and pH. The T<sub>m</sub> is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at T<sub>m</sub>, 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes, primers or oligonucleotides (*e.g.*, 10 nt to 50 nt) and at least about 60°C for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

Stringent conditions are known to those skilled in the art and can be found in Ausubel *et al.*, (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65°C, followed by one or more washes in 0.2X SSC, 0.01% BSA at 50°C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NO: 1, 3, 5, 7, 8, 9, 10, 11, or 12, corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (*e.g.*, encodes a natural protein).

In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1, 3, 5, 7, 8, 9, 10, 11, or



12, or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization conditions are hybridization in 6X SSC, 5X Denhardt's solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55°C, followed by one or more washes in 1X SSC, 0.1% SDS at 37°C. Other  
5 conditions of moderate stringency that may be used are well-known in the art. See, *e.g.*, Ausubel *et al.* (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY.

In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule  
10 comprising the nucleotide sequence of SEQ ID NO: 1, 3, 5, 7, 8, 9, 10, 11, or 12, or fragments, analogs or derivatives thereof, under conditions of low stringency, is provided. A non-limiting example of low stringency hybridization conditions are hybridization in 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40°C, followed by one  
15 or more washes in 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS at 50°C. Other conditions of low stringency that may be used are well known in the art (*e.g.*, as employed for cross-species hybridizations). See, *e.g.*, Ausubel *et al.* (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY; Shilo and  
20 Weinberg, 1981, *Proc Natl Acad Sci USA* 78: 6789-6792.

#### Conservative mutations

In addition to naturally-occurring allelic variants of the BLAA sequence that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequence of SEQ ID NO: 1, 3, 5, 7, 9, or 11, thereby leading to  
25 changes in the amino acid sequence of the encoded BLAA polypeptide, without altering the functional ability of the BLAA polypeptide. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence of SEQ ID NO: 1, 3, 5, 7, 9, or 11. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of BLAA without altering the biological activity, whereas  
30 an "essential" amino acid residue is required for biological activity. For example, amino acid

residues that are conserved among the BLAA polypeptides of the present invention, are predicted to be particularly unamenable to alteration. (See Figure 4 and discussion above).

In addition, amino acid residues that are conserved among family members of the BLAA polypeptides of the present invention, as indicated by the alignment presented in Figure 4, and as described above, are also predicted to be particularly unamenable to alteration. Other amino acid residues, however, (e.g., those that are not conserved or only semi-conserved among members of the BLAA polypeptides) may not be essential for activity and thus are likely to be amenable to alteration.

Another aspect of the invention pertains to nucleic acid molecules encoding BLAA polypeptides that contain changes in amino acid residues that are not essential for activity. Such BLAA polypeptides differ in amino acid sequence from SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a polypeptide, wherein the polypeptide comprises an amino acid sequence at least about 45% homologous to the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6. Preferably, the polypeptide encoded by the nucleic acid molecule is at least about 60% homologous to SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, more preferably at least about 70% homologous to SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, still more preferably at least about 80% homologous to SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, even more preferably at least about 90% homologous to SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, and most preferably at least about 95% homologous to SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6.

An isolated nucleic acid molecule encoding a BLAA polypeptide homologous to the polypeptide of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6 can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO: 1, 3, 5, 7, 9, or 11 such that one or more amino acid substitutions, additions or deletions are introduced into the encoded polypeptide.

Mutations can be introduced into SEQ ID NO: 1, 3, 5, 7, 9, or 11 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue

is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in BLAA is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a BLAA coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for BLAA biological activity to identify mutants that retain activity. Following mutagenesis of SEQ ID NO: 1, 3, 5, 7, 9, or 11, the encoded polypeptide can be expressed by any recombinant technology known in the art and the activity of the polypeptide can be determined.

In one embodiment, a mutant BLAA polypeptide can be assayed for (1) the ability to form protein:protein interactions with other BLAA polypeptides, other cell-surface proteins, or biologically active portions thereof, (2) complex formation between a mutant BLAA polypeptide and a BLAA ligand, *e.g.*, CTLA4; (3) the ability of a mutant BLAA polypeptide to bind to an intracellular target protein or biologically active portion thereof (*e.g.* avidin proteins).

In yet another embodiment, a mutant BLAA can be assayed for the ability to perform immunoglobulin superfamily member activities, such as, (i) complex formation between a BLAA polypeptide and activated T lymphocytes; (ii) interaction of a BLAA polypeptide with a protein having substantial homology to the human B lymphocyte activation antigen B7 family of proteins; (iii) interaction of a BLAA polypeptide with a human B lymphocyte activation antigen B7 family member protein; and (iv) interaction of a BLAA polypeptide with other proteins. In yet another embodiment, a BLAA activity is at least one or more of the following activities: (i) modulation of immunoglobulin superfamily-related protein activity; (ii) regulation of T lymphocyte growth; and (iii) regulation of T lymphocyte activation.

### Antisense

Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1, 3, 5, 7, 8, 9, 10, 11, or 12, or fragments, analogs or derivatives thereof. An "antisense" nucleic acid comprises a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein, *e.g.*, complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire BLAA coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of a BLAA polypeptide of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6 or antisense nucleic acids complementary to a BLAA nucleic acid sequence of SEQ ID NO: 1, 3, 5, 7, 8, 9, 10, 11, or 12, are additionally provided.

In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding BLAA. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues (*e.g.*, the coding region of human BLAA corresponds to nucleotides 111-1130 of SEQ ID NO: 1 (SEQ ID NO: 7), nucleotides 2-1324 of SEQ ID NO: 3 (SEQ ID NO: 9), or nucleotides 60-1601 of SEQ ID NO: 5 (SEQ ID NO: 11)). In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding BLAA. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (*i.e.*, also referred to as 5' and 3' untranslated regions). Examples of "noncoding regions" include the non-translated regions ("NTRs") of SEQ ID NO: 8, SEQ ID NO: 10, and SEQ ID NO: 12.

Given the coding strand sequences encoding BLAA disclosed herein (*e.g.*, SEQ ID NO: 5, SEQ ID NO: 7, and SEQ ID NO: 9), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of BLAA mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of BLAA mRNA. For example, the antisense oligonucleotide can be

complementary to the region surrounding the translation start site of BLAA mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, *e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used.

Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a BLAA polypeptide to thereby inhibit expression of the protein, *e.g.*, by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an

antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an  $\alpha$ -anomeric nucleic acid molecule. An  $\alpha$ -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual  $\beta$ -units, the strands run parallel to each other (Gaultier *et al.* (1987) *Nucleic Acids Res* 15: 6625-6641). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue *et al.* (1987) *Nucleic Acids Res* 15: 6131-6148) or a chimeric RNA-DNA analogue (Inoue *et al.* (1987) *FEBS Lett* 215: 327-330).

#### Ribozymes and PNA moieties

Nucleic acid modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.

In one embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes (described in Haselhoff and Gerlach (1988) *Nature* 334:585-591)) can be used to catalytically cleave BLAA mRNA transcripts to thereby inhibit translation of BLAA mRNA. A ribozyme having specificity for a BLAA-encoding

nucleic acid can be designed based upon the nucleotide sequence of a BLAA cDNA disclosed herein (*i.e.*, SEQ ID NO: 1, 3, 5, 7, 9, or 11). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a BLAA-encoding mRNA. See, *e.g.*, Cech *et al.* U.S. Pat. No. 4,987,071; and Cech *et al.* U.S. Pat. No. 5,116,742. Alternatively, BLAA mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, *e.g.*, Bartel *et al.*, (1993) *Science* 261:1411-1418.

Alternatively, BLAA gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the BLAA (*e.g.*, the BLAA promoter and/or enhancers) to form triple helical structures that prevent transcription of the BLAA gene in target cells. See generally, Helene. (1991) *Anticancer Drug Des.* 6: 569-84; Helene. *et al.* (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher (1992) *Bioassays* 14: 807-15.

In various embodiments, the nucleic acids of BLAA can be modified at the base moiety, sugar moiety or phosphate backbone to improve, *e.g.*, the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup *et al.* (1996) *Bioorg Med Chem* 4: 5-23). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, *e.g.*, DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup *et al.* (1996) above; Perry-O'Keefe *et al.* (1996) *PNAS* 93: 14670-675.

PNAs of BLAA can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, *e.g.*, inducing transcription or translation arrest or inhibiting replication. PNAs of BLAA can also be used, *e.g.*, in the analysis of single base pair mutations in a gene by, *e.g.*, PNA directed PCR clamping; as artificial restriction enzymes when used in combination with

other enzymes, *e.g.*, S1 nucleases (Hyrup B. (1996) above); or as probes or primers for DNA sequence and hybridization (Hyrup *et al.* (1996), above; Perry-O'Keefe (1996), above).

In another embodiment, PNAs of BLAA can be modified, *e.g.*, to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of BLAA can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, *e.g.*, RNase H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup (1996) above). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996) above and Finn *et al.* (1996) *Nucl Acids Res* 24: 3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, *e.g.*, 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5' end of DNA (Mag *et al.* (1989) *Nucl Acid Res* 17: 5973-88). PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn *et al.* (1996) above). Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment. See. Petersen *et al.* (1975) *Bioorg Med Chem Lett* 5: 1119-11124.

In other embodiments, the oligonucleotide may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger *et al.*, 1989, *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556; Lemaitre *et al.*, 1987, *Proc. Natl. Acad. Sci.* 84:648-652; PCT Publication No. W088/09810) or the blood-brain barrier (see, *e.g.*, PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (See, *e.g.*, Krol *et al.*, 1988, *BioTechniques* 6:958-976) or intercalating agents. (See, *e.g.*, Zon, 1988, *Pharm. Res.* 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, *e.g.*, a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, etc.



**BLAA polypeptides**

As used herein, the terms "protein" and "polypeptide" are intended to be interchangeable. The novel polypeptides of the invention include the BLAA polypeptides whose sequence is provided in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6. The invention also includes mutant or variant polypeptides any of whose residues may be changed from the corresponding residue shown in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6 while still encoding a polypeptide that maintains its BLAA activities and physiological functions, or a functional fragment thereof. In the mutant or variant protein, up to 20% or more of the residues may be so changed.

In general, an BLAA variant that preserves BLAA-like function includes any variant in which residues at a particular position in the sequence have been substituted by other amino acids, and further include the possibility of inserting an additional residue or residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed by the invention. In favorable circumstances, the substitution is a conservative substitution as defined above.

One aspect of the invention pertains to isolated BLAA polypeptides, and biologically active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to raise anti-BLAA antibodies. In one embodiment, native BLAA polypeptides can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, BLAA polypeptides are produced by recombinant DNA techniques. Alternative to recombinant expression, a BLAA protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" polypeptide or biologically active portion thereof is substantially free of cellular material or other contaminating proteins or polypeptides from the cell or tissue source from which the BLAA polypeptide is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of BLAA polypeptide in which the polypeptide is separated from cellular components of the cells from which it is isolated or

recombinantly produced. In one embodiment, the language "substantially free of cellular material" includes preparations of BLAA polypeptide having less than about 30% (by dry weight) of non-BLAA protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-BLAA protein, still more preferably less than about 10% of non-BLAA protein, and most preferably less than about 5% non-BLAA protein.

When the BLAA polypeptide or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, *i.e.*, culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation.

10 The language "substantially free of chemical precursors or other chemicals" includes preparations of BLAA polypeptide in which the polypeptide is separated from chemical precursors or other chemicals that are involved in the synthesis of the polypeptide. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of BLAA polypeptide having less than about 30% (by dry weight) of  
15 chemical precursors or non-BLAA chemical, more preferably less than about 20% chemical precursors or non-BLAA chemicals, still more preferably less than about 10% chemical precursors or non-BLAA chemicals, and most preferably less than about 5% chemical precursors or non-BLAA chemicals.

Biologically active portions of a BLAA polypeptide include peptides comprising  
20 amino acid sequences sufficiently homologous to or derived from the amino acid sequence of the BLAA polypeptides, *e.g.*, the amino acid sequence shown in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, that include fewer amino acids than the full length BLAA polypeptides, and exhibit at least one activity of a BLAA polypeptide. Typically, biologically active portions comprise a domain or motif with at least one activity of the BLAA polypeptide. A  
25 biologically active portion of a BLAA polypeptide can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length.

The polypeptide disclosed in SEQ ID NO: 2 has two Ig-like domains, followed by a transmembrane domain and a 44 amino acid cytoplasmic domain. The polypeptide disclosed in SEQ ID NO: 4 has three Ig-like domains, followed by a transmembrane domain and a 44  
30 amino acid cytoplasmic domain. The polypeptide disclosed in SEQ ID NO: 6 has four Ig-like

domains, followed by a transmembrane domain and a 44 amino acid cytoplasmic domain. Its hydrophobicity plot analysis is shown in Figure 5.

In an embodiment, the BLAA polypeptide has an amino acid sequence shown in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6. In other embodiments, the BLAA polypeptide is substantially homologous to SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6 and retains the functional activity of the polypeptide of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail below. Accordingly, in another embodiment, the BLAA polypeptide is a polypeptide that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6 and retains the functional activity of the BLAA polypeptides of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6.

#### Determining homology between two or more sequences

To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (*i.e.*, as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity").

The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. See, Needleman and Wunsch 1970 *J Mol Biol* 48: 443-453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence shown in SEQ ID NO: 1, 3, 5, 7, 9, or 11.

The term "sequence identity" refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (*e.g.*, A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (*i.e.*, the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term "substantial identity" as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region.

#### Chimeric and fusion proteins

The invention also provides for BLAA chimeric or fusion proteins. As used herein, a BLAA "chimeric protein" or "fusion protein" comprises a BLAA polypeptide operatively linked to a non-BLAA polypeptide. A "BLAA polypeptide" refers to a polypeptide having an amino acid sequence corresponding to BLAA, whereas a "non-BLAA polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially homologous to the BLAA polypeptide, *e.g.*, a protein that is different from the BLAA polypeptide and that is derived from the same or a different organism. Within a BLAA fusion protein the BLAA polypeptide can correspond to all or a portion of a BLAA polypeptide. In one embodiment, a BLAA fusion protein comprises at least one biologically active portion of a BLAA protein. In another embodiment, a BLAA fusion protein comprises at least two biologically active portions of a BLAA polypeptide. In yet another embodiment, a BLAA fusion protein comprises at least three biologically active portions of a BLAA polypeptide. Within the fusion protein, the term "operatively linked" is intended to indicate that the BLAA polypeptide and the non-BLAA polypeptide are fused in-frame to each other. The non-BLAA polypeptide can be fused to the N-terminus or C-terminus of the BLAA polypeptide.

Such fusion proteins can be further utilized in screening assays for compounds which modulate BLAA activity (such assays are described in detail below).

In one embodiment, the fusion protein is a GST-BLAA fusion protein in which the BLAA sequences are fused to the C-terminus of the GST (i.e., glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant BLAA.

In another embodiment, the fusion protein is a BLAA polypeptide containing a heterologous signal sequence at its N-terminus. For example, the nature BLAA signal sequence (e.g., about amino acids 1 to 26 of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6) can be removed and replaced with a signal sequence from another protein. In certain host cells (e.g., mammalian host cells), expression and/or secretion of BLAA can be increased through use of a heterologous signal sequence.

In yet another embodiment, the fusion protein is a BLAA-immunoglobulin fusion protein in which the BLAA sequences are fused to sequences derived from a member of the immunoglobulin protein family. The BLAA-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a BLAA ligand and a BLAA protein on the surface of a cell, to thereby suppress BLAA-mediated signal transduction *in vivo*. The BLAA-immunoglobulin fusion proteins can be used to affect the bioavailability of a BLAA cognate ligand. Inhibition of the BLAA ligand/BLAA interaction may be useful therapeutically for both the treatment of immune response-associated disorders. Moreover, the BLAA-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-BLAA antibodies in a subject, to purify BLAA ligands, and in screening assays to identify molecules that inhibit the interaction of BLAA with a BLAA ligand.

A BLAA chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including

automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, Ausubel *et al.* (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (*e.g.*, a GST polypeptide). A BLAA-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the BLAA polypeptide.

#### BLAA agonists and antagonists

- 10 The present invention also pertains to variants of the BLAA polypeptides that function as either BLAA agonists (mimetics) or as BLAA antagonists. Variants of the BLAA polypeptide can be generated by mutagenesis, *e.g.*, discrete point mutation or truncation of the BLAA polypeptide. An agonist of the BLAA polypeptide can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the BLAA polypeptide.
- 15 An antagonist of the BLAA polypeptide can inhibit one or more of the activities of the naturally occurring form of the BLAA polypeptide by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the BLAA polypeptide. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of
- 20 the biological activities of the naturally occurring form of the polypeptide has fewer side effects in a subject relative to treatment with the naturally occurring form of the BLAA polypeptides.

- Variants of the BLAA polypeptide that function as either BLAA agonists (mimetics) or as BLAA antagonists can be identified by screening combinatorial libraries of mutants, *e.g.*, truncation mutants, of the BLAA polypeptide for BLAA polypeptide agonist or antagonist activity. In one embodiment, a variegated library of BLAA variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of BLAA variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a
- 30 degenerate set of potential BLAA sequences is expressible as individual polypeptides, or

alternatively, as a set of larger fusion proteins (*e.g.*, for phage display) containing the set of BLAA sequences therein. There are a variety of methods which can be used to produce libraries of potential BLAA variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential BLAA sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, *e.g.*, Narang (1983) *Tetrahedron* 39:3; Itakura *et al.* (1984) *Annu Rev Biochem* 53:323; Itakura *et al.* (1984) *Science* 198:1056; Ike *et al.* (1983) *Nucl Acid Res* 11:477.

#### Polypeptide libraries

In addition, libraries of fragments of the BLAA protein coding sequence can be used to generate a variegated population of BLAA fragments for screening and subsequent selection of variants of a BLAA polypeptide. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a BLAA coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal and internal fragments of various sizes of a BLAA polypeptide.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of a BLAA polypeptide. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates





either with or without Fourier transformation. See, e.g., Hopp and Woods, 1981, *Proc. Nat. Acad. Sci. USA* 78: 3824-3828; Kyte and Doolittle 1982, *J. Mol. Biol.* 157: 105-142, each reference is incorporated herein by reference in their entirety.

As disclosed herein, BLAA polypeptide sequence of SEQ ID NO: 2, SEQ ID NO: 4, or  
5 SEQ ID NO: 6, or derivatives, fragments, analogs or homologs thereof, may be utilized as immunogens in the generation of antibodies that immunospecifically-bind these protein components. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, *i.e.*, molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen, such as BLAA.  
10 Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain,  $F_{ab}$  and  $F_{(ab)2}$  fragments, and an  $F_{ab}$  expression library. In a specific embodiment, antibodies to human BLAA polypeptides are disclosed. Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies to a BLAA polypeptide sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, or derivative, fragment, analog  
15 or homolog thereof. Some of these proteins are discussed below.

For the production of polyclonal antibodies, various suitable host animals (*e.g.*, rabbit, goat, mouse or other mammal) may be immunized by injection with the native polypeptide, or a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, recombinantly expressed BLAA polypeptide or a  
20 chemically synthesized BLAA polypeptide. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (*e.g.*, aluminum hydroxide), surface active substances (*e.g.*, lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), human adjuvants such as *Bacille Calmette-Guerin* and *Corynebacterium*  
25 *parvum*, or similar immunostimulatory agents. If desired, the antibody molecules directed against BLAA can be isolated from the mammal (*e.g.*, from the blood) and further purified by well known techniques, such as protein A chromatography to obtain the IgG fraction.

The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen  
30 binding site capable of immunoreacting with a particular epitope of BLAA. A monoclonal

antibody composition thus typically displays a single binding affinity for a particular BLAA polypeptide with which it immunoreacts. For preparation of monoclonal antibodies directed towards a particular BLAA polypeptide, or derivatives, fragments, analogs or homologs thereof, any technique that provides for the production of antibody molecules by continuous cell line culture may be utilized. Such techniques include, but are not limited to, the hybridoma technique (see Kohler & Milstein, 1975 *Nature* 256: 495-497); the trioma technique; the human B-cell hybridoma technique (see Kozbor, *et al.*, 1983 *Immunol Today* 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, *et al.*, 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, *et al.*, 1983. *Proc Natl Acad Sci USA* 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus *in vitro* (see Cole, *et al.*, 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Each of the above citations are incorporated herein by reference in their entirety.

According to the invention, techniques can be adapted for the production of single-chain antibodies specific to a BLAA polypeptide (see *e.g.*, U.S. Patent No. 4,946,778). In addition, methodologies can be adapted for the construction of  $F_{ab}$  expression libraries (see *e.g.*, Huse, *et al.*, 1989 *Science* 246: 1275-1281) to allow rapid and effective identification of monoclonal  $F_{ab}$  fragments with the desired specificity for a BLAA polypeptide or derivatives, fragments, analogs or homologs thereof. Non-human antibodies can be "humanized" by techniques well known in the art. See *e.g.*, U.S. Patent No. 5,225,539. Antibody fragments that contain the idiotypes to a BLAA polypeptide may be produced by techniques known in the art including, but not limited to: (i) an  $F_{(ab)2}$  fragment produced by pepsin digestion of an antibody molecule; (ii) an  $F_{ab}$  fragment generated by reducing the disulfide bridges of an  $F_{(ab)2}$  fragment; (iii) an  $F_{ab}$  fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv)  $F_c$  fragments.

Additionally, recombinant anti-BLAA antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA

techniques known in the art, for example using methods described in International Application No. PCT/US86/02269; European Patent Application No. 184,187; European Patent Application No. 171,496; European Patent Application No. 173,494; PCT International Publication No. WO 86/01533; U.S. Pat. No. 4,816,567; U.S. Pat. No. 5,225,539; European Patent Application No. 125,023; Better *et al.* (1988) *Science* 240:1041-1043; Liu *et al.* (1987) *PNAS* 84:3439-3443; Liu *et al.* (1987) *J Immunol.* 139:3521-3526; Sun *et al.* (1987) *PNAS* 84:214-218; Nishimura *et al.* (1987) *Cancer Res* 47:999-1005; Wood *et al.* (1985) *Nature* 314:446-449; Shaw *et al.* (1988) *J Natl Cancer Inst* 80:1553-1559; Morrison (1985) *Science* 229:1202-1207; Oi *et al.* (1986) *BioTechniques* 4:214; Jones *et al.* (1986) *Nature* 321:552-525; Verhoeyan *et al.* (1988) *Science* 239:1534; and Beidler *et al.* (1988) *J Immunol* 141:4053-4060. Each of the above citations are incorporated herein by reference in their entirety.

In one embodiment, methodologies for the screening of antibodies that possess the desired specificity include, but are not limited to, enzyme-linked immunosorbent assay (ELISA) and other immunologically-mediated techniques known within the art. In a specific embodiment, selection of antibodies that are specific to a particular domain of a BLAA polypeptide is facilitated by generation of hybridomas that bind to the fragment of a BLAA polypeptide possessing such a domain. Antibodies that are specific for an Ig-like domain within a BLAA polypeptide, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

Anti-BLAA antibodies may be used in methods known within the art relating to the localization and/or quantitation of a BLAA polypeptide (*e.g.*, for use in measuring levels of the BLAA polypeptide within appropriate physiological samples, for use in diagnostic methods, for use in imaging the polypeptide, and the like). In a given embodiment, antibodies for BLAA polypeptides, or derivatives, fragments, analogs or homologs thereof, that contain the antibody derived binding domain, are utilized as pharmacologically-active compounds [hereinafter "therapeutics"].

An anti-BLAA antibody (*e.g.*, monoclonal antibody) can be used to isolate BLAA by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-BLAA antibody can facilitate the purification of natural BLAA from cells and of recombinantly

produced BLAA expressed in host cells. Moreover, an anti-BLAA antibody can be used to detect BLAA polypeptide (*e.g.*, in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the BLAA polypeptide. Anti-BLAA antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, *e.g.*, to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (*i.e.*, physically linking) the antibody to a detectable substance.

Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials.

Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase,

- 10  $\beta$ -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include
- 15 luciferase, luciferin, and aequorin, and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{35}\text{S}$  or  $^3\text{H}$ .

#### BLAA Recombinant Expression Vectors and Host Cells

- Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding BLAA polypeptide, or derivatives, fragments, analogs or
- 20 homologs thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous
- 25 replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are
- 30 operatively linked. Such vectors are referred to herein as "expression vectors". In general,

expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (*e.g.*, in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (*e.g.*, tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (*e.g.*, BLAA polypeptides, mutant forms of BLAA, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of BLAA in prokaryotic or eukaryotic cells. For example, BLAA can be expressed in bacterial cells such as *E. coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990).

Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (1) to increase expression of recombinant protein; (2) to increase the solubility of the recombinant protein; and (3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amrann *et al.*, (1988) *Gene* 69:301-315) and pET 11d (Studier *et al.*, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein. See, Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada *et al.*, (1992) *Nucleic Acids Res.* 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the BLAA expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1 (Baldari, *et al.*,

(1987) *EMBO J* 6:229-234), pMFa (Kurjan and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz *et al.*, (1987) *Gene* 54:113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (Invitrogen Corp, San Diego, Calif.).

Alternatively, BLAA can be expressed in insect cells using baculovirus expression  
5 vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (*e.g.*, SF9 cells) include the pAc series (Smith *et al.* (1983) *Mol Cell Biol* 3:2156-2165) and the pVL series (Lucklow and Summers (1989) *Virology* 170:31-39).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors  
10 include pCDM8 (Seed (1987) *Nature* 329:840) and pMT2PC (Kaufman *et al.* (1987) *EMBO J* 6: 187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells. See, *e.g.*, Chapters 16  
15 and 17 of Sambrook *et al.*, MOLECULAR CLONING: A LABORATORY MANUAL, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (*e.g.*,  
20 tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert *et al.* (1987) *Genes Dev* 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) *Adv Immunol* 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) *EMBO J* 8:729-733) and immunoglobulins (Banerji *et al.* (1983) *Cell* 33:729-740; Queen and Baltimore (1983) *Cell* 33:741-748), neuron-specific promoters (*e.g.*, the neurofilament promoter; Byrne and Ruddle (1989) *PNAS* 86:5473-5477), pancreas-specific promoters (Edlund *et al.* (1985) *Science* 230:912-916), and mammary gland-specific promoters (*e.g.*, milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No.  
25 264,166). Developmentally-regulated promoters are also encompassed, *e.g.*, the murine hox  
30

promoters (Kessel and Gruss (1990) *Science* 249:374-379) and the  $\alpha$ -fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev* 3:537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to BLAA mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub *et al.*, "Antisense RNA as a molecular tool for genetic analysis," Reviews--Trends in Genetics, Vol. 1(1) 1986.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, BLAA polypeptide can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing



foreign nucleic acid (*e.g.*, DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (*e.g.*, resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding BLAA or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (*e.g.*, cells that have incorporated the selectable marker gene will survive, while the other cells die).

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (*i.e.*, express) BLAA polypeptide. Accordingly, the invention further provides methods for producing BLAA polypeptide using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding BLAA has been introduced) in a suitable medium such that BLAA polypeptide is produced. In another embodiment, the method further comprises isolating BLAA from the medium or the host cell.

#### **Transgenic animals**

The host cells of the invention can also be used to produce nonhuman transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which BLAA-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous BLAA sequences have been introduced into their genome or homologous recombinant animals in which endogenous BLAA sequences have been altered. Such animals are useful for studying

the function and/or activity of BLAA and for identifying and/or evaluating modulators of BLAA activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human  
5 primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a mammal, more  
10 preferably a mouse, in which an endogenous BLAA gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, *e.g.*, an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing BLAA-encoding nucleic acid into the male pronuclei of a fertilized oocyte, *e.g.*, by microinjection, retroviral  
15 infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The human BLAA cDNA sequence of SEQ ID NO: 1, 3, 5, 7, 9, or 11, can be introduced as a transgene into the genome of a non-human animal. Alternatively, a nonhuman homologue of the human BLAA gene, such as a mouse BLAA gene, can be isolated based on hybridization to the human BLAA cDNA (described further above) and used as a transgene. Intronic  
20 sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to the BLAA transgene to direct expression of BLAA polypeptide to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for  
25 example, in U.S. Pat. Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan 1986, In: MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the BLAA transgene in its genome and/or expression of BLAA mRNA in tissues or cells of the animals. A transgenic  
30 founder animal can then be used to breed additional animals carrying the transgene.

Moreover, transgenic animals carrying a transgene encoding BLAA can further be bred to other transgenic animals carrying other transgenes.

To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a BLAA gene into which a deletion, addition or substitution has been introduced to thereby alter, *e.g.*, functionally disrupt, the BLAA gene. The BLAA gene can be a human gene (*e.g.*, the cDNA of SEQ ID NO: 1, 3, 5, 7, 9, or 11), but more preferably, is a non-human homologue of a human BLAA gene. For example, a mouse homologue of human BLAA gene of SEQ ID NO: 1, 3, 5, 7, 9, or 11 can be used to construct a homologous recombination vector suitable for altering an endogenous BLAA gene in the mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the endogenous BLAA gene is functionally disrupted (*i.e.*, no longer encodes a functional protein; also referred to as a "knock out" vector).

Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous BLAA gene is mutated or otherwise altered but still encodes functional protein (*e.g.*, the upstream regulatory region can be altered to thereby alter the expression of the endogenous BLAA polypeptide). In the homologous recombination vector, the altered portion of the BLAA gene is flanked at its 5' and 3' ends by additional nucleic acid of the BLAA gene to allow for homologous recombination to occur between the exogenous BLAA gene carried by the vector and an endogenous BLAA gene in an embryonic stem cell. The additional flanking BLAA nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector. See *e.g.*, Thomas *et al.* (1987) *Cell* 51:503 for a description of homologous recombination vectors. The vector is introduced into an embryonic stem cell line (*e.g.*, by electroporation) and cells in which the introduced BLAA gene has homologously recombined with the endogenous BLAA gene are selected (see *e.g.*, Li *et al.* (1992) *Cell* 69:915).

The selected cells are then injected into a blastocyst of an animal (*e.g.*, a mouse) to form aggregation chimeras. See *e.g.*, Bradley 1987, In: TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. IRL, Oxford, pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the

embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley (1991) *Curr Opin Biotechnol* 2:823-829; PCT International Publication Nos.: WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169.

In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, see, e.g., Lakso *et al.* (1992) *PNAS* 89:6232-6236. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman *et al.* (1991) *Science* 251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut *et al.* (1997) *Nature* 385:810-813. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G<sub>0</sub> phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.

#### Pharmaceutical Compositions

The BLAA nucleic acid molecules, BLAA polypeptides, and anti-BLAA antibodies (also referred to herein as "active compounds") of the invention, and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable

for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, *e.g.*, intravenous, intradermal, subcutaneous, oral (*e.g.*, inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF,



WO 01/18204

PCT/US00/24220

adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a  
5 lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, *e.g.*, a gas  
10 such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid  
15 derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (*e.g.*, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal  
20 delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides,  
25 polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared

WO 01/18204

PCT/US00/24220

according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used  
5 herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be  
10 achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Pat. No. 5,328,470) or by stereotactic  
15 injection (see *e.g.*, Chen *et al.* (1994) *PNAS* 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, *e.g.*, retroviral vectors, the pharmaceutical preparation can include one or more cells that produce  
20 the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

#### Uses and Methods of the Invention

The immunoglobulin superfamily members include multifunctional secreted and  
25 membrane-bound proteins that modulate a number of functions. B7 molecules known in the prior art are located on the cell surface. (See Selvakumar *et al.* 1992, *Immunogenetics* 36:175-181 and Linsley *et al.* 1994, *Protein Sc.* 3:1341-1343). Sequence analysis studies using programs known in the prior art (*e.g.*, PSORT) show that the polypeptides of the instant invention are most likely localized in the membrane of the endoplasmic reticulum. The



nucleic acid molecules, proteins, protein homologues, and antibodies described herein can be used in one or more of the following methods: (a) screening assays; (b) detection assays (*e.g.*, chromosomal mapping, tissue typing, forensic biology), (c) predictive medicine (*e.g.*, diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenomics); and  
5 (d) methods of treatment (*e.g.*, therapeutic and prophylactic). As described herein, in one embodiment, a BLAA polypeptide of the invention has the ability to bind to activated T lymphocytes and provide regulatory signals for T lymphocyte cell growth and activation. A BLAA polypeptide interacts with other cellular proteins and can thus be used to modulate immune response-associated protein activity. Such modulation may have an effect on the  
10 regulation of cellular proliferation, the regulation of cellular differentiation, and/or the regulation of cell survival.

The isolated nucleic acid molecules of the invention can be used to express BLAA polypeptide (*e.g.*, via a recombinant expression vector in a host cell in gene therapy applications), to detect BLAA mRNA (*e.g.*, in a biological sample) or a genetic lesion in a  
15 BLAA gene, and to modulate BLAA activity, as described further below. In addition, the BLAA polypeptides can be used to screen drugs or compounds that modulate the BLAA activity or expression as well as to treat disorders characterized by insufficient or excessive production of BLAA polypeptide or production of BLAA polypeptide forms that have decreased or aberrant activity compared to BLAA wild type polypeptide (*e.g.* infectious  
20 diseases, cancers, autoimmune disorders, and complications associated with transplantation). In addition, the anti-BLAA antibodies of the invention can be used to detect and isolate BLAA polypeptides and modulate BLAA activity.

This invention further pertains to novel agents identified by the above described screening assays and uses thereof for treatments as described herein.

## 25       **Screening Assays**

The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, *i.e.*, candidate or test compounds or agents (*e.g.*, peptides, peptidomimetics, small molecules or other drugs) that bind to BLAA polypeptides or have a stimulatory or inhibitory effect on, for example, BLAA expression or BLAA activity.

In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of a BLAA protein or polypeptide or biologically active portion thereof. The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam  
5 (1997) *Anticancer Drug Des* 12:145).

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt *et al.* (1993) *Proc Natl Acad Sci U.S.A.* 90:6909; Erb *et al.* (1994) *Proc Natl Acad Sci U.S.A.* 91:11422; Zuckermann *et al.* (1994) *J Med Chem* 37:2678; Cho *et al.* (1993) *Science* 261:1303; Carrell *et al.* (1994) *Angew Chem Int Ed Engl* 33:2059; Carell *et al.* (1994) *Angew Chem Int Ed Engl* 33:2061; and Gallop *et al.* (1994) *J Med Chem* 37:1233.  
15

Libraries of compounds may be presented in solution (*e.g.*, Houghten (1992) *Biotechniques* 13:412-421), or on beads (Lam (1991) *Nature* 354:82-84), on chips (Fodor (1993) *Nature* 364:555-556), bacteria (Ladner U.S. Pat. No. 5,223,409), spores (Ladner USP '409), plasmids (Cull *et al.* (1992) *Proc Natl Acad Sci USA* 89:1865-1869) or on phage (Scott and Smith (1990) *Science* 249:386-390; Devlin (1990) *Science* 249:404-406; Cwirla *et al.* (1990) *Proc Natl Acad Sci U.S.A.* 87:6378-6382; Felici (1991) *J Mol Biol* 222:301-310; Ladner above.).  
20

In one embodiment, an assay is a cell-based assay in which a cell which expresses a form of BLAA polypeptide, or a biologically active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to a BLAA protein determined. The cell, for example, can be of mammalian origin or be a yeast cell. Determining the ability of the test compound to bind to the BLAA polypeptide can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the BLAA polypeptide or biologically active  
25 portion thereof can be determined by detecting the labeled compound in a complex. For  
30

example, test compounds can be labeled with  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , or  $^3\text{H}$ , either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting.

Alternatively, test compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by

- 5 determination of conversion of an appropriate substrate to product. In one embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of BLAA polypeptide, or a biologically active portion thereof, on the cell surface with a known compound which binds BLAA to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a BLAA
- 10 polypeptide, wherein determining the ability of the test compound to interact with a BLAA polypeptide comprises determining the ability of the test compound to preferentially bind to BLAA or a biologically active portion thereof as compared to the known compound.

- In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of BLAA polypeptide, or a biologically active portion
- 15 thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (*e.g.*, stimulate or inhibit) the activity of the BLAA polypeptide or biologically active portion thereof. Determining the ability of the test compound to modulate the activity of BLAA or a biologically active portion thereof can be accomplished, for example, by determining the ability of the BLAA polypeptide to bind to or interact with a
- 20 BLAA target molecule. As used herein, a "target molecule" is a molecule with which a BLAA polypeptide binds or interacts in nature, for example, a molecule on the surface of a cell which expresses a BLAA-interacting protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. A BLAA target molecule can be a non-BLAA molecule or a
- 25 BLAA protein or polypeptide of the present invention. In one embodiment, a BLAA target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (*e.g.* a signal generated by binding of a compound to a membrane-bound BLAA molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the
- 30 association of downstream signaling molecules with BLAA.

Determining the ability of the BLAA polypeptide to bind to or interact with a BLAA target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of the BLAA polypeptide to bind to or interact with a BLAA target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (*i.e.* intracellular  $\text{Ca}^{2+}$ , diacylglycerol,  $\text{IP}_3$ , etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising a BLAA-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, *e.g.*, luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.

In yet another embodiment, an assay of the present invention is a cell-free assay comprising contacting a BLAA polypeptide or biologically active portion thereof with a test compound and determining the ability of the test compound to bind to the BLAA polypeptide or biologically active portion thereof. Binding of the test compound to the BLAA polypeptide can be determined either directly or indirectly as described above. In one embodiment, the assay comprises contacting the BLAA polypeptide or biologically active portion thereof with a known compound which binds BLAA to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a BLAA polypeptide, wherein determining the ability of the test compound to interact with a BLAA polypeptide comprises determining the ability of the test compound to preferentially bind to BLAA or biologically active portion thereof as compared to the known compound.

In another embodiment, an assay is a cell-free assay comprising contacting BLAA polypeptide or biologically active portion thereof with a test compound and determining the ability of the test compound to modulate (*e.g.* stimulate or inhibit) the activity of the BLAA polypeptide or biologically active portion thereof. Determining the ability of the test compound to modulate the activity of BLAA can be accomplished, for example, by determining the ability of the BLAA polypeptide to bind to a BLAA target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of BLAA can be

accomplished by determining the ability of the BLAA polypeptide further modulate a BLAA target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as previously described.

In yet another embodiment, the cell-free assay comprises contacting the BLAA  
5 polypeptide or biologically active portion thereof with a known compound which binds BLAA to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a BLAA polypeptide, wherein determining the ability of the test compound to interact with a BLAA polypeptide comprises determining the ability of the BLAA polypeptide to preferentially bind to or modulate the activity of a BLAA  
10 target molecule.

The cell-free assays of the present invention are amenable to use of both the soluble form or the membrane-bound form of BLAA. In the case of cell-free assays comprising the membrane-bound form of BLAA, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of BLAA is maintained in solution. Examples of such solubilizing  
15 agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton® X-100, Triton® X-114, Thesit®, Isotridecypoly(ethylene glycol ether), N-dodecyl--N,N-dimethyl-3-ammonio-1-propane sulfonate, 3-(3-cholamidopropyl)dimethylamminiol-1-propane sulfonate (CHAPS), or 3-(3-cholamidopropyl)dimethylamminiol-2-hydroxy-  
20 1-propane sulfonate (CHAPSO).

In more than one embodiment of the above assay methods of the present invention, it may be desirable to immobilize either BLAA or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to BLAA, or interaction of BLAA with a  
25 target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-BLAA fusion proteins or GST-target fusion proteins can be adsorbed onto  
30 glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized

microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or BLAA polypeptide, and the mixture is incubated under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of BLAA binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either BLAA or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated BLAA or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with BLAA or target molecules, but which do not interfere with binding of the BLAA protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or BLAA trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the BLAA or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the BLAA or target molecule.

In another embodiment, modulators of BLAA expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of BLAA mRNA or polypeptide in the cell is determined. The level of expression of BLAA mRNA or polypeptide in the presence of the candidate compound is compared to the level of expression of BLAA mRNA or polypeptide in the absence of the candidate compound. The candidate compound can then be identified as a modulator of BLAA expression based on this comparison. For example, when expression of BLAA mRNA or polypeptide is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of BLAA mRNA or polypeptide expression.

Alternatively, when expression of BLAA mRNA or polypeptide is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of BLAA mRNA or polypeptide expression. The level of BLAA mRNA or protein expression in the cells can be determined by methods described  
5 herein for detecting BLAA mRNA or protein.

In yet another aspect of the invention, a BLAA polypeptide can be used as "bait proteins" in a two-hybrid assay or three hybrid assay (see, *e.g.*, U.S. Pat. No. 5,283,317; Zervos *et al.* (1993) Cell 72:223-232; Madura *et al.* (1993) J Biol Chem 268:12046-12054; Bartel *et al.* (1993) Biotechniques 14:920-924; Iwabuchi *et al.* (1993) Oncogene 8:1693-1696;  
10 and Brent WO94/10300), to identify other proteins that bind to or interact with BLAA ("BLAA-binding proteins" or "BLAA-bp") and modulate BLAA activity. Such BLAA-binding proteins are also likely to be involved in the propagation of signals by the BLAA polypeptides as, for example, upstream or downstream elements of the BLAA pathway.

The two-hybrid system is based on the modular nature of most transcription factors,  
15 which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for BLAA is fused to a gene encoding the DNA binding domain of a known transcription factor (*e.g.*, GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation  
20 domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming a BLAA-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (*e.g.*, LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be  
25 detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with BLAA.

In another embodiment, modulators of activity or latency of (*i.e.*, the lack of activity) or predisposition to an immune response-associated disorder are identified wherein a test animal at increased risk for an immune response-associated disorder is administered with a test  
30 compound. The test animal of this embodiment recombinantly expresses a BLAA

polypeptide. The activity of said polypeptide is then measured in the test animal. Next, the activity of the polypeptide is measured in a control animal that recombinantly expresses the polypeptide but that is not at an increased risk for an immune response-associated disorder. Finally, expression in the test animal is compared to the expression in the control animal. A  
5 difference in the test animal relative to the control animal indicates that the test compound is a modulation of activity or latency of or predisposition to an immune response-associated disorder. For example, an increase in expression in the test animal indicates that the test compound is a stimulator of an immune response-associated disorder. Likewise, a decrease in the test animal indicates that the test compound is an inhibitor of an immune response-  
10 associated disorder.

The test animal may be a recombinant test animal that expresses a test protein transgene, as described above, or expresses said transgene under the control of a promoter at increased levels compared to a wild type test animal. In this embodiment, the promoter is not the native promoter of the transgene.

15 This invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.

#### Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. For  
20 example, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; and (ii) identify an individual from a minute biological sample (tissue typing). These applications are described in the subsections below.

#### Chromosome Mapping

25 Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the BLAA sequences described herein, can be used to map the location of the BLAA genes, respectively, on a chromosome.





WO 01/18204

PCT/US00/24220

bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases.

However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000  
5 bases, and more preferably 2,000 bases, will suffice to get good results at a reasonable amount of time. For a review of this technique, see Verma *et al.*, HUMAN CHROMOSOMES: A MANUAL OF BASIC TECHNIQUES (Pergamon Press, New York 1988).

Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for  
10 marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

Once a sequence has been mapped to a precise chromosomal location, the physical  
15 position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in McKusick, MENDELIAN INHERITANCE IN MAN, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, for example,  
20 Egeland *et al.* (1987) *Nature*, 325:783-787.

Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the BLAA gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of  
25 affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

WO 01/18204

PCT/US00/24220

### Tissue Typing

The BLAA sequences of the present invention can also be used to identify individuals from minute biological samples. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for  
5 identification. The sequences of the present invention are useful as additional DNA markers for RFLP ("restriction fragment length polymorphisms," described in U.S. Pat. No. 5,272,057).

Furthermore, the sequences of the present invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected  
10 portions of an individual's genome. Thus, the BLAA sequences described herein can be used to prepare two PCR primers from the 5' and 3' ends of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such  
15 DNA sequences due to allelic differences. The sequences of the present invention can be used to obtain such identification sequences from individuals and from tissue. The BLAA sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs  
20 with a frequency of about once per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction fragment length polymorphisms (RFLPs).

Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because  
25 greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences of SEQ ID NO: 1, SEQ ID NO: 3, and SEQ ID NO: 5 (SEQ ID NOs: 8, 10, and 12, respectively) can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in

SEQ ID NO: 1, 3, 5, 7, 9, and 11 are used, a more appropriate number of primers for individual positive identification would be 500-2000.

### Predictive Medicine

The present invention also pertains to the field of predictive medicine in which  
5 diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the present invention relates to diagnostic assays for determining BLAA polypeptide and/or nucleic acid expression as well as BLAA activity, in the context of a biological sample (*e.g.*, blood, serum, cells, tissue) to thereby determine whether an  
10 individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant BLAA expression or activity. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with BLAA polypeptide or nucleic acid expression or activity. For example, mutations in a BLAA gene can be assayed in a biological sample. Such assays can  
15 be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with BLAA polypeptide or nucleic acid expression or activity.

Another aspect of the invention provides methods for determining BLAA polypeptide or nucleic acid expression or BLAA activity in an individual to thereby select appropriate  
20 therapeutic or prophylactic agents for that individual (referred to herein as "pharmacogenomics"). Pharmacogenomics allows for the selection of agents (*e.g.*, drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (*e.g.*, the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.)

25 Yet another aspect of the invention pertains to monitoring the influence of agents (*e.g.*, drugs, compounds) on the expression or activity of BLAA in clinical trials.

These and other agents are described in further detail in the following sections.

### Diagnostic Assays

An exemplary method for detecting the presence or absence of BLAA in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting BLAA polypeptide or nucleic acid (e.g., mRNA, genomic DNA) that encodes BLAA polypeptide such that the presence of BLAA is detected in the biological sample. An agent for detecting BLAA mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to BLAA mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length BLAA nucleic acid, such as the nucleic acid of SEQ ID NO: 1, 3, 5, 7, 8, 9, 10, 11, or 12, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to BLAA mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

An agent for detecting BLAA polypeptide is an antibody capable of binding to BLAA protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')<sub>2</sub>) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect BLAA mRNA, polypeptide, or genomic DNA in a biological sample *in vitro* as well as *in vivo*. For example, *in vitro* techniques for detection of BLAA mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of BLAA polypeptide include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. *In vitro* techniques for detection of BLAA genomic DNA include Southern hybridizations. Furthermore, *in vivo* techniques for detection of BLAA protein

include introducing into a subject a labeled anti-BLAA antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

5 In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

10 In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting BLAA polypeptide, mRNA, or genomic DNA, such that the presence of BLAA polypeptide, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of BLAA polypeptide, mRNA or genomic DNA in the control sample with the presence of BLAA polypeptide, mRNA or genomic DNA in the test sample.

15 The invention also encompasses kits for detecting the presence of BLAA in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting BLAA polypeptide or mRNA in a biological sample; means for determining the amount of BLAA in the sample; and means for comparing the amount of BLAA in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect BLAA polypeptide or nucleic acid.

## 20 **Prognostic Assays**

The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant BLAA expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk  
25 of developing an immune response-associated disorder associated with BLAA polypeptide or nucleic acid expression or activity such as cancers, infectious diseases, autoimmune disorders, and complications associated with transplantation. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the present invention provides a method for identifying a disease or disorder associated with  
30 aberrant BLAA expression or activity in which a test sample is obtained from a subject and

BLAA polypeptide or nucleic acid (*e.g.*, mRNA, genomic DNA) is detected, wherein the presence of BLAA polypeptide or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant BLAA expression or activity. As used herein, a "test sample" refers to a biological sample obtained from a subject of interest.

5 For example, a test sample can be a biological fluid (*e.g.*, serum), cell sample, or tissue.

Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (*e.g.*, an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant BLAA expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder, such as cancer, infectious disease, autoimmune disorders, and complications associated with transplantation. Thus, the present invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant BLAA expression or activity in which a test sample is obtained and a BLAA polypeptide or nucleic acid is detected (*e.g.*, wherein the presence of a BLAA polypeptide or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant BLAA expression or activity.)

10

15

The methods of the invention can also be used to detect genetic lesions in a BLAA gene, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation. In various embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding a BLAA polypeptide, or the mis-expression of the BLAA gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of (1) a deletion of one or more nucleotides from a BLAA gene; (2) an addition of one or more nucleotides to a BLAA gene; (3) a substitution of one or more nucleotides of a BLAA gene, (4) a chromosomal rearrangement of a BLAA gene; (5) an alteration in the level of a messenger RNA transcript of a BLAA gene, (6) aberrant modification of a BLAA gene, such as of the methylation pattern of the genomic DNA, (7) the presence of a non-wild type splicing pattern of a messenger RNA transcript of a BLAA gene, (8) a non-wild type level of a BLAA polypeptide, (9) allelic loss of

20

25

30

a BLAA gene, and (10) inappropriate post-translational modification of a BLAA polypeptide. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in a BLAA gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. However, any  
5 biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, *e.g.*, U.S. Pat. Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, *e.g.*,  
10 Landegran *et al.* (1988) *Science* 241:1077-1080; and Nakazawa *et al.* (1994) *PNAS* 91:360-364), the latter of which can be particularly useful for detecting point mutations in the BLAA-gene (see Abravaya *et al.* (1995) *Nucl Acids Res* 23:675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (*e.g.*, genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or  
15 more primers that specifically hybridize to a BLAA gene under conditions such that hybridization and amplification of the BLAA gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the  
20 techniques used for detecting mutations described herein.

Alternative amplification methods include: self sustained sequence replication (Guatelli *et al.*, 1990, *Proc Natl Acad Sci USA* 87:1874-1878), transcriptional amplification system (Kwoh, *et al.*, 1989, *Proc Natl Acad Sci USA* 86:1173-1177), Q-Beta Replicase (Lizardi *et al.*, 1988, *BioTechnology* 6:1197), or any other nucleic acid amplification method,  
25 followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

In an alternative embodiment, mutations in a BLAA gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and  
30 control DNA is isolated, amplified (optionally), digested with one or more restriction



endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, for example, U.S. Pat. No. 5,493,531) can be used to score for the presence of specific mutations by development  
5 or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in BLAA can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high density arrays containing hundreds or thousands of oligonucleotide probes (Cronin *et al.* (1996) *Human Mutation* 7: 244-255; Kozal *et al.* (1996) *Nature Medicine* 2: 753-759). For example, genetic mutations in  
10 BLAA can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin *et al.* above. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This step is followed by a second hybridization array that  
15 allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art  
20 can be used to directly sequence the BLAA gene and detect mutations by comparing the sequence of the sample BLAA with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert (1977) *PNAS* 74:560 or Sanger (1977) *PNAS* 74:5463. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the  
25 diagnostic assays (Naeve *et al.*, (1995) *Biotechniques* 19:448), including sequencing by mass spectrometry (see, e.g., PCT International Publ. No. WO 94/16101; Cohen *et al.* (1996) *Adv Chromatogr* 36:127-162; and Griffin *et al.* (1993) *Appl Biochem Biotechnol* 38:147-159).

Other methods for detecting mutations in the BLAA gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or  
30 RNA/DNA heteroduplexes (Myers *et al.* (1985) *Science* 230:1242). In general, the art

technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type BLAA sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S1 nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, for example, Cotton *et al* (1988) *Proc Natl Acad Sci USA* 85:4397; Saleeba *et al* (1992) *Methods Enzymol* 217:286-295. In an embodiment, the control DNA or RNA can be labeled for detection.

In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in BLAA cDNAs obtained from samples of cells. For example, the mutY enzyme of *E. coli* cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches (Hsu *et al.* (1994) *Carcinogenesis* 15:1657-1662). According to an exemplary embodiment, a probe based on a BLAA sequence, *e.g.*, a wild-type BLAA sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, for example, U.S. Pat. No. 5,459,039.

In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in BLAA genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids (Orita *et al.* (1989) *Proc Natl Acad Sci USA*: 86:2766, see also Cotton (1993) *Mutat Res* 285:125-144; Hayashi (1992) *Genet Anal Tech Appl* 9:73-79). Single-stranded DNA fragments of sample and control BLAA nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to

sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject  
5 method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen *et al.* (1991) *Trends Genet* 7:5).

In yet another embodiment the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers *et al.* (1985) *Nature* 313:495). When DGGE is used as the  
10 method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA (Rosenbaum and Reissner (1987) *Biophys Chem* 265:12753).

15 Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found (Saiki *et al.* (1986) *Nature* 324:163); Saiki *et al.*  
20 (1989) *Proc Natl Acad. Sci USA* 86:6230). Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

Alternatively, allele specific amplification technology that depends on selective PCR  
25 amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization) (Gibbs *et al.* (1989) *Nucleic Acids Res* 17:2437-2448) or at the extreme 3' end of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (Prossner  
30 (1993) *Tibtech* 11:238). In addition it may be desirable to introduce a novel restriction site in

5 making it possible to detect the presence of a known mutation at a specific site by looking for  
the presence or absence of amplification.

10 patients exhibiting symptoms or family history of a disease or illness involving a BLAA gene.

Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which BLAA is expressed may be utilized in the prognostic assays described herein. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

15                      **Pharmacogenomics**

Agents, or modulators that have a stimulatory or inhibitory effect on BLAA activity (e.g., BLAA gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders (e.g., cancer, infectious disease, autoimmune disorders, and complications associated with transplantation) associated with aberrant BLAA activity. In conjunction with such treatment, the pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of BLAA polypeptide, expression of BLAA nucleic acid, or mutation content of BLAA genes in an individual can be determined

to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See  
5 *e.g.*, Eichelbaum, *Clin Exp Pharmacol Physiol*, 1996, 23:983-985 and Linder, *Clin Chem*, 1997, 43:254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur  
10 either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is haemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major  
15 determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (*e.g.*, N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are  
20 expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side  
25 effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. The other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.





activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, (i) an aforementioned polypeptide, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to an aforementioned polypeptide; (iii) nucleic acids encoding an aforementioned polypeptide; (iv) administration of antisense nucleic acid and nucleic acids that are "dysfunctional" (*i.e.*, due to a heterologous insertion within the coding sequences of coding sequences to an aforementioned polypeptide) that are utilized to "knockout" endogenous function of an aforementioned peptide by homologous recombination (*sec, e.g.*, Capecchi, 1989, *Science* 244: 1288-1292); or (v) modulators (*i.e.*, inhibitors, agonists and antagonists, including additional polypeptide mimetic of the invention or antibodies specific to a peptide of the invention) that alter the interaction between an aforementioned polypeptide and its binding partner.

Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with therapeutics that increase (*i.e.*, are agonists to) activity. Therapeutics that upregulate activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, an aforementioned polypeptide, or analogs, derivatives, fragments or homologs thereof; or an agonist that increases bioavailability.

Increased or decreased levels can be readily detected by quantifying polypeptide and/or RNA, by obtaining a patient tissue sample (*e.g.*, from biopsy tissue) and assaying it *in vitro* for RNA or peptide levels, structure and/or activity of the expressed polypeptides (or mRNAs of an aforementioned polypeptide). Methods that are well-known within the art include, but are not limited to, immunoassays (*e.g.*, by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect expression of mRNAs (*e.g.*, Northern assays, dot blots, *in situ* hybridization, etc.).

### Prophylactic Methods

In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an aberrant BLAA expression or activity, by administering to the subject an agent that modulates BLAA expression or at least one BLAA activity. Subjects at risk for a disease that is caused or contributed to by aberrant BLAA expression or activity can





Stimulation of BLAA activity is desirable in situations in which BLAA is abnormally downregulated and/or in which increased BLAA activity is likely to have a beneficial effect. One example of such a situation is where a subject has a disorder characterized by aberrant cell proliferation and/or differentiation (*e.g.*, cancer). Another example of such a situation is where the subject has an immune response-associated disorder (*e.g.*, autoimmune disorders, infectious diseases, and complications associated with transplantation).

In one embodiment, this invention involves a method of treating a pathological state in a mammal comprising administering a therapeutic amount of a polypeptide that is at least 95% identical to a polypeptide with an amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, or a biologically active fragment thereof. An alternative embodiment involves administering to a subject an antibody that selectively binds to a BLAA polypeptide, and fragments, homologs, analogs, and derivatives thereof.

#### **Determination of the Biological Effect of the Therapeutic**

In various embodiments of the present invention, suitable *in vitro* or *in vivo* assays are utilized to determine the effect of a specific therapeutic and whether its administration is indicated for treatment of the affected tissue.

In various specific embodiments, *in vitro* assays may be performed with representative cells of the type(s) involved in the patient's disorder, to determine if a given therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for *in vivo* testing, any of the animal model system known in the art may be used prior to administration to human subjects.

#### **Malignancies**

An aforementioned BLAA polypeptide may be involved in the regulation of cell proliferation. Accordingly, therapeutics of the present invention may be useful in the therapeutic or prophylactic treatment of diseases or disorders that are associated with cell hyperproliferation and/or loss of control of cell proliferation (*e.g.*, cancers, malignancies and

tumors). For a review of such hyperproliferation disorders, see *e.g.*, Fishman, *et al.*, 1985. MEDICINE, 2nd ed., J.B. Lippincott Co., Philadelphia, PA.

Therapeutics of the present invention may be assayed by any method known within the art for determining efficacy in treating or preventing malignancies and related disorders. Such assays include, but are not limited to, *in vitro* assays utilizing transformed cells or cells derived from the patient's tumor, as well as *in vivo* assays using animal models of cancer or malignancies. Potentially effective therapeutics are those that, for example, inhibit the proliferation of tumor-derived or transformed cells in culture or cause a regression of tumors in animal models, in comparison to the controls.

In the practice of the present invention, once a malignancy or cancer has been shown to be amenable to treatment by modulating (*i.e.*, inhibiting, antagonizing, or agonizing) activity, that cancer or malignancy may subsequently be treated or prevented by the administration of a therapeutic that serves to modulate polypeptide function.

#### Disorders related to organ transplantation

BLAA has been implicated in disorders related to organ transplantation, in particular, but not limited to, organ rejection. Therapeutics of the invention, particularly those that modulate (or supply) activity, may be effective in treating or preventing diseases or disorders related to organ transplantation. Therapeutics of the invention (particularly therapeutics that modulate the levels or activity of an aforementioned protein) can be assayed by any method known in the art for efficacy in treating or preventing such diseases and disorders related to organ transplantation. Such assays include *in vitro* assays for using cell culture models as described below, or *in vivo* assays using animal models of diseases and disorders related to organ transplantation, see *e.g.*, below. Potentially effective therapeutics, for example, but not by way of limitation, reduce immune rejection responses in animal models in comparison to controls.

Accordingly, once diseases and disorders related to organ transplantation are shown to be amenable to treatment by modulation of activity, such diseases or disorders can be treated or prevented by administration of a therapeutic that modulates activity.

### **T lymphocyte Growth and Activation Cell Proliferation/Differentiation Activity**

The BLAA polypeptide disclosed in the instant invention is a new B7 family member. B7 family members, such as B7-1 and B7-2, are members of the immunoglobulin superfamily and bind to activated T lymphocytes and provide regulatory signals for T lymphocyte cell growth than activation.

### **Immune Stimulating or Suppressing Activity**

A BLAA polypeptide of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), *e.g.*, in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (*e.g.*, HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases caused by viral, bacterial, fungal or other infection may be treatable using a polypeptide of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania species, malaria species, and various fungal infections such as candidiasis. Of course, in this regard, a polypeptide of the present invention may also be useful where a boost to the immune system generally may be desirable, *i.e.*, in the treatment of cancer.

Autoimmune disorders which may be treated using a polypeptide of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a polypeptide of the present invention may also be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a polypeptide of the present invention.

Using the polypeptide of the invention to modulate immune responses in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response

already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or energy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon re-exposure to specific antigen in the absence of the tolerizing agent.

Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as, for example, B7)), *e.g.*, preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (*e.g.*, B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to energize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of B lymphocyte antigens.

The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans.

Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins *in vivo* as described in Lenschow *et al.*, Science 257:789-792 (1992) and Turka *et al.*, Proc Natl Acad Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., FUNDAMENTAL IMMUNOLOGY, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function *in vivo* on the development of that disease.

Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and auto-antibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of auto-antibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythematosus in MRL/lpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., FUNDAMENTAL IMMUNOLOGY, Raven Press, New York, 1989, pp. 840-856).

Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.

Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells *in vitro* with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the *in vitro* activated T cells  
5 into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T  
10 cells *in vivo*.

In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (*e.g.*, sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a  
15 subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected *ex vivo* with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to  
20 result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection *in vivo*.

The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor  
25 cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (*e.g.*, a cytoplasmic-domain truncated portion) of an MHC class I  $\alpha$  chain protein and  $\beta_2$  microglobulin protein or an MHC class II  $\alpha$  chain protein and an MHC class II  $\beta$  chain protein to thereby express MHC class I or MHC  
30 class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in

conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell.

Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA

- 5 encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

- The activity of a polypeptide of the invention may, among other means, be measured  
10 by the following methods: Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described In: CURRENT PROTOCOLS IN IMMUNOLOGY. Coligan *et al.*, eds. Greene Publishing Associates and Wiley-Interscience (Chapter 3, Chapter 7); Herrmann *et al.*, *Proc Natl Acad Sci USA* 78:2488-2492, 1981; Herrmann *et al.*, *J Immunol* 128:1968-1974, 1982; Handa *et al.*, *J Immunol* 135:1564-1572, 1985; Takai *et al.*, *J Immunol* 137:3494-3500, 1986; Takai *et al.*, *J Immunol* 140:508-512, 1988; Herrmann *et al.*, *Proc Natl Acad Sci USA* 78:2488-2492, 1981; Herrmann *et al.*, *J Immunol* 128:1968-1974, 1982; Handa *et al.*, *J Immunol* 135:1564-1572, 1985; Takai *et al.*, *J Immunol* 137:3494-3500, 1986; Bowman *et al.*, *J Virology* 61:1992-1998; Takai *et al.*, *J Immunol* 140:508-512, 1988; Bertagnolli *et al.*, *Cell Immunol* 133:327-341, 1991; Brown *et al.*, *J Immunol* 153:3079-3092,  
15 1994.  
20

- Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, *J Immunol* 144:3028-3033, 1990; and Mond and Brunswick In: CURRENT PROTOCOLS IN  
25 IMMUNOLOGY. Coligan *et al.*, (eds.) Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto 1994.

- Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described In: CURRENT PROTOCOLS IN IMMUNOLOGY. Coligan *et al.*, eds. Greene Publishing  
30 Associates and Wiley-Interscience (Chapter 3, Chapter 7); Takai *et al.*, *J Immunol*



137:3494-3500, 1986; Takai *et al.*, *J Immunol* 140:508-512, 1988; Bertagnolli *et al.*, *J Immunol* 149:3778-3783, 1992.

Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in:

- 5 Guery *et al.*, *J Immunol* 134:536-544, 1995; Inaba *et al.*, *J Exp Med* 173:549-559, 1991; Macatonia *et al.*, *J Immunol* 154:5071-5079, 1995; Porgador *et al.*, *J Exp Med* 182:255-260, 1995; Nair *et al.*, *J Virol* 67:4062-4069, 1993; Huang *et al.*, *Science* 264:961-965, 1994; Macatonia *et al.*, *J Exp Med* 169:1255-1264, 1989; Bhardwaj *et al.*, *J Clin Investig* 94:797-807, 1994; and Inaba *et al.*, *J Exp Med* 172:631-640, 1990.

- 10 Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz *et al.*, *Cytometry* 13:795-808, 1992; Gorczyca *et al.*, *Leukemia* 7:659-670, 1993; Gorczyca *et al.*, *Cancer Res* 53:1945-1951, 1993; Itoh *et al.*, *Cell* 66:233-243, 1991; Zacharchuk, *J Immunol* 15  
15 145:4037-4045, 1990; Zamai *et al.*, *Cytometry* 14:891-897, 1993; Gorczyca *et al.*, *Internat J Oncol* 1:639-648, 1992.

- Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica *et al.*, *Blood* 84:111-117, 1994; Fine *et al.*, *Cell Immunol* 155: 111-122, 1994; Galy *et al.*, *Blood* 85:2770-2778, 1995; Toki *et al.*,  
20 *Proc Nat Acad Sci USA* 88:7548-7551, 1991.

#### Other Activities

- A polypeptide of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites;  
25 effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism,  
30 processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate,

vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and 15 accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

The contents of all references, patents and published patent applications cited throughout this application are hereby incorporated by reference.

## EQUIVALENTS

20 It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

We Claim:

1. An isolated nucleic acid molecule encoding a B lymphocyte activation antigen ("BLAA"), wherein said molecule comprises a nucleotide sequence encoding a polypeptide having a sequence that is at least 95% identical to SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, or the complement of said nucleic acid molecule.
2. The nucleic acid molecule of claim 1, wherein said molecule hybridizes under stringent conditions to a nucleic acid sequence complementary to a nucleic acid molecule comprising the sequence of nucleotides of SEQ ID NO: 1, SEQ ID NO: 3, or SEQ ID NO: 5, or the complement of said nucleic acid molecule.
3. The nucleic acid molecule of claim 1, wherein said nucleotide sequence encodes a human BLAA.
4. The nucleic acid molecule of claim 1, wherein said molecule encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, or an amino acid sequence comprising one or more conservative substitutions in the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6.
5. The nucleic acid molecule of claim 1, wherein said molecule encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, or the complement of said nucleic acid molecule.
6. An oligonucleotide of less than 100 nucleotides in length and comprising at least 6 contiguous nucleotides of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, or SEQ ID NO: 12, or a complement thereof.
7. A vector comprising the nucleic acid molecule of claim 1.
8. The vector of claim 7, wherein said vector is an expression vector.
9. The vector of claim 7, further comprising a regulatory element operably linked to said nucleic acid molecule.

10. An isolated polypeptide at least 80% identical to a polypeptide selected from the group consisting of:
- (a) a polypeptide comprising an amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6;
  - (b) a fragment of a polypeptide comprising an amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, wherein the fragment comprises at least 6 contiguous amino acids of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6;
  - (c) a derivative of a polypeptide comprising an amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6;
  - (d) an analog of a polypeptide comprising an amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6;
  - (e) a homolog of a polypeptide comprising an amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6;
  - (f) a naturally occurring allelic variant of a polypeptide comprising an amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, wherein the polypeptide is encoded by a nucleic acid molecule that hybridizes to a nucleic acid molecule of SEQ ID NO: 1, SEQ ID NO: 3, or SEQ ID NO: 5 under stringent conditions.
11. The polypeptide of claim 10, wherein the polypeptide, or fragment thereof, has human B lymphocyte activation antigen B7-like activity.
12. An antibody that selectively binds to the polypeptide of claim 10.
13. A method of producing the polypeptide of claim 10, said method comprising the step of culturing a host cell under conditions in which the nucleic acid molecule is expressed.

14. A method of detecting the presence of the polypeptide of claim 10 in a sample, the method comprising contacting the sample with a compound that selectively binds to the polypeptide of claim 10 and determining whether the compound bound to the polypeptide of claim 10 is present in the sample.
15. A method of detecting the presence of the nucleic acid molecule of claim 1 in a sample, the method comprising contacting the sample with a nucleic acid probe or primer that selectively binds to the nucleic acid molecule of claim 1 and determining whether the nucleic acid probe or primer bound to the nucleic acid molecule of claim 1 is present in the sample.
16. A method for modulating the activity of the polypeptide of claim 10, the method comprising contacting a cell sample comprising the polypeptide of claim 10 with a compound that binds to said polypeptide in an amount sufficient to modulate the activity of the polypeptide.
17. A method of treating or preventing an immune response-associated disorder, said method comprising administering, to a subject, in which such treatment or prevention is desired, an effective amount of a therapeutic selected from the group consisting of:
- (a) the nucleic acid of claim 1;
  - (b) the polypeptide of claim 10; and
  - (c) the antibody of claim 12,
- wherein said therapeutic is administered in an amount sufficient to treat said immune response-associated disorder in said subject.
18. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of a therapeutic selected from the group consisting of:
- (a) the nucleic acid of claim 1;
  - (b) the polypeptide of claim 10; and



22. The method of claim 21, wherein said test animal is a recombinant test animal that expresses a test protein transgene or expresses said transgene under the control of a promoter at an increased level relative to a wild-type test animal, and wherein said promoter is not the native promoter of said transgene.
23. A method for determining the presence of or predisposition to a disease associated with altered levels of a BLAA polypeptide of claim 10, the method comprising:
- (a) measuring the amount of the polypeptide in a sample from a mammalian subject; and
  - (b) comparing the amount of said polypeptide in step (a) to the amount of the polypeptide present in a control sample.
- wherein an alteration in the level of the polypeptide in step (a) as compared to the control sample indicates a disease condition.
24. A method for determining the presence of or predisposition to a disease associated with altered levels of a BLAA nucleic acid of claim 1, the method comprising:
- (a) measuring the amount of the nucleic acid in a sample from a mammalian subject; and
  - (b) comparing the amount of the nucleic acid in step (a) to the amount of the nucleic acid present in a control sample,
- wherein an alteration in the level of the nucleic acid in step (a) as compared to the control sample indicates a disease condition.
25. A method of treating a pathological state in a mammal, the method comprising administering to the subject a polypeptide of claim 10, in an amount to alleviate the pathological state.
26. A method of treating a pathological state in a mammal, the method comprising administering to a subject, the antibody of claim 12 in an amount sufficient to alleviate the pathological state.

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
15 March 2001 (15.03.2001)

PCT

(10) International Publication Number  
**WO 01/18204 A1**(51) International Patent Classification: **C12N 15/12**,  
15/85, C07K 14/705, 16/28, C12Q 1/68, G01N 33/50,  
33/53, A61K 38/17

(21) International Application Number: PCT/US00/24220

(22) International Filing Date: 31 August 2000 (31.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/152,383 3 September 1999 (03.09.1999) US  
60/172,909 21 December 1999 (21.12.1999) US  
60/183,578 18 February 2000 (18.02.2000) US  
09/651,200 30 August 2000 (30.08.2000) US(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier applications:  
US 60/152,383 (CIP)  
Filed on 3 September 1999 (03.09.1999)  
US 60/172,909 (CIP)  
Filed on 21 December 1999 (21.12.1999)  
US 60/183,578 (CIP)  
Filed on 18 February 2000 (18.02.2000)  
US Not furnished (CIP)  
Filed on 30 August 2000 (30.08.2000)(71) Applicants (for all designated States except US): CURA-  
GEN CORPORATION [US/US]; 555 Long Wharf Drive,  
11th Floor, New Haven, CT 06511 (US). BIOGEN, INC.  
[US/US]; 14 Cambridge Center, Cambridge, MA 02142  
(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GREEN, Cynthia

[US/US]; 29 Twin Bridge Road, Madison, CT 06443  
(US), KOTELIANSKI, Victor [RU/US]; 4 Charlesgate  
East, Apartment 405, Boston, MA 02215 (US). DE  
FOUGEROLLES, Antonin [CA/US]; 11 Lancaster  
Terrace, Brookline, MA 02446 (US). CARULLI, John  
[US/US]; 9 Harris Drive, Southborough, MA 01772  
(US). HESSION, Catherine [US/US]; 35 Otis Hill Road,  
Hingham, MA 02043 (US).(74) Agent: ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris,  
Glovsky and Popeo, P.C., One Financial Center, Boston,  
MA 02111 (US).(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

## Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: POLYNUCLEOTIDES ENCODING MEMBERS OF THE HUMAN B LYMPHOCYTE ACTIVATION ANTIGEN B7 FAMILY AND POLYPEPTIDES ENCODED THEREBY

(57) Abstract: The present invention provides novel isolated BLAA polynucleotides and the membrane-associated or secreted polypeptides encoded by the BLAA polynucleotides. Also provided are the antibodies that immunospecifically bind to a BLAA polypeptide or any derivative, variant, mutant or fragment of the BLAA polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the BLAA polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.

WO 01/18204 A1



1/13

Translated Protein-Frame: 3-Nucleotide 111 to 1130  
mz5004\_vh.seq Length: 2691 24/Aug/1999

1 GCGGCCGCGTGACCATCACGTGCTCCAGCTACCAGGGCTACCCTG  
46 AGGCTGAGGTGTTCTGGCAGGATGGGCAGGGTGTGCCCTGACTG  
91 GCAACGTGACCACGTGCGCAGATGGCCAACGAGCAGGGCTTGTTTG  
MetAlaAsnGluGlnGlyLeuPheA  
136 ATGTGCACAGCATCCTGCGGGTGGTGTGGGTGCAAATGGCACCT  
spValHisSerIleLeuArgValValLeuGlyAlaAsnGlyThrT  
181 ACAGCTGCCTGGTGCACAACCCCGTGCTGCAGCAGGATGCGCACA  
yrSerCysLeuValArgAsnProValLeuGlnGlnAspAlaHisS  
226 GCTCTGTCAACCATCACACCCAGAGAAGCCCCACAGGAGCCGTGG  
erSerValThrIleThrProGlnArgSerProThrGlyAlaValG  
271 AGGTCCAGGTCCCTGAGGACCCGGTGGTGGCCCTAGTGGGCACCG  
luValGlnValProGluAspProValValAlaLeuValGlyThrA  
316 ATGCCACCCCTGCACTGCTCCTTCTCCCCGAGCCTGGCTTCAGCC  
spAlaThrLeuHisCysSerPheSerProGluProGlyPheSerL  
361 TGACACAGCTCAACCTCATCTGGCAGCTGACAGACACCAAACAGC  
euThrGlnLeuAsnLeuIleTrpGlnLeuThrAspThrLysGlnL  
406 TGGTGCACAGTTTCACCGAAGGCCGGGACCAGGGCAGCGCCTATG  
euValHisSerPheThrGluGlyArgAspGlnGlySerAlaTyrA  
451 CCAACCGCACGGCCCTCTTCCCGGACCTGCTGGCACAAGGCAATG  
laAsnArgThrAlaLeuPheProAspLeuLeuAlaGlnGlyAsnA  
496 CATCCCTGAGGCTGCAGCGCGTGGTGTGGCGGACGAGGGCAGCT  
laSerLeuArgLeuGlnArgValArgValAlaAspGluGlySerP  
541 TCACCTGCTTCGTGAGCATCCGGGATTTCCGGCAGCGCTGCCGTCA  
heThrCysPheValSerIleArgAspPheGlySerAlaAlaValS  
586 GCCTGCAGGTGGCCGCTCCCTACTCGAAGCCCAGCATGACCCCTGG  
erLeuGlnValAlaAlaProTyrSerLysProSerMetThrLeuG  
631 AGCCCAACAAGGACCTGCGGCCAGGGGACACGGTGACCATCACGT  
luProAsnLysAspLeuArgProGlyAspThrValThrIleThrc  
676 GCTCCAGCTACCGGGGCTACCCTGAGGCTGAGGTGTTCTGGCAGG  
ysSerSerTyrArgGlyTyrProGluAlaGluValPheTrpGlnA  
721 ATGGGCAGGGTGTGCCCCTGACTGGCAACGTGACCACGTGCGAGA  
spGlyGlnGlyValProLeuThrGlyAsnValThrThrSerGLNM  
766 TGGCCAACGAGCAGGGCTTGTTTGATGTGCACAGCGTCCTGCGGG  
etAlaAsnGluGlnGlyLeuPheAspValHisSerValLeuArgV

Fig. 1

SUBSTITUTE SHEET (RULE 26)

2/13

811 TGGTGCTGGGTGCGAATGGCACCTACAGCTGCCTGGTGCGCAACC  
alValLeuGlyAlaAsnGlyThrTyrSerCysLeuValArgAsnP

856 CCGTGCTGCAGCAGGATGCGCACGGCTCTGTACCATCACAGGGC  
roValLeuGlnGlnAspAlaHisGlySerValThrIleThrGlyG

901 AGCCTATGACATTCCCCCAGAGGCCCTGTGGGTGACCGTGGGGC  
lnProMetThrPheProProGluAlaLeuTrpValThrValGlyL

946 TCTCTGTCTGTCTCATTGCACTGCTGGTGGCCCTGGCTTTCGTGT  
euSerValCysLeuIleAlaLeuLeuValAlaLeuAlaPheValC

991 GCTGGAGAAAGATCAAACAGAGCTGTGAGGAGGAGAATGCAGGAG  
ysTrpArgLysIleLysGlnSerCysGluGluGluAsnAlaGlyA

1036 CCGAGGACCAGGATGGGGAGGGAGAAGGCTCCAAGACAGCCCTGC  
laGluAspGlnAspGlyGluGlyGluGlySerLysThrAlaLeuG

1081 AGCCTCTGAAACACTCTGACAGCAAAGAAGATGATGGACAAGAAA  
lnProLeuLysHisSerAspSerLysGluAspAspGlyGlnGluI

1126 TAGCCTGACCATGAGGACCAGGGAGCTGCTACCCCTCCCTACAGC  
leAla

1171 TCCTACCCTCTGGCTGCAATGGGGCTGCACTGTGAGCCCTGCCCC  
1216 CAACAGATGCATCCTGCTCTGACAGGTGGGCTCCTTCTCCAAAGG  
1261 ATGCGATACACAGACCCTGTGCAGCCTTATTTCTCCAATGGACA  
1306 TGATTCCCAAGTCATCCTGCTGCCTTTTTTCTTATAGACACAATG  
1351 AACAGACCACCCACAACCTTAGTTCTCTAAGTCATCCTGCCTGCT  
1396 GCCTTATTTTACAGTACATACATTTCTTAGGGACACAGTACACTG  
1441 ACCACATCACACCCTCTTCTTCCAGTGCTGCGTGGACCATCTGG  
1486 CTGCCTTTTTTCTCCAAAAGATGCAATATTCAGACTGACTGACCC  
1531 CCTGCCTTATTTACCAAAGACACGATGCATAGTCACCCCGGCCT  
1576 TGTTTCTCCAATGGCCGTGATACACTAGTGATCATGTTACGCCCT  
1621 GCTTCCACCTGCATAGAATCTTTTCTTCTCAGACAGGGACAGTGC  
1666 GGCCTCAACATCTCCTGGAGTCTAGAAGCTGTTTCTTCCCTC  
1711 CTTCTCCTCTTGCTCTAGCCTTAATACTGGCCTTTTCCCTCCCT  
1756 GCCCCAAGTGAAAGACAGGGCACTCTGCGCCCAACCATGCACAGC  
1801 TGTGCATGGAGACCTGCAGGTGCACGTGCTGGAACACGTGTGGTT  
1846 CCCCCCTGGCCAGCCTCCTCTGCAGTGCCCCCTCTCCCCCTGCCCA  
1891 TCCTCCCCACGGAAGCATGTGCTGGTCACACTGGTTCTCCAGGGG  
1936 TCTGTGATGGGGCCCCCTGGGGGTGAGCTTCTGTCCCTCTGCCTTC  
1981 TCACCTCTTTGTTCTTTCTTTTTCATGTATCCATTTCAGTTGATGT  
2026 TTATTGAGCAACTACAGATGTCAGCACTGTGTTAGGTGCTGGGGG  
2071 CCCTGCGTGGGAAGATAAAGTTCCCTCCCTCAAGGACTCCCCATCC  
2116 AGCTGGGAGACAGACAACCTAATACTGACACTGCACCCCTGCGGTTTGCA  
2161 GGGGGCTCCTGCCTGGCTCCCTGCTCCACACCTCCTCTGTGGCTC  
2206 AAGGCTTCTTGGATACCTCACCCCATCCCAACCCATAATTCTTAC  
2251 CCAGAGCATGGGGTTGGGGCGGAAACCTGGAGAGAGGGACATAGC  
2296 CCCTCGCCACGGCTAGAGAATCTGGTGGTGTCCAAAATGTCTGTC  
2341 CAGGTGTGGGCAGGTGGGCAGGCACCAAGGCCCTCTGGACCTTTC  
2386 ATAGCAGCAGAAAAGGCAGAGCCTGGGGCAGGGCAGGGCCAGGAA  
2431 TGCTTTGGGGACACCGAGGGGACTGCCCCCAACCCCAACCATGGT  
2476 GCTATTCTGGGGCTGGGGCAGTCTTTTCTGCTTGCCTCTGGCC  
2521 AGCTCCCGGCCTCTGGTAGAGTGAGACTTCAGACGTTCTGATGCC

Fig. 1 Continued

10/069626

WO 01/18204

PCT/US00/24220

3/13

2566 TTCCGGATGTCATCTCTCCCTGCCCCAGGAATGGAAGATGTGAGG  
2611 ACTTCTAATTTAAATGTGGGACTCGGAGGGATTTTGTAAACTGGG  
2656 GGTATATTTTGGGGAAAATAAATGTCTTTGTAAAAA

Fig. 1 Continued

SUBSTITUTE SHEET (RULE 26)

Translated Protein-Frame: 2-Nucleotide 2 to 1324  
Mz5004 12/16/99

1 CCCTCTTCCCGGACCTGCTGGCACAGGGCAACGCATCCCTGAGGC  
ProLeuProGlyProAlaGlyThrGlyGlnArgIleProGluAl  
46 TGCAGCGCGTGCCTGTAGCGGACGAGGGCAGCTTCACCTGCTTCG  
aAlaAlaArgAlaCysSerGlyArgGlyGlnLeuHisLeuLeuAr  
91 TGAGCATCCGGGATTTCCGGCAGCGCTGCCGTCAGCCTGCAGGTGG  
gGluHisProGlyPheArgGlnArgCysArgGlnProAlaGlyGl  
136 CCGCTCCCTACTCGAAGCCCAGCATGACCCTGGAGCCCAACAAGG  
yArgSerLeuLeuGluAlaGlnHisAspProGlyAlaGlnGlnGl  
181 ACCTGCGGCCAGGGGACACGGTGTGACCATCACGTGCTCCAGCTA  
yProAlaAlaArgGlyHisGlyValThrIleThrCysSerSerTy  
226 CCAGGGCTACCCTGAGGCTGAGGTGTTCTGGCAGGATGGGCAGGG  
rGlnGlyTyrProGluAlaGluValPheTrpGlnAspGlyGlnGl  
271 TGTGCCCCCTGACTGGCAACGTGACCACGTCGCAGATGGCCAACGA  
yValProLeuThrGlyAsnValThrThrSerGlnMetAlaAsnGl  
316 GCAGGGCTTGTTTGATGTGCACAGCATCCTGCGGGTGGTGCTGGG  
uGlnGlyLeuPheAspValHisSerIleLeuArgValValLeuGl  
361 TGCAAATGGCACCTACAGCTGCCTGGTGCACAACCCCGTGCTGCA  
yAlaAsnGlyThrTyrSerCysLeuValArgAsnProValLeuGl  
406 GCAGGATGCGCACAGCTCTGTCAACCATCACACCCAGAGAAGCCC  
nGlnAspAlaHisSerSerValThrIleThrProGlnArgSerPr  
451 CACAGGAGCCGTGGAGGTCCAGGTCCCTGAGGACCCGGTGGTGGC  
oThrGlyAlaValGluValGlnValProGluAspProValValAl  
496 CCTAGTGGGCACCGATGCCACCCCTGCACTGCTCCTTCTCCCCGA  
aLeuValGlyThrAspAlaThrLeuHisCysSerPheSerProGl  
541 GCCTGGCTTCAGCCTGACACAGCTCAACCTCATCTGGCAGCTGAC  
uProGlyPheSerLeuThrGlnLeuAsnLeuIleTrpGlnLeuTh  
586 AGACACCAAACAGCTGGTGCACAGTTTCACCGAAGGCCGGGACCA  
rAspThrLysGlnLeuValHisSerPheThrGluGlyArgAspGl  
631 GGGCAGCGCCTATGCCAACCGCACGGCCCTCTTCCCGGACCTGCT  
nGlySerAlaTyrAlaAsnArgThrAlaLeuPheProAspLeuLe  
676 GGCACAAGGCAATGCATCCCTGAGGCTGCAGCGCGTCCGTGTGGC  
uAlaGlnGlyAsnAlaSerLeuArgLeuGlnArgValArgValAl  
721 GGACGAGGGCAGCTTCACCTGCTTCGTGAGCATCCGGGATTTCCG  
aAspGluGlySerPheThrCysPheValSerIleArgAspPheGl

Fig. 2

SUBSTITUTE SHEET (RULE 26)

766 CAGCGCTGCCGTCAGCCTGCAGGTGGCCGCTCCCTACTCGAAGCC  
ySerAlaAlaValSerLeuGlnValAlaAlaProTyrSerLysPr  
811 CAGCATGACCCTGGAGCCCAACAAGGACCTGCGGCCAGGGGACAC  
oSerMetThrLeuGluProAsnLysAspLeuArgProGlyAspTh  
856 GGTGACCATCACGTGCTCCAGCTACCGGGGCTACCCTGAGGCTGA  
rValThrIleThrCysSerSerTyrArgGlyTyrProGluAlaGl  
901 GGTGTTCTGGCAGGATGGGCAGGGTGTGCCCTGACTGGCAACGT  
uValPheTrpGlnAspGlyGlnGlyValProLeuThrGlyAsnVa  
946 GACCACGTCGCAGATGGCCAACGAGCAGGGCTTGTGTTGATGTGCA  
lThrThrSerGlnMetAlaAsnGluGlnGlyLeuPheAspValHi  
991 CAGCGTCCTGCGGGTGGTGCTGGGTGCGAATGGCACCTACAGCTG  
sSerValLeuArgValValLeuGlyAlaAsnGlyThrTyrSerCy  
1036 CCTGGTGCGCAACCCCGTGCTGCAGCAGGATGCGCACGGCTCTGT  
sLeuValArgAsnProValLeuGlnGlnAspAlaHisGlySerVa  
1081 CACCATCACAGGGCAGCCTATGACATTCCCCCAGAGGCCCTGTG  
lThrIleThrGlyGlnProMetThrPheProProGluAlaLeuTr  
1126 GGTGACCGTGGGGCTCTCTGTCTGTCTCATTGCACTGCTGGTGGC  
pValThrValGlyLeuSerValCysLeuIleAlaLeuLeuValAl  
1171 CCTGGCTTTCGTGTGCTGGAGAAAGATCAAACAGAGCTGTGAGGA  
aLeuAlaPheValCysTrpArgLysIleLysGlnSerCysGluGl  
1216 GGAGAATGCAGGAGCCGAGGACCAGGATGGGGAGGGAGAAGGCTC  
uGluAsnAlaGlyAlaGluAspGlnAspGlyGluGlyGluGlySe  
1261 CAAGACAGCCCTGCAGCCTCTGAAACACTCTGACAGCAAAGAAGA  
rLysThrAlaLeuGlnProLeuLysHisSerAspSerLysGluAs  
1306 TGATGGACAAGAAATAGCCTGACCATGAGGACCAGGGAGCTGCTA  
pAspGlyGlnGluIleAla  
1351 CCCCTCCCTACAGCTCCTACCCTCTGGCTGCAATGGGGCTGCACT  
1396 GTGAGCCCTGCCCCCAACAGATGCATCCTGCTCTGACAGGTGGGC  
1441 TCCTTCTCCAAAGGATGCGATACACAGACCACTGTGCAGCCTTAT  
1486 TTCTCCAATGGACATGATTCCCAAGTCATCCTGCTGCCTTTTTTC  
1531 TTATAGACACAATGAACAGACCACCCACAACCTTAGTTCTCTAAG  
1576 TCATCCTGCCTGCTGCCTTATTTACAGTACATACATTTCTTAGG  
1621 GACACAGTACACTGACCACATCACCACCCTCTTCTTCCAGTGCTG  
1666 CGTGGACCATCTGGCTGCCTTTTTTCTCCAAAAGATGCAATATTC

Fig. 2 Continued

6/13

1711 AGACTGACTGACCCCCCTGCCTTATTTACCAAAGACACGATGCAT  
1756 AGTCACCCCGGCCTTGTTTCTCCAATGGCCGTGATACACTAGTGA  
1801 TCATGTTTCAGCCCTGCTTCCACCTGCATAGAATCTTTTCTTCTCA  
1846 GACAGGGACAGTGCGGCCTCAACATCTCCTGGAGTCTAGAAGCTG  
1891 TTTCCCTTTCCCTCCTTCCCTCCTCTTGCTCTAGCCTTAATACTGG  
1936 CCTTTTCCCTCCCTGCCCCAAGTGAAGACAGGGCACTCTGCGCCC  
1981 ACCACATGCACAGCTGTGCATGGAGACCTGCAGGTGCACGTGCTG  
2026 GAACACGTGTGGTTCCCCCCTGGCCCAGCCTCCTCTGCAGTGCCC  
2071 CTCTCCCCCTGCCCATCCTCCCCACGGAAGCATGTGCTGGTCACAC  
2116 TGGTTCTCCAGGGGTCTGTGATGGGGCCCCCTGGGGGTGAGCTTCT  
2161 GTCCCTCTGCCTTCTCACCTCTTTGTTCCCTTTCTTTTCATGTATC  
2206 CATTTCAGTTGATGTTTATTGAGCAACTACAGATGTCAGCACTGTG  
2251 TTAGGTGCTGGGGGCCCTGCGTGGAAGATAAAGTTCCTCCCTCA  
2296 AGGACTCCCCATCCAGCTGGGAGACAGACAACTAACTACACTGCA  
2341 CCCTGCGGTTTGCAGGGGGCTCCTGCCTGGCTCCCTGCTCCACAC  
2386 CTCCTCTGTGGCTCAAGGCTTCTGATACCTCACCCCCATCCCA  
2431 CCCATAATTCTTACCCAGAGCATGGGGTTGGGGCGGAAACCTGGA  
2476 GAGAGGGACATAGCCCCCTCGCCACGGCTAGAGAATCTGGTGGTGT  
2521 CCAAAATGTCTGTCCAGGTGTGGGCAGGTGGGCAGGCACCAAGGC  
2566 CCTCTGGACCTTTCATAGCAGCAGAAAAGGCAGAGCCTGGGGCAG  
2611 GGCAGGGCCAGGAATGCTTTGGGGACACCGAGGGGACTGCCCCC  
2656 ACCCCCCACCATGGTGCTATTCTGGGGCTGGGGCAGTCTTTTCCTG  
2701 GCTTGCCTCTGGCCAGCTCCCGGCCTCTGGTAGAGTGAGACTTCA  
2746 GACGTTCTGATGCCCTCCGGATGTCATCTCTCCCTGCCCCAGGAA  
2791 TGGAAGATGTGAGGACTTCTAATTTAAATGTGGGACTCGGAGGGA  
2836 TTTTGTAAGTGGGGGTATATTTTGGGGAAAATAAATGTCTTTGT  
2881 AAAAA

Fig. 2 Continued

7/13

Translated Protein 534 aa-Frame: 3-Nucleotide 60 to 1661  
2/14/00

1 GCGGCCGCGGGGCAGCCTTCCACCACGGGGAGCCCAGCTGTCAGC  
46 CGCCTCACAGGAAGATGCTGCGTCGGCGGGGCAGCCCTGGCATGG  
MetLeuArgArgArgGlySerProGlyMetG  
91 GTGTGCATGTGGGTGCAGCCCTGGGAGCACTGTGGTTCTGCCTCA  
lyValHisValGlyAlaAlaLeuGlyAlaLeuTrpPheCysLeuT  
136 CAGGAGCCCTGGAGGTCCAGGTCCCTGAAGACCCAGTGGTGGCAC  
hrGlyAlaLeuGluValGlnValProGluAspProValValAlaL  
181 TGGTGGGCACCGATGCCACCCTGTGCTGCTCCTTCTCCCCTGAGC  
euValGlyThrAspAlaThrLeuCysCysSerPheSerProGluP  
226 CTGGCTTCAGCCTGGCACAGCTCAACCTCATCTGGCAGCTGACAG  
roGlyPheSerLeuAlaGlnLeuAsnLeuIleTrpGlnLeuThrA  
271 ATACCAAACAGCTGGTGCACAGCTTTGCTGAGGGCCAGGACCAGG  
spThrLysGlnLeuValHisSerPheAlaGluGlyGlnAspGlnG  
316 GCAGCGCCTATGCCAACC GCACGGCCCTCTTCCCGGACCTGCTGG  
lySerAlaTyrAlaAsnArgThrAlaLeuPheProAspLeuLeuA  
361 CACAGGGCAACGCATCCCTGAGGCTGCAGCGCGTGCCTGTGGCGG  
laGlnGlyAsnAlaSerLeuArgLeuGlnArgValArgValAlaA  
406 ACGAGGGCAGCTTCACCTGCTTCGTGAGCATCCGGGATTTCGGCA  
spGluGlySerPheThrCysPheValSerIleArgAspPheGlyS  
451 GCGCTGCCGTCAGCCTGCAGGTGGCCGCTCCCTACTCGAAGCCCA  
erAlaAlaValSerLeuGlnValAlaAlaProTyrSerLysPros  
496 GCATGACCCTGGAGCCCAACAAGGACCTGCGGCCAGGGGACACGG  
erMetThrLeuGluProAsnLysAspLeuArgProGlyAspThrV  
541 TGACCATCACGTGCTCCAGCTACCAGGGCTACCCTGAGGCTGAGG  
alThrIleThrCysSerSerTyrGlnGlyTyrProGluAlaGluV  
586 TGTTC TGGCAGGATGGGCAGGGTGTGCCCCCTGACTGGCAACGTGA  
alPheTrpGlnAspGlyGlnGlyValProLeuThrGlyAsnValT  
631 CCACGTGCGCAGATGGCCAACGAGCAGGGCTTGTTTGATGTGCACA  
hrThrSerGlnMetAlaAsnGluGlnGlyLeuPheAspValHisS  
676 GCATCCTGCGGGTGGTGCTGGGTGCAAATGGCACCTACAGCTGCC  
erIleLeuArgValValLeuGlyAlaAsnGlyThrTyrSerCysL  
721 TGGTGC GCAACCCCGTGCTGCAGCAGGATGCGCACAGCTCTGTCA  
euValArgAsnProValLeuGlnGlnAspAlaHisSerSerValT

Fig. 3

8/13

766 CCATCACACCCCAGAGAAGCCCCACAGGAGCCGTGGAGGTCCAGG  
hrIleThrProGlnArgSerProThrGlyAlaValGluValGlnV  
811 TCCCTGAGGACCCGGTGGTGGCCCTAGTGGGCACCGATGCCACCC  
alProGluAspProValValAlaLeuValGlyThrAspAlaThrL  
856 TGCCTGCTCCTTCTCCCCGAGCCTGGCTTCAGCCTGGCACAGC  
euArgCysSerPheSerProGluProGlyPheSerLeuAlaGlnL  
901 TCAACCTCATCTGGCAGCTGACAGACACCAAACAGCTGGTGCACA  
euAsnLeuIleTrpGlnLeuThrAspThrLysGlnLeuValHisS  
946 GTTTCACCGAAGGCCGGGACCAGGGCAGCGCCTATGCCAACCGCA  
erPheThrGluGlyArgAspGlnGlySerAlaTyrAlaAsnArgT  
991 CGGCCCTCTTCCCGGACCTGCTGGCACAAGGCAATGCATCCCTGA  
hrAlaLeuPheProAspLeuLeuAlaGlnGlyAsnAlaSerLeuA  
1036 GGCTGCAGCGCGTGCCTGTGGCGGACGAGGGCAGCTTCACCTGCT  
rgLeuGlnArgValArgValAlaAspGluGlySerPheThrCysP  
1081 TCGTGAGCATCCGGGATTTCCGGCAGCGCTGCCGTCAGCCTGCAGG  
heValSerIleArgAspPheGlySerAlaAlaValSerLeuGlnV  
1126 TGGCCGCTCCCTACTCGAAGCCCAGCATGACCCTGGAGCCCAACA  
alAlaAlaProTyrSerLysProSerMetThrLeuGluProAsnL  
1171 AGGACCTGCGGCCAGGGGACACGGTGACCATCACGTGCTCCAGCT  
ysAspLeuArgProGlyAspThrValThrIleThrCysSerSerT  
1216 ACCGGGGCTACCCTGAGGCTGAGGTGTTCTGGCAGGATGGGCAGG  
yrArgGlyTyrProGluAlaGluValPheTrpGlnAspGlyGlnG  
1261 GTGTGCCCCCTGACTGGCAACGTGACCACGTGCGCAGATGGCCAACG  
lyValProLeuThrGlyAsnValThrThrSerGlnMetAlaAsnG  
1306 AGCAGGGCTTGTTTGATGTGCACAGCGTCCTGCGGGTGGTGCTGG  
luGlnGlyLeuPheAspValHisSerValLeuArgValValLeuG  
1351 GTGCGAATGGCACCTACAGCTGCCTGGTGGCGCAACCCCGTGCTGC  
lyAlaAsnGlyThrTyrSerCysLeuValArgAsnProValLeuG  
1396 AGCAGGATGCGCACGGCTCTGTCACCATCACAGGGCAGCCTATGA  
lnGlnAspAlaHisGlySerValThrIleThrGlyGlnProMetT  
1441 CATTCCCCCCAGAGGCCCTGTGGGTGACCGTGGGGCTGTCTGTCT  
hrPheProProGluAlaLeuTrpValThrValGlyLeuSerValC  
1486 GTCTCATTGCACTGCTGGTGGCCCTGGCTTTCGTGTGCTGGAGAA  
ysLeuIleAlaLeuLeuValAlaLeuAlaPheValCysTrpArgL  
1531 AGATCAAACAGAGCTGTGAGGAGGAGAATGCAGGAGCTGAGGACC  
ysIleLysGlnSerCysGluGluGluAsnAlaGlyAlaGluAspG  
1576 AGGATGGGGAGGGAGAAGGCTCCAAGACAGCCCTGCAGCCTCTGA  
lnAspGlyGluGlyGluGlySerLysThrAlaLeuGlnProLeuL

Fig. 3 Continued



9/13

1621 AACACTCTGACAGCAAAGAAGATGATGGACAAGAAATAGCCTGAC  
ysHisSerAspSerLysGluAspAspGlyGlnGluIleAla  
1666 CATGAGGACCAGGGAGCTGCTACCCCTCCCTACAGCTCCTACCCCT  
1711 CTGGCTGCAATGGGGCTGCACTGTGAGCCCTGCCCCAACAGATG  
1756 CATCCTGCTCTGACAGGTGGGCTCCTTCTCCAAAGGATGCGATAC  
1801 ACAGACCACTGTGCAGCCTTATTTCTCCAATGGACATGATTCCCA  
1846 AGTCATCCTGCTGCCTTTTTTCTTATAGACACAATGAACAGACCA  
1891 CCCACAACCTTAGTTCTCTAAGTCATCCTGCCTGCTGCCTTATTT  
1936 CACAGTACATACATTTCTTAGGGACACAGTACACTGACCACATCA  
1981 CCACCCCTCTTCTTCCAGTGCTGCGTGGACCATCTGGCTGCCTTTT  
2026 TTCTCCAAAAGATGCAATATTTCAGACTGACTGACCCCTGCCTTA  
2071 TTTCACCAAAGACACGATGCATAGTCACCCCGACCTTGTTTCTCC  
2116 AATGGCCGTGATACACTAGTGATCATGTTTCAGCCCTGCTTCCACC  
2161 TGCATAGAATCTTTTCTTCTCAGACAGGGACAGTGCGGCCTCAAC  
2206 ATCTCCTGGAGTCTAGGCGGCCGC

Fig. 3 Continued

WO 01/18204

PCT/US00/24220

10/13

## Multiple Alignment:

```

B7-1 HUMAN      --MGHTRRQGTSPSPCPYLNFQAVLAGES--HFCSSVHVTKKREVAITSGHNVS
Q28499_rhesus_B7-1 --MGHTRRQETSPSPCPYLKFFQAVLAGES--HFCSSVHVTKKREVAITSGHNVS
B7-1 RABBIT     --MGHTLRPGTLPPLCLHLKCLAPALAG--HFSSGISQVTKSVREMAISQDNIST
U57755_cat_B7-1 --MGHAARKWRTPLLEKHPYKPLFPFVLASF--YFCSSGILQVTKIVEEVAISQDNIST
B7_1 MOUSE      MACNCQLMQDTPLLEKFPCLRLTFVLLRLSCVSSDVDEQLSKSVKLVLCGRNSPH
AF157827_cat_B7-2 -----MGICDSTMGCSHTTAVLALD-----LSGVSSAKSQVFNKIGELPGHETNSQ
aaf17297_dog_B7-2 -----MYLECTMGANNHFFVATLP-----LYGASAKSQVFNKIGELPGHETNSQ
176088_pig_B7-2 -----MGPSNBEFVAVLL-----LSGASAKSQVFNKIGELPGHETNSQ
u04343_hu_B7-2 -----MGPSNBEFVAVLL-----LSGASAKSQVFNKIGELPGHETNSQ
P42082_mus_B7-2 -----MDPRCTMGFAILLFVTVLL-----LSDAVSVETQVFNKIGELPGHETNSQ
aac52336_mus_B7-2_alt.spl -----MGFAILLFVTVLL-----LSDAVSVETQVFNKIGELPGHETNSQ
mz5020.protein    -----MLRRRGSPGMGVHGAALGATWFLTGALGVQVPEHVVAVGTGTAECSSSEPEP
Q99420q99420_put_hum_B7-3 -----MASFLAFLLLNFRVCLLLQLAPPSAQFVSLGPSGPHLAAGEQALTEGELFPTM

```

```

B7-1 HUMAN      E-EFAQTRVWOKENKAVITMS--GDMN--WPEYKRTIEDITNN--LSIVLLAI
Q28499_rhesus_B7-1 E-EFAQTRVWOKENKAVITMS--GDMN--WPEYKRTIEDITNN--LSIVLLAI
B7-1 RABBIT     D-EFARMVWODDOQVLSIS--GQVE--WPEYKRTIEDITNN--LSIVLLAI
U57755_cat_B7-1 K-ELDSIRWODDOQVLSIS--GKVO--WPEYKRTIEDITNN--LSIVLLAI
B7_1 MOUSE      E-DESDRLWOKHDSVLSIA--GRLK--WPEYKRTIEDITNN--LSIVLLAI
AF157827_cat_B7-2 NISLDEWVWODDOQVLSIEHLR--GKNPQNVHLYKGRITSEDKLN--WPERLHN
aaf17297_dog_B7-2 NISLDEWVWODDOQVLSIEHLR--GKNPQNVHLYKGRITSEDKLN--WPERLHN
176088_pig_B7-2 NISLDEWVWODDOQVLSIEHLR--GKPHNVSKYKGRITSEDKLN--WPERLHN
u04343_hu_B7-2 NISLDEWVWODDOQVLSIEHLR--GKPHNVSKYKGRITSEDKLN--WPERLHN
P42082_mus_B7-2 NISLDEWVWODDOQVLSIEHLR--GKPHNVSKYKGRITSEDKLN--WPERLHN
aac52336_mus_B7-2_alt.spl NISLDEWVWODDOQVLSIEHLR--GKPHNVSKYKGRITSEDKLN--WPERLHN
mz5020.protein    GFSLAQNLILQTLTKLVHVSAGGQDQ--GSAYANALFDPDLAQNAGSLRLQRY
Q99420q99420_put_hum_B7-3 S--AETMELNVSSSLRQVNVYADGREVEDROSAPYSGRTSILRDGITAGKAALRHNV

```

```

B7-1 HUMAN      RPSDEGAYECVWLRYEKDAFKRE--LALVNESVRADEPTES--SDFEIPPSN--ZRRHIGCS
Q28499_rhesus_B7-1 RPSDEGAYECVWLRYEKDAFKRE--LAEVNESVRADEPTES--SDFEIPPSN--ZRRHIGCS
B7-1 RABBIT     RESDNGAYTCVWQVNGSFRRE--LTSVALSIRADFPVED--ADIGHPDFN--VKKRIGCS
U57755_cat_B7-1 RESDNGAYTCVWQVNGSFRRE--LTSVALSIRADFPVED--ADIGHPDFN--VKKRIGCS
B7_1 MOUSE      VESDNGAYSCVWQVNGSFRRE--LALVNESVRADEPTES--SDFEIPPSN--ZRRHIGCS
AF157827_cat_B7-2 QIKDNGAYECVWHEGPKLVPM--OMSSQSVLANESQPE--MTSNTSG--HNMIGCS
aaf17297_dog_B7-2 QIKDNGAYECVWHEGPKLVPM--OMSSQSVLANESQPE--MTSNTSG--HNMIGCS
176088_pig_B7-2 QIKDNGAYECVWHEGPKLVPM--OMSSQSVLANESQPE--MTSNTSG--HNMIGCS
u04343_hu_B7-2 QIKDNGAYECVWHEGPKLVPM--OMSSQSVLANESQPE--MTSNTSG--HNMIGCS
P42082_mus_B7-2 QIKDNGAYECVWHEGPKLVPM--OMSSQSVLANESQPE--MTSNTSG--HNMIGCS
aac52336_mus_B7-2_alt.spl QIKDNGAYECVWHEGPKLVPM--OMSSQSVLANESQPE--MTSNTSG--HNMIGCS
mz5020.protein    RVADGSGVLCVWHEGPKLVPM--OMSSQSVLANESQPE--MTSNTSG--HNMIGCS
Q99420q99420_put_hum_B7-3 TGSDEWVWLYCFQDGFY-----EKALVSVAAALGSDLEMTYKGYKDG--LH--LEGR

```

```

B7-1 HUMAN      TSCGPPPEHLSMLENGE--ELNAINITVS--ODPEHMYAVSKLDNMTTNH--SFGC
Q28499_rhesus_B7-1 NSCGPPPEHLSMLENGE--ELNAISITVS--ODPEHMYAVSKLDNMTTNH--SFGC
B7-1 RABBIT     ASCGPPPEHLSMLENGE--ELNAVIMTV--ODPEHMYAVSKLDNMTTNH--SFGC
U57755_cat_B7-1 TSCGPPPEHLSMLENEE--ELNAINITVS--ODPEHMYAVSKLDNMTTNH--SFGC
B7_1 MOUSE      ASCGPPPEHLSMLENGR--ELPGINITVS--ODPEHMYAVSKLDNMTTNH--SFGC
AF157827_cat_B7-2 SIQCPPEPEMYFQINTENSTTKYD--VKKSONNVIELYAVSISEP--SYPEAH--NV--SFGC
aaf17297_dog_B7-2 SIQCPPEPEMYFLVKTNSTTKYD--VKKSONNVIELYAVSISEP--SYPEAH--NV--SFGC
176088_pig_B7-2 SIQCPPEPEMYFLVKTNSTTKYD--VKKSONNVIELYAVSISEP--SYPEAH--NV--SFGC
u04343_hu_B7-2 SIQCPPEPEMYFLVKTNSTTKYD--VKKSONNVIELYAVSISEP--SYPEAH--NV--SFGC
P42082_mus_B7-2 SIQCPPEPEMYFLVKTNSTTKYD--VKKSONNVIELYAVSISEP--SYPEAH--NV--SFGC
aac52336_mus_B7-2_alt.spl SIQCPPEPEMYFLVKTNSTTKYD--VKKSONNVIELYAVSISEP--SYPEAH--NV--SFGC
mz5020.protein    SIQCPPEPEMYFLVKTNSTTKYD--VKKSONNVIELYAVSISEP--SYPEAH--NV--SFGC
Q99420q99420_put_hum_B7-3 SIQCPPEPEMYFLVKTNSTTKYD--VKKSONNVIELYAVSISEP--SYPEAH--NV--SFGC

```

Fig. 4

SUBSTITUTE SHEET (RULE 26)

WO 01/18204

PCT/US00/24220

11/13

B7-1 HUMAN	LIKYGHPRVN--QT--NNNTTKQE---HF--DN--LLPSWAILLS---VAGHFW
Q28499_rhesus_B7-1	LIKYGHPRVN--QT--NNNTPKQE---HF--DN--LLPSWAILLS---VAGHFW
B7-1 RABBIT	LIKYGHESVS--QI--EWSKPKQ---EP--ID--QLPFVPIIPMSG--AL--VITAVV
U57755_cat_B7_1	LVNYGNELNS--QI--EYOKSEP---QPSNN--QLWIIILSSVSGIV---VITAVV
B7-1 MOUSE	LIKYGDHVS--ED--EWEKPPE---DPPDS--KNTLVLFQAGFG--A--QTVVA
AF157827_cat_B7-2	AKNLETPEMLL--SLP--NIDAKPKD---KD--EQ--GHFLIDAAVIV--MF--VIFCGV
aaf17297_dog_B7-2	VIOLESKPL--SLP--NIDAKTKP---TDG--DHILIDAAVIV--ML--VILCGV
176088-pig_B7-2	VIOLESKPL--SLP--NIDAKPFV---QPV--VP--DHILIDAAVIV--TV--VIVCGV
u04343_hu_B7-2	LIETDKTILL--SP--SIELEDPC---EP--DHILIDAAVIV--TV--VIVCGV
P42082_mus_B7_2	VLETESKPLS--SKPL--TQEFPS---QTY--KEITAS--VT--VALLVM
aac52336_mus_B7-2_alt.spl	VLETESKPLS--SKPL--TQEFPS---QTY--KEITAS--VT--VALLVM
mz5020.protein	LVKNPVVQDDAH--SVTITPQRSPTGAVEVQV--EDFVVALVGTDA--LRCSFSPEPGFSQAQ
Q99420q99420_put_hum_B7-3	TDNSLIGLEK--ASISLARPFPR-----SAQRIDARLAG--TLFVILILGGA
B7-1 HUMAN	CCITYCFAPFC---RERARN---RLRRESVRPV-----
Q28499_rhesus_B7-1	CCITYCFAPFC---RERARN---RLRRESVRPV-----
B7-1 RABBIT	YCLACRHVAVW---KRTERNEE---YVGTERLSPI---YLGSAQSSG--
U57755_cat_B7_1	RCLVHRPAAVW---RQREMGR---RKWKRSHTST-----
B7-1 MOUSE	VVLAKCFCHH---SCFERNEA---RETNNSLTF---GPEEALAEQTVFL--
AF157827_cat_B7-2	SFKTLRKRKK---QPGSEHC---ETIKERKESK---QTNERVYPYHVPERSDE
aaf17297_dog_B7-2	FFTLRKRKK---QPGSEHC---ETIKERKESK---QTKERVYHETERSDE
176088-pig_B7-2	SFVTLRKRKK---QPGSEHCG---ETIKERKASE---QTKNRAEVHE--RSD
u04343_hu_B7-2	CLLWKWKKK---RPRNSYKC---GVNIMERESE---QTKKREKIHIPERSDE
P42082_mus_B7_2	LLLVCHKSPN---QPSFPSNT---ASKLERDSN---ADRETINL---KE
aac52336_mus_B7-2_alt.spl	LLLVCHKSPN---QPSFPSNT---ASKLERDSN---ADRETINL---KE
mz5020.protein	LNKINQLTDTH---QLVHSFTEGRDQGSAYAN--TALFPDILAQGNASLRQRVRVADEG
Q99420q99420_put_hum_B7-3	GYFLWQQQEKKTKQFRKKRREQELREMAWSTMKQEOSTRVKLLLELRWRSIQYASRGERH
B7-1 HUMAN	-----
Q28499_rhesus_B7-1	-----
B7-1 RABBIT	-----
U57755_cat_B7_1	-----
B7-1 MOUSE	-----
AF157827_cat_B7-2	-AQC-VNILKTASGDKNQ-----
aaf17297_dog_B7-2	-AQC-VNISKTAGDINSTTQF-----
176088-pig_B7-2	-AQCDVNILKTASDINSTTDF-----
u04343_hu_B7-2	-AQRVFKSSKTSSCDKSDTCF-----
P42082_mus_B7_2	-LEPQIASAKPNAE-----
aac52336_mus_B7-2_alt.spl	-LEPQIASAKPNAE-----
mz5020.protein	SFTCFVSIIRDFGSAAVSLQVAAPYSKPSMTLEPNKDLRPGDVTVTITCSSYRGYPEAEVFW
Q99420q99420_put_hum_B7-3	SAYNEWKKALFKPGEEMLMRLHFVK-----
B7-1 HUMAN	-----
Q28499_rhesus_B7-1	-----
B7-1 RABBIT	-----
U57755_cat_B7_1	-----
B7-1 MOUSE	-----
AF157827_cat_B7-2	-----
aaf17297_dog_B7-2	-----
176088-pig_B7-2	-----
u04343_hu_B7-2	-----
P42082_mus_B7_2	-----
aac52336_mus_B7-2_alt.spl	-----
mz5020.protein	QDQGVPLTGNVTTSQMANEQGLFDVHSLRVVLGANGTYSCLVRNPVLQDDAHGSVTTIT
Q99420q99420_put_hum_B7-3	-----

Fig. 4 Continued

SUBSTITUTE SHEET (RULE 26)

12/13

B7-1_HUMAN	-----
Q28499_rhesus_B7-1	-----
B7-1_RABBIT	-----
U57755_cat_B7_1	-----
B7-1_MOUSE	-----
AF157827_cat_B7-2	-----
aaf17297_dog_B7-2	-----
176088-pig_B7-2	-----
u04343_hu_B7-2	-----
P42082_mus_B7_2	-----
aac52336_mus_B7-2_alt.spl	-----
mz5020.protein	GQPMTFPPPEALWVTVGLSVCLIALLLVALAFVCWRKIKQSCEENAGAEDQDGEGEKSKTA
Q99420q99420_put_hum_B7-3	-----
B7-1_HUMAN	-----
Q28499_rhesus_B7-1	-----
B7-1_RABBIT	-----
U57755_cat_B7_1	-----
B7-1_MOUSE	-----
AF157827_cat_B7-2	-----
aaf17297_dog_B7-2	-----
176088-pig_B7-2	-----
u04343_hu_B7-2	-----
P42082_mus_B7_2	-----
aac52336_mus_B7-2_alt.spl	-----
mz5020.protein	LQPLKHSDSKEDDGQEIA
Q99420q99420_put_hum_B7-3	-----

Fig. 4 Continued




Fig. 5

Attorney Docket No. 15966-562 NATL

[illegible]

- ☒ I hereby claim the benefit under Title 35, United States Code, § 119(e) or §120 of any United States application(s), or §365(c) of any PCT International application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

<b>Application No.</b> (U.S.S.N.)	<b>Filing Date</b> (dd/mm/yy)	<b>Status</b> (Patented, Pending, Abandoned)

PCT International Applications designating the United States:

<b>PCT Appln No.</b>	<b>US Serial No.</b>	<b>PCT Filing Date</b>	<b>Status</b>
PCT/US00/24220	10/069,626	31 August 2000	National Stage

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

<b>Attorney or Agent</b>	<b>Registration No.</b>	<b>Attorney or Agent</b>	<b>Registration No.</b>
Kevin Ainsworth	39,586	Shane Hunter	41,858
Ingrid Beattie	42,306	David E. Johnson	41,874
William Belanger	40,509	Christina Karnakis	45,899
Charles E. Bell	48,128	Kristin E. Konzak	44,848
Naomi Biswas	38,384	Cynthia Kozakiewicz	42,764
Bradford C. Blaise	47,429	Barry J. Marenberg	40,715
Sean M. Coughlin	48,593	Scott D. Miller	43,803
David F. Crosby	36,400	A. Jason Mirabito	28,161
Christopher J. Cuneo	42,450	Michel Morency	50,183
Brett N. Dorny	35,860	Carol H. Peters	45,010
Marianne Downing	42,870	Matthew Pavao	50,572
Ivor R. Elrifi	39,529	David Poirier	43,007
Heidi A. Erlacher	45,409	Michael Renaud	44,299
John M. Garvey	37,833	Brian Rosenbloom	41,276
James G. Gatto	32,694	Robert J. Sayre	42,124
Richard Gervase	46,725	C. Eric Schulman	43,350
Matthew J. Golden	35,161	Gregory J. Sieczkiewicz	48,223
Sonia K. Guterman	44,729	Thomas M. Sullivan	39,392
John A. Harre	37,345	Janine Susan	46,119
Brian P. Hopkins	42,669	Nicholas P. Triano III	36,397
		Howard Susser	33,556

Address all telephone calls to Ivor R. Elrifi, Esq. at telephone number 617/348-1747.  
Address all correspondence to:

Ivor R. Elrifi, Esq.  
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.  
One Financial Center  
Boston, Massachusetts 02111

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or patent issued thereon.

\_\_\_\_\_  
Inventor's Signature


Full Name of Inventor: Cynthia Green

Citizenship: USA

Residence: Madison, CT 06443

Post Office Address: 29 Twin Bridge Road

\_\_\_\_\_  
Date

  
\_\_\_\_\_  
Inventor's Signature


Full Name of Inventor: Victor Kotelianski

Citizenship: USA

Residence: Boston, MA 02215

Post Office Address: 4 Charlesgate East, Apartment 405

  
\_\_\_\_\_  
Date

  
\_\_\_\_\_  
Inventor's Signature

Full Name of Inventor: Antonin de Fougères


Citizenship: Canada

Residence: Brookline, MA 02446

Post Office Address: 119 Lancaster Terrace

  
\_\_\_\_\_  
Date





---


Inventor's Signature

Full Name of Inventor: John Carulli


Citizenship: USA

Residence: Southborough, MA 01772

Post Office Address: 9 Harris Drive

  
JUL 15, 2002

---

Date

---


Inventor's Signature

Full Name of Inventor: Catherine Hession

Citizenship: USA

Residence: Hingham, MA 02043

Post Office Address: 35 Otis Hill Road

  
JULY 17, 2002

---

Date

TRA 1664226v1

100694625 07-06-02

## COMBINED DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

My residence, post office address and citizenship are as stated below next to my name.

**POLYNUCLEOTIDES ENCODING MEMBERS OF THE HUMAN B LYMPHOCYTE  
ACTIVATION ANTIGEN B-7 FAMILY AND POLYPEPTIDES ENCODED THEREBY**

☒ was filed on February 26, 2002 as United States non-provisional application U.S.S.N. 10/069,626, bearing Attorney Docket No.15966-562 NATL.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

☐ I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application designating at least one country other than the United States listed below and have also identified below any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

[illegible]

- ☒ I hereby claim the benefit under Title 35, United States Code, § 119(e) or §120 of any United States application(s), or §365(c) of any PCT International application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

Application No. (U.S.S.N.)	Filing Date (dd/mm/yy)	Status (Patented, Pending, Abandoned)

PCT International Applications designating the United States:

PCT Appln No.	US Serial No.	PCT Filing Date	Status
PCT/US00/24220	10/069,626	31 August 2000	National Stage

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Attorney or Agent	Registration No.	Attorney or Agent	Registration No.
Kevin Ainsworth	<u>39,586</u>	Shane Hunter	<u>41,858</u>
Ingrid Beattie	<u>42,306</u>	David E. Johnson	<u>41,874</u>
William Belanger	<u>40,509</u>	Christina Karnakis	<u>45,899</u>
Charles E. Bell	<u>48,128</u>	Kristin E. Konzak	<u>44,848</u>
Naomi Biswas	<u>38,384</u>	Cynthia Kozakiewicz	<u>42,764</u>
Bradford C. Blaise	<u>47,429</u>	Barry J. Marenberg	<u>40,715</u>
Sean M. Coughlin	<u>48,593</u>	Scott D. Miller	<u>43,803</u>
David F. Crosby	<u>36,400</u>	A. Jason Mirabito	<u>28,161</u>
Christopher J. Cuneo	<u>42,450</u>	Michel Morency	<u>50,183</u>
Brett N. Dorny	<u>35,860</u>	Carol H. Peters	<u>45,010</u>
Marianne Downing	<u>42,870</u>	Matthew Pavao	<u>50,572</u>
Ivor R. Elrifi	<u>39,529</u>	David Poirier	<u>43,007</u>
Heidi A. Erlacher	<u>45,409</u>	Michael Renaud	<u>44,299</u>
John M. Garvey	<u>37,833</u>	Brian Rosenbloom	<u>41,276</u>
James G. Gatto	<u>32,694</u>	Robert J. Sayre	<u>42,124</u>
Richard Gervase	<u>46,725</u>	C. Eric Schulman	<u>43,350</u>
Matthew J. Golden	<u>35,161</u>	Gregory J. Sieczkiewicz	<u>48,223</u>
Sonia K. Guterman	<u>44,729</u>	Thomas M. Sullivan	<u>39,392</u>
John A. Harre	<u>37,345</u>	Janine Susan	<u>46,119</u>
Brian P. Hopkins	<u>42,669</u>	Nicholas P. Triano III	<u>36,397</u>
		Howard Susser	<u>33,556</u>

Address all telephone calls to Ivor R. Elrifi, Esq. at telephone number 617/348-1747.  
Address all correspondence to:

Ivor R. Elrifi, Esq.  
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.  
One Financial Center  
Boston, Massachusetts 02111

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or patent issued thereon.

Cynthia Green  
Inventor's Signature  
Full Name of Inventor: Cynthia Green  
Citizenship: USA  
Residence: Madison, CT 06443 CT  
Post Office Address: 29 Twin Bridge Road

7/23/02  
Date

Victor Kotelianski  
Inventor's Signature  
Full Name of Inventor: Victor Kotelianski  
Citizenship: USA  
Residence: Boston, MA 02215  
Post Office Address: 4 Charlesgate East, Apartment 405

\_\_\_\_\_  
Date

Antonin de Fougères  
Inventor's Signature  
Full Name of Inventor: Antonin de Fougères  
Citizenship: Canada  
Residence: Brookline, MA 02446  
Post Office Address: 119 Lancaster Terrace

\_\_\_\_\_  
Date

4-0 Inventor's Signature

Full Name of Inventor: John Carulli

Citizenship: USA

Residence: Southborough, MA 01772

Post Office Address: 9 Harris Drive

Date

5-0 Inventor's Signature

Full Name of Inventor: Catherine Hession

Citizenship: USA

Residence: Hingham, MA 02043

Post Office Address: 35 Otis Hill Road

Date

TRA 1664226v1

PTO/PCT Rec'd 25 JUL 2002

10069626 072502

#3

SEQUENCE LISTING

<110> Green et al.

<120> Polynucleotides Encoding Members of the Human B  
Lymphocyte Activation Antigen B-7 Family and  
Polypeptides Encoded Thereby

<130> 15966-562 NATL

<140> 10/069,626

<141> 2000-08-31

<150> PCT/US00/24220

<151> 2000-08-31

<150> 60/152383

<151> 1999-09-03

<150> 60/172909

<151> 1999-12-21

<150> 60/183578

<151> 2000-02-18

<150> 09/651200

<151> 2000-08-30

<160> 25



35	40	45	50	
gga gcc gtg gag gtc cag gtc cct gag gac ccg gtg gtg gcc cta gtg				308
Gly Ala Val Glu Val Gln Val Pro Glu Asp Pro Val Val Ala Leu Val				
	55	60	65	
ggc acc gat gcc acc ctg cac tgc tcc ttc tcc ccc gag cct ggc ttc				356
Gly Thr Asp Ala Thr Leu His Cys Ser Phe Ser Pro Glu Pro Gly Phe				
	70	75	80	
agc ctg aca cag ctc aac ctc atc tgg cag ctg aca gac acc aaa cag				404
Ser Leu Thr Gln Leu Asn Leu Ile Trp Gln Leu Thr Asp Thr Lys Gln				
	85	90	95	
ctg gtg cac agt ttc acc gaa ggc cgg gac cag ggc agc gcc tat gcc				452
Leu Val His Ser Phe Thr Glu Gly Arg Asp Gln Gly Ser Ala Tyr Ala				
100	105	110		
aac cgc acg gcc ctc ttc ccg gac ctg ctg gca caa ggc aat gca tcc				500
Asn Arg Thr Ala Leu Phe Pro Asp Leu Leu Ala Gln Gly Asn Ala Ser				
115	120	125	130	
ctg agg ctg cag cgc gtg cgt gtg gcg gac gag ggc agc ttc acc tgc				548
Leu Arg Leu Gln Arg Val Arg Val Ala Asp Glu Gly Ser Phe Thr Cys				
	135	140	145	
ttc gtg agc atc cgg gat ttc ggc agc gct gcc gtc agc ctg cag gtg				596
Phe Val Ser Ile Arg Asp Phe Gly Ser Ala Ala Val Ser Leu Gln Val				



150	155	160	
gcc gct ccc tac tcg aag ccc agc atg acc ctg gag ccc aac aag gac			644
Ala Ala Pro Tyr Ser Lys Pro Ser Met Thr Leu Glu Pro Asn Lys Asp			
165	170	175	
ctg cgg cca ggg gac acg gtg acc atc acg tgc tcc agc tac cgg ggc			692
Leu Arg Pro Gly Asp Thr Val Thr Ile Thr Cys Ser Ser Tyr Arg Gly			
180	185	190	
tac cct gag gct gag gtg ttc tgg cag gat ggg cag ggt gtg ccc ctg			740
Tyr Pro Glu Ala Glu Val Phe Trp Gln Asp Gly Gln Gly Val Pro Leu			
195	200	205	210
act ggc aac gtg acc acg tcg cag atg gcc aac gag cag ggc ttg ttt			788
Thr Gly Asn Val Thr Thr Ser Gln Met Ala Asn Glu Gln Gly Leu Phe			
215	220	225	
gat gtg cac agc gtc ctg cgg gtg gtg ctg ggt gcg aat ggc acc tac			836
Asp Val His Ser Val Leu Arg Val Val Leu Gly Ala Asn Gly Thr Tyr			
230	235	240	
agc tgc ctg gtg cgc aac ccc gtg ctg cag cag gat gcg cac ggc tct			884
Ser Cys Leu Val Arg Asn Pro Val Leu Gln Gln Asp Ala His Gly Ser			
245	250	255	
gtc acc atc aca ggg cag cct atg aca ttc ccc cca gag gcc ctg tgg			932
Val Thr Ile Thr Gly Gln Pro Met Thr Phe Pro Pro Glu Ala Leu Trp			





ggctcaaggc ttcttgata cctcacccc atcccacca taattcttac ccagagcatg 2260

gggttggggc ggaaacctgg agagaggac atagcccctc gccacggcta gagaatctgg 2320

tggtgtccaa aatgtctgtc caggtgtggg caggtgggca ggcaccaagg ccctctggac 2380

ctttcatagc agcagaaaag gcagagcctg gggcagggca gggccaggaa tgctttgggg 2440

acaccgaggg gactgcccc caccaccacc atggtgctat tctggggctg gggcagtctt 2500

ttcttgctt gcctctggcc agctcccgcc ctctggtaga gtgagacttc agacgttctg 2560

atgccttccg gatgtcatct ctccctgcc caggaatgga agatgtgagg acttctaatt 2620

taaatgtggg actcggaggg attttgtaaa ctgggggtat attttgggga aaataaatgt 2680

ctttgtaaaa a 2691

<210> 2

<211> 340

<212> PRT

<213> Homo sapiens

<400> 2

Met Ala Asn Glu Gln Gly Leu Phe Asp Val His Ser Ile Leu Arg Val

1

5

10

15

SECRET

Val Leu Gly Ala Asn Gly Thr Tyr Ser Cys Leu Val Arg Asn Pro Val

20

30

Leu Gln Gln Asp Ala His Ser Ser Val Thr Ile Thr Pro Gln Arg Ser

35

40

45

Pro Thr Gly Ala Val Glu Val Gln Val Pro Glu Asp Pro Val Val Ala

50

55

60

Leu Val Gly Thr Asp Ala Thr Leu His Cys Ser Phe Ser Pro Glu Pro

65

70

75

80

Gly Phe Ser Leu Thr Gln Leu Asn Leu Ile Trp Gln Leu Thr Asp Thr

85

90

95

Lys Gln Leu Val His Ser Phe Thr Glu Gly Arg Asp Gln Gly Ser Ala

100

105

110

Tyr Ala Asn Arg Thr Ala Leu Phe Pro Asp Leu Leu Ala Gln Gly Asn

115

120

125

Ala Ser Leu Arg Leu Gln Arg Val Arg Val Ala Asp Glu Gly Ser Phe

130

135

140

Thr Cys Phe Val Ser Ile Arg Asp Phe Gly Ser Ala Ala Val Ser Leu

145

150

155

160

Gln Val Ala Ala Pro Tyr Ser Lys Pro Ser Met Thr Leu Glu Pro Asn

165	170	175	
Lys Asp Leu Arg Pro Gly Asp Thr Val Thr Ile Thr Cys Ser Ser Tyr			
180	185	190	
Arg Gly Tyr Pro Glu Ala Glu Val Phe Trp Gln Asp Gly Gln Gly Val			
195	200	205	
Pro Leu Thr Gly Asn Val Thr Thr Ser Gln Met Ala Asn Glu Gln Gly			
210	215	220	
Leu Phe Asp Val His Ser Val Leu Arg Val Val Leu Gly Ala Asn Gly			
225	230	235	240
Thr Tyr Ser Cys Leu Val Arg Asn Pro Val Leu Gln Gln Asp Ala His			
245	250	255	
Gly Ser Val Thr Ile Thr Gly Gln Pro Met Thr Phe Pro Pro Glu Ala			
260	265	270	
Leu Trp Val Thr Val Gly Leu Ser Val Cys Leu Ile Ala Leu Leu Val			
275	280	285	
Ala Leu Ala Phe Val Cys Trp Arg Lys Ile Lys Gln Ser Cys Glu Glu			
290	295	300	
Glu Asn Ala Gly Ala Glu Asp Gln Asp Gly Glu Gly Glu Gly Ser Lys			
305	310	315	320

*(The following information was obtained from the above-mentioned sources.)*

Thr Ala Leu Gln Pro Leu Lys His Ser Asp Ser Lys Glu Asp Asp Gly

325

330

335

Gln Glu Ile Ala

340

<210> 3

<211> 2885

<212> DNA

<213> Homo sapiens

 $\langle 220 \rangle$ 

<221> CDS

$\langle 222 \rangle \quad (2) \dots (1324)$

<400> 3

c cct ctt ccc gga cct gct ggc aca ggg caa cgc atc cct gag gct gca 49

Pro Leu Pro Gly Pro Ala Gly Thr Gly Gln Arg Ile Pro Glu Ala Ala

1

5

10

15

gcg cgt gcg tgt agc gga cga ggg cag ctt cac ctg ctt cgt gag cat 97

Ala Arg Ala Cys Ser Gly Arg Gly Gln Leu His Leu Leu Arg Glu His

20

25

30

ccg gga ttt cgg cag cgc tgc cgt cag cct gca ggt ggc cgc tcc cta 145

Pro Gly Phe Arg Gln Arg Cys Arg Gln Pro Ala Gly Gly Arg Ser Leu

111346-562 077

35	40	45	
ctc gaa gcc cag cat gac cct gga gcc caa caa gga cct gcg gcc agg	193		
Leu Glu Ala Gln His Asp Pro Gly Ala Gln Gln Gly Pro Ala Ala Arg			
50	55	60	
gga cac ggt gtg acc atc acg tgc tcc agc tac cag ggc tac cct gag	241		
Gly His Gly Val Thr Ile Thr Cys Ser Ser Tyr Gln Gly Tyr Pro Glu			
65	70	75	80
gct gag gtg ttc tgg cag gat ggg cag ggt gtg ccc ctg act ggc aac	289		
Ala Glu Val Phe Trp Gln Asp Gly Gln Gly Val Pro Leu Thr Gly Asn			
85	90	95	
gtg acc acg tcg cag atg gcc aac gag cag ggc ttg ttt gat gtg cac	337		
Val Thr Thr Ser Gln Met Ala Asn Glu Gln Gly Leu Phe Asp Val His			
100	105	110	
agc atc ctg cgg gtg gtg ctg ggt gca aat ggc acc tac agc tgc ctg	385		
Ser Ile Leu Arg Val Val Leu Gly Ala Asn Gly Thr Tyr Ser Cys Leu			
115	120	125	
gtg cgc aac ccc gtg ctg cag cag gat gcg cac agc tct gtc acc atc	433		
Val Arg Asn Pro Val Leu Gln Gln Asp Ala His Ser Ser Val Thr Ile			
130	135	140	
aca ccc cag aga agc ccc aca gga gcc gtg gag gtc cag gtc cct gag	481		
Thr Pro Gln Arg Ser Pro Thr Gly Ala Val Glu Val Gln Val Pro Glu			



145	150	155	160	
gac ccg gtg gtg gcc cta gtg ggc acc gat gcc acc ctg cac tgc tcc				529
Asp Pro Val Val Ala Leu Val Gly Thr Asp Ala Thr Leu His Cys Ser				
	165	170	175	
ttc tcc ccc gag cct ggc ttc agc ctg aca cag ctc aac ctc atc tgg				577
Phe Ser Pro Glu Pro Gly Phe Ser Leu Thr Gln Leu Asn Leu Ile Trp				
	180	185	190	
cag ctg aca gac acc aaa cag ctg gtg cac agt ttc acc gaa ggc cgg				625
Gln Leu Thr Asp Thr Lys Gln Leu Val His Ser Phe Thr Glu Gly Arg				
	195	200	205	
gac cag ggc agc gcc tat gcc aac cgc acg gcc ctc ttc ccg gac ctg				673
Asp Gln Gly Ser Ala Tyr Ala Asn Arg Thr Ala Leu Phe Pro Asp Leu				
	210	215	220	
ctg gca caa ggc aat gca tcc ctg agg ctg cag cgc gtg cgt gtg gcg				721
Leu Ala Gln Gly Asn Ala Ser Leu Arg Leu Gln Arg Val Arg Val Ala				
	225	230	235	240
gac gag ggc agc ttc acc tgc ttc gtg agc atc cgg gat ttc ggc agc				769
Asp Glu Gly Ser Phe Thr Cys Phe Val Ser Ile Arg Asp Phe Gly Ser				
	245	250	255	
gct gcc gtc agc ctg cag gtg gcc gct ccc tac tcg aag ccc agc atg				817
Ala Ala Val Ser Leu Gln Val Ala Ala Pro Tyr Ser Lys Pro Ser Met				

260	265	270	
acc ctg gag ccc aac aag gac ctg cgg cca ggg gac acg gtg acc atc			865
Thr Leu Glu Pro Asn Lys Asp Leu Arg Pro Gly Asp Thr Val Thr Ile			
275	280	285	
acg tgc tcc agc tac cgg ggc tac cct gag gct gag gtg ttc tgg cag			913
Thr Cys Ser Ser Tyr Arg Gly Tyr Pro Glu Ala Glu Val Phe Trp Gln			
290	295	300	
gat ggg cag ggt gtg ccc ctg act ggc aac gtg acc acg tcg cag atg			961
Asp Gly Gln Gly Val Pro Leu Thr Gly Asn Val Thr Thr Ser Gln Met			
305	310	315	320
gcc aac gag cag ggc ttg ttt gat gtg cac agc gtc ctg cgg gtg gtg			1009
Ala Asn Glu Gln Gly Leu Phe Asp Val His Ser Val Leu Arg Val Val			
325	330	335	
ctg ggt gcg aat ggc acc tac agc tgc ctg gtg cgc aac ccc gtg ctg			1057
Leu Gly Ala Asn Gly Thr Tyr Ser Cys Leu Val Arg Asn Pro Val Leu			
340	345	350	
cag cag gat gcg cac ggc tct gtc acc atc aca ggg cag cct atg aca			1105
Gln Gln Asp Ala His Gly Ser Val Thr Ile Thr Gly Gln Pro Met Thr			
355	360	365	
ttc ccc cca gag gcc ctg tgg gtg acc gtg ggg ctc tct gtc tgt ctc			1153
Phe Pro Pro Glu Ala Leu Trp Val Thr Val Gly Leu Ser Val Cys Leu			

44-38861-975

370 375 380

att gca ctg ctg gtg gcc ctg gct ttc gtg tgc tgg aga aag atc aaa 1201  
Ile Ala Leu Leu Val Ala Leu Ala Phe Val Cys Trp Arg Lys Ile Lys  
385 390 395 400  
cag agc tgt gag gag gag aat gca gga gcc gag gac cag gat ggg gag 1249  
Gln Ser Cys Glu Glu Glu Asn Ala Gly Ala Glu Asp Gln Asp Gly Glu  
405 410 415  
gga gaa ggc tcc aag aca gcc ctg cag cct ctg aaa cac tct gac agc 1297  
Gly Glu Gly Ser Lys Thr Ala Leu Gln Pro Leu Lys His Ser Asp Ser  
420 425 430  
aaa gaa gat gat gga caa gaa ata gcc tgaccatgag gaccagggag 1344  
Lys Glu Asp Asp Gly Gln Glu Ile Ala  
435 440  
ctgctacccc tccctacagc tcctaccctc tggctgcaat ggggctgcac tgtgagccct 1404  
gcccccaaca gatgcatcct gctctgacag gtgggctcct tctccaaagg atcgatata 1464  
cagaccactg tgcagcctta tttctccaat ggacatgatt cccaagtcac cctgctgcct 1524  
tttttcttat agacacaatg aacagaccac ccacaacctt agttctctaa gtcacccctgc 1584  
ctgctgcctt atttcacagt acatacattt cttagggaca cagtacactg accacatcac 1644

caccctcttc ttccagtgt gctgggacca tctggctgcc tttttctcc aaaagatgca 1704

atattcagac tgactgaccc cctgccttat ttcaccaaag acacgatgca tagtcacccc 1764

ggccttgttt ctccaatggc cgtgatacac tagtgatcat gttcagccct gcttcacct 1824

gcatagaatc ttttcttctc agacagggac agtgccgcct caacatctcc tggagtctag 1884

aagctgtttc ctttccctc cttctctctc ttgctctagc ctttaactg gccttttccc 1944

tcctgcccc aagtgaagac agggcactct gcgcccacca catgcacagc tgtgcatgga 2004

gacctgcagg tgcacgtgt ggaacacgtg tggttcccc ctggcccagc ctctctgca 2064

gtgcccctct cccctgccc tctctccac ggaagcatgt gctggtcaca ctggttctcc 2124

aggggtctgt gatggggccc ctgggggtca gcttctgtcc ctctgccttc tcacctctt 2184

gttctttct tttcatgtat ccattcagtt gatgtttatt gagcaactac agatgtcagc 2244

actgtgttag gtgctggggg ccctgcgtgg gaagataaag ttctccctc aaggactccc 2304

catccagctg ggagacagac aactaactac actgcacct gcggtttgca gggggctcct 2364

gcctggctcc ctgctccaca cctctctgt ggctcaaggc ttctggata cctcaccccc 2424

atccccacca taattcttac ccagagcatg ggggtggggc ggaaacctg agagagggac 2484

THE UNIVERSITY OF CHICAGO

atagcccctc gccacggcta gagaatctgg tgggtgtccaa aatgtctgtc caggtgtggg 2544

caggtgggca ggcaccaagg ccctctggac ctttcatagc agcagaaaaag gcagagcctg 2604

gggcagggca gggccaggaa tgctttgggg acaccgaggg gactgcccc cacccccacc 2664

atggtgctat tctggggctg gggcagttctt ttcttggett gcctctggcc agctcccggc 2724

ctctggtaga gtgagacttc agacgttctg atgccttccg gatgtcatct ctccctgccc 2784

caggaatgga agatgtgagg acttctaatt taaatgtggg actcggaggg attttgtaaa 2844

ctgggggtat attttgggga aaataaatgt ctttgtaaaa a 2885

<210> 4

<211> 441

<212> PRT

<213> Homo sapiens

<400> 4

Pro Leu Pro Gly Pro Ala Gly Thr Gly Gln Arg Ile Pro Glu Ala Ala

1                      5                      10                      15

Ala Arg Ala Cys Ser Gly Arg Gly Gln Leu His Leu Leu Arg Glu His

20                      25                      30

Pro Gly Phe Arg Gln Arg Cys Arg Gln Pro Ala Gly Gly Arg Ser Leu

35

40

45

Leu Glu Ala Gln His Asp Pro Gly Ala Gln Gln Gly Pro Ala Ala Arg

50

55

60

Gly His Gly Val Thr Ile Thr Cys Ser Ser Tyr Gln Gly Tyr Pro Glu

65

70

75

80

Ala Glu Val Phe Trp Gln Asp Gly Gln Gly Val Pro Leu Thr Gly Asn

85

90

95

Val Thr Thr Ser Gln Met Ala Asn Glu Gln Gly Leu Phe Asp Val His

100

105

110

Ser Ile Leu Arg Val Val Leu Gly Ala Asn Gly Thr Tyr Ser Cys Leu

115

120

125

Val Arg Asn Pro Val Leu Gln Gln Asp Ala His Ser Ser Val Thr Ile

130

135

140

Thr Pro Gln Arg Ser Pro Thr Gly Ala Val Glu Val Gln Val Pro Glu

145

150

155

160

Asp Pro Val Val Ala Leu Val Gly Thr Asp Ala Thr Leu His Cys Ser

165

170

175

Phe Ser Pro Glu Pro Gly Phe Ser Leu Thr Gln Leu Asn Leu Ile Trp

180

185

190

Gln Leu Thr Asp Thr Lys Gln Leu Val His Ser Phe Thr Glu Gly Arg  
 195 200 205

Asp Gln Gly Ser Ala Tyr Ala Asn Arg Thr Ala Leu Phe Pro Asp Leu  
 210 215 220

Leu Ala Gln Gly Asn Ala Ser Leu Arg Leu Gln Arg Val Arg Val Ala  
 225 230 235 240

Asp Glu Gly Ser Phe Thr Cys Phe Val Ser Ile Arg Asp Phe Gly Ser  
 245 250 255

Ala Ala Val Ser Leu Gln Val Ala Ala Pro Tyr Ser Lys Pro Ser Met  
 260 265 270

Thr Leu Glu Pro Asn Lys Asp Leu Arg Pro Gly Asp Thr Val Thr Ile  
 275 280 285

Thr Cys Ser Ser Tyr Arg Gly Tyr Pro Glu Ala Glu Val Phe Trp Gln  
 290 295 300

Asp Gly Gln Gly Val Pro Leu Thr Gly Asn Val Thr Thr Ser Gln Met  
 305 310 315 320

Ala Asn Glu Gln Gly Leu Phe Asp Val His Ser Val Leu Arg Val Val  
 325 330 335

130666 05-11

Leu Gly Ala Asn Gly Thr Tyr Ser Cys Leu Val Arg Asn Pro Val Leu

345

350

Gln Gln Asp Ala His Gly Ser Val Thr Ile Thr Gly Gln Pro Met Thr

360

365

Phe Pro Pro Glu Ala Leu Trp Val Thr Val Gly Leu Ser Val Cys Leu

375

380

Ile Ala Leu Leu Val Ala Leu Ala Phe Val Cys Trp Arg Lys Ile Lys

390

395

400

Gln Ser Cys Glu Glu Glu Asn Ala Gly Ala Glu Asp Gln Asp Gly Glu

410

415

Gly Glu Gly Ser Lys Thr Ala Leu Gln Pro Leu Lys His Ser Asp Ser

425

430

Lys Glu Asp Asp Gly Gln Glu Ile Ala

440

<210> 5

<211> 2229

<212> DNA

<213> Homo sapiens

<220>





85	90	95	
ccg gac ctg ctg gca cag ggc aac gca tcc ctg agg ctg cag cgc gtg			395
Pro Asp Leu Leu Ala Gln Gly Asn Ala Ser Leu Arg Leu Gln Arg Val			
100	105	110	
cgt gtg gcg gac gag ggc agc ttc acc tgc ttc gtg agc atc cgg gat			443
Arg Val Ala Asp Glu Gly Ser Phe Thr Cys Phe Val Ser Ile Arg Asp			
115	120	125	
ttc ggc agc gct gcc gtc agc ctg cag gtg gcc gct ccc tac tcg aag			491
Phe Gly Ser Ala Ala Val Ser Leu Gln Val Ala Ala Pro Tyr Ser Lys			
130	135	140	
ccc agc atg acc ctg gag ccc aac aag gac ctg cgg cca ggg gac acg			539
Pro Ser Met Thr Leu Glu Pro Asn Lys Asp Leu Arg Pro Gly Asp Thr			
145	150	155	160
gtg acc atc acg tgc tcc agc tac cag ggc tac cct gag gct gag gtg			587
Val Thr Ile Thr Cys Ser Ser Tyr Gln Gly Tyr Pro Glu Ala Glu Val			
165	170	175	
ttc tgg cag gat ggg cag ggt gtg ccc ctg act ggc aac gtg acc acg			635
Phe Trp Gln Asp Gly Gln Gly Val Pro Leu Thr Gly Asn Val Thr Thr			
180	185	190	
tcg cag atg gcc aac gag cag ggc ttg ttt gat gtg cac agc atc ctg			683
Ser Gln Met Ala Asn Glu Gln Gly Leu Phe Asp Val His Ser Ile Leu			

195	200	205	
cgg gtg gtg ctg ggt gca aat ggc acc tac agc tgc ctg gtg cgc aac	731		
Arg Val Val Leu Gly Ala Asn Gly Thr Tyr Ser Cys Leu Val Arg Asn			
210	215	220	
ccc gtg ctg cag cag gat gcg cac agc tct gtc acc atc aca ccc cag	779		
Pro Val Leu Gln Gln Asp Ala His Ser Ser Val Thr Ile Thr Pro Gln			
225	230	235	240
aga agc ccc aca gga gcc gtg gag gtc cag gtc cct gag gac ccg gtg	827		
Arg Ser Pro Thr Gly Ala Val Glu Val Gln Val Pro Glu Asp Pro Val			
245	250	255	
gtg gcc cta gtg ggc acc gat gcc acc ctg cgc tgc tcc ttc tcc ccc	875		
Val Ala Leu Val Gly Thr Asp Ala Thr Leu Arg Cys Ser Phe Ser Pro			
260	265	270	
gag cct ggc ttc agc ctg gca cag ctc aac ctc atc tgg cag ctg aca	923		
Glu Pro Gly Phe Ser Leu Ala Gln Leu Asn Leu Ile Trp Gln Leu Thr			
275	280	285	
gac acc aaa cag ctg gtg cac agt ttc acc gaa ggc cgg gac cag ggc	971		
Asp Thr Lys Gln Leu Val His Ser Phe Thr Glu Gly Arg Asp Gln Gly			
290	295	300	
agc gcc tat gcc aac cgc acg gcc ctc ttc ccg gac ctg ctg gca caa	1019		
Ser Ala Tyr Ala Asn Arg Thr Ala Leu Phe Pro Asp Leu Leu Ala Gln			

20069494 07215011

305	310	315	320	
ggc aat gca tcc ctg agg ctg cag cgc gtg cgt gtg gcg gac gag ggc				1067
Gly Asn Ala Ser Leu Arg Leu Gln Arg Val Arg Val Ala Asp Glu Gly				
325		330	335	
agc ttc acc tgc ttc gtg agc atc cgg gat ttc ggc agc gct gcc gtc				1115
Ser Phe Thr Cys Phe Val Ser Ile Arg Asp Phe Gly Ser Ala Ala Val				
340		345	350	
agc ctg cag gtg gcc gct ccc tac tcg aag ccc agc atg acc ctg gag				1163
Ser Leu Gln Val Ala Ala Pro Tyr Ser Lys Pro Ser Met Thr Leu Glu				
355		360	365	
ccc aac aag gac ctg cgg cca ggg gac acg gtg acc atc acg tgc tcc				1211
Pro Asn Lys Asp Leu Arg Pro Gly Asp Thr Val Thr Ile Thr Cys Ser				
370		375	380	
agc tac cgg ggc tac cct gag gct gag gtg ttc tgg cag gat ggg cag				1259
Ser Tyr Arg Gly Tyr Pro Glu Ala Glu Val Phe Trp Gln Asp Gly Gln				
385		390	395	400
ggg gtc ccc ctg act ggc aac gtg acc acg tcg cag atg gcc aac gag				1307
Gly Val Pro Leu Thr Gly Asn Val Thr Thr Ser Gln Met Ala Asn Glu				
405		410	415	
cag ggc ttg ttt gat gtg cac agc gtc ctg cgg gtg gtg ctg ggt gcg				1355
Gln Gly Leu Phe Asp Val His Ser Val Leu Arg Val Val Leu Gly Ala				

```

420
425
430

aat ggc acc tac agc tgc ctg gtg cgc aac ccc gtg ctg cag cag gat 1403
Asn Gly Thr Tyr Ser Cys Leu Val Arg Asn Pro Val Leu Gln Gln Asp
435 440 445

gcg cac ggc tct gtc acc atc aca ggg cag cct atg aca ttc ccc cca 1451
Ala His Gly Ser Val Thr Ile Thr Gly Gln Pro Met Thr Phe Pro Pro
450 455 460

gag gcc ctg tgg gtg acc gtg ggg ctg tct gtc tgt ctc att gca ctg 1499
Glu Ala Leu Trp Val Thr Val Gly Leu Ser Val Cys Leu Ile Ala Leu
465 470 475 480

ctg gtg gcc ctg gct ttc gtg tgc tgg aga aag atc aaa cag agc tgt 1547
Leu Val Ala Leu Ala Phe Val Cys Trp Arg Lys Ile Lys Gln Ser Cys
485 490 495

gag gag gag aat gca gga gct gag gac cag gat ggg gag gga gaa ggc 1595
Glu Glu Glu Asn Ala Gly Ala Glu Asp Gln Asp Gly Glu Gly Glu Gly
500 505 510

tcc aag aca gcc ctg cag cct ctg aaa cac tct gac agc aaa gaa gat 1643
Ser Lys Thr Ala Leu Gln Pro Leu Lys His Ser Asp Ser Lys Glu Asp
515 520 525

gat gga caa gaa ata gcc tgaccatgag gaccagggag ctgctacccc 1691
Asp Gly Gln Glu Ile Ala

```



```

1           5           10           15
Ala Leu Gly Ala Leu Trp Phe Cys Leu Thr Gly Ala Leu Glu Val Gln
20           25           30
Val Pro Glu Asp Pro Val Val Ala Leu Val Gly Thr Asp Ala Thr Leu
35           40           45
Cys Cys Ser Phe Ser Pro Glu Pro Gly Phe Ser Leu Ala Gln Leu Asn
50           55           60
Leu Ile Trp Gln Leu Thr Asp Thr Lys Gln Leu Val His Ser Phe Ala
65           70           75           80
Glu Gly Gln Asp Gln Gly Ser Ala Tyr Ala Asn Arg Thr Ala Leu Phe
85           90           95
Pro Asp Leu Leu Ala Gln Gly Asn Ala Ser Leu Arg Leu Gln Arg Val
100          105          110
Arg Val Ala Asp Glu Gly Ser Phe Thr Cys Phe Val Ser Ile Arg Asp
115          120          125
Phe Gly Ser Ala Ala Val Ser Leu Gln Val Ala Ala Pro Tyr Ser Lys
130          135          140
Pro Ser Met Thr Leu Glu Pro Asn Lys Asp Leu Arg Pro Gly Asp Thr
145          150          155          160

```

Val Thr Ile Thr Cys Ser Ser Tyr Gln Gly Tyr Pro Glu Ala Glu Val

165

170

175

Phe Trp Gln Asp Gly Gln Gly Val Pro Leu Thr Gly Asn Val Thr Thr

180

185

190

Ser Gln Met Ala Asn Glu Gln Gly Leu Phe Asp Val His Ser Ile Leu

195

200

205

Arg Val Val Leu Gly Ala Asn Gly Thr Tyr Ser Cys Leu Val Arg Asn

210

215

220

Pro Val Leu Gln Gln Asp Ala His Ser Ser Val Thr Ile Thr Pro Gln

225

230

235

240

Arg Ser Pro Thr Gly Ala Val Glu Val Gln Val Pro Glu Asp Pro Val

245

250

255

Val Ala Leu Val Gly Thr Asp Ala Thr Leu Arg Cys Ser Phe Ser Pro

260

265

270

Glu Pro Gly Phe Ser Leu Ala Gln Leu Asn Leu Ile Trp Gln Leu Thr

275

280

285

Asp Thr Lys Gln Leu Val His Ser Phe Thr Glu Gly Arg Asp Gln Gly

290

295

300



Ser Ala Tyr Ala Asn Arg Thr Ala Leu Phe Pro Asp Leu Leu Ala Gln

305 310 315 320

Gly Asn Ala Ser Leu Arg Leu Gln Arg Val Arg Val Ala Asp Glu Gly

325 330 335

Ser Phe Thr Cys Phe Val Ser Ile Arg Asp Phe Gly Ser Ala Ala Val

340 345 350

Ser Leu Gln Val Ala Ala Pro Tyr Ser Lys Pro Ser Met Thr Leu Glu

355 360 365

Pro Asn Lys Asp Leu Arg Pro Gly Asp Thr Val Thr Ile Thr Cys Ser

370 375 380

Ser Tyr Arg Gly Tyr Pro Glu Ala Glu Val Phe Trp Gln Asp Gly Gln

385 390 395 400

Gly Val Pro Leu Thr Gly Asn Val Thr Thr Ser Gln Met Ala Asn Glu

405 410 415

Gln Gly Leu Phe Asp Val His Ser Val Leu Arg Val Val Leu Gly Ala

420 425 430

Asn Gly Thr Tyr Ser Cys Leu Val Arg Asn Pro Val Leu Gln Gln Asp

435 440 445

Ala His Gly Ser Val Thr Ile Thr Gly Gln Pro Met Thr Phe Pro Pro

450

455

460

Glu Ala Leu Trp Val Thr Val Gly Leu Ser Val Cys Leu Ile Ala Leu

465

470

475

480

Leu Val Ala Leu Ala Phe Val Cys Trp Arg Lys Ile Lys Gln Ser Cys

485

490

495

Glu Glu Glu Asn Ala Gly Ala Glu Asp Gln Asp Gly Glu Gly Glu Gly

500

505

510

Ser Lys Thr Ala Leu Gln Pro Leu Lys His Ser Asp Ser Lys Glu Asp

515

520

525

Asp Gly Gln Glu Ile Ala

530

<210> 7

<211> 1020

<212> DNA

<213> Homo sapiens

<400> 7

atggccaacg agcagggcctt gtttgatgtg cacagcatcc tgcgggtggt gctgggtgca 60

aatggcacct acagctgcct ggtgcgcaac cccgtgctgc agcaggatgc gcacagctct 120



11-11-66 07:00

acagccctgc agcctctgaa acactctgac agcaaagaag atgatggaca agaaatagcc 1020

<210> 8

<211> 1561

<212> DNA

<213> Homo sapiens

<400> 8

tgaccatgag gaccagggag ctgctacccc tccctacagc tcctaccctc tggctgcaat 60

ggggctgcac tgtgagccct gcccccaaca gatgcatacct gctctgacag gtgggctcct 120

tctccaaagg atgcgataca cagaccactg tgcagcctta tttctccaat ggacatgatt 180

cccaagtcac cctgctgcct tttttcttat agacacaatg aacagaccac ccacaacctt 240

agttctctaa gtcacctgc ctgctgcctt atttcacagt acatacatTT cttagggaca 300

cagtacactg accacatcac caccctcttc ttccagtgtc gcgtggacca tctggctgcc 360

ttttttctcc aaaagatgca atattcagac tgactgaccc cctgccttat ttcaccaaag 420

acacgatgca tagtcacccc ggcttggttt ctccaatggc cgtgatacac tagtgatcat 480

gttcagccct gcttcacct gcatagaatc tttctttctc agacagggac agtgcggcct 540

caacatctcc tggagtctag aagctgtttc ctttcccttc cttcctcttc ttgctctagc 600

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 10

cttaataactg gccttttccc tccttgcccc aagtgaagac agggcactct gcgcccacca 660

catgcacagc tgtgcatgga gacctgcagg tgcacgtgct ggaacacgtg tggttccccc 720

ctggcccagc ctctcttgca gtgcccctct ccctgcccc tcttccccac ggaagcatgt 780

gctggtcaca ctggttctcc aggggtctgt gatggggccc ctgggggtca gcttctgtcc 840

ctctgccttc tcacctcttt gtctctttct tttcatgtat ccattcagtt gatgtttatt 900

gagcaactac agatgtcagc actgtgttag gtgctggggg ccctgcgtgg gaagataaag 960

ttctccctc aaggactccc catccagctg ggagacagac aactaactac actgcaccct 1020

gcggtttgca gggggctcct gcctggctcc ctgctccaca cctcctctgt ggctcaaggg 1080

ttcttgata cctcaccccc atcccaccca taattcttac ccagagcatg gggttggggc 1140

ggaaacctgg agagagggac atagcccctc gccacggcta gagaatctgg tgggtgtccaa 1200

aatgtctgtc caggtgtggg caggtgggca ggcaccaagg ccctctggac ctttcatagc 1260

agcagaaaag gcagagcctg gggcagggca gggccaggaa tgctttgggg acaccgaggg 1320

gactgcccc cacccccacc atggtgctat tctggggctg gggcagtctt ttctggctt 1380

gcctctggcc agctcccggc ctctggtaga gtgagacttc agacgttctg atgccttccg 1440

THE UNIVERSITY OF CHICAGO

gatgtcatct ctccctgccc caggaatgga agatgtgagg acttctaatt taaatgtggg 1500

actcggaggg attttgtaaa ctgggggtat attttgggga aaataaatgt ctttgtaaaa 1560

a 1561

<210> 9

<211> 1323

<212> DNA

<213> Homo sapiens

<400> 9

cctcttcccc gacctgctgg cacagggcaa cgcattccctg aggctgcagc gcgtgcgtgt 60

agcggacgag ggcagcttca cctgcttcgt gagcatccgg gatttcggca gcgctgccgt 120

cagcctgcag gtggccgctc cctactcgaa gcccgagcatg accctggagc ccaacaagga,180

cctgcggcc a ggggacacgg tgtgaccatc acgtgctcca gctaccaggg ctaccctgag 240

gctgaggtgt tctggcagga tgggcagggg gtgccctga ctggcaacgt gaccacgtcg 300

cagatggcca acgagcaggg cttgtttgat gtgcacagca tcctgcgggt ggtgctgggt 360

gcaaattggca cctacagctg cctggtgcgc aaccccgctgc tgcagcagga tgcgcacagc 420

tctgtcacca tcacacccca gagaagcccc acaggagccg tggagggtcca ggtccctgag 480

gacccggtgg tggccctagt gggcacccgat gccaccctgc actgctcctt ctcccccgag 540

cctggcttca gcctgacaca gctcaacctc atctggcagc tgacagacac caaacagctg 600

gtgcacagtt tcaccgaagg ccgggaccag ggcagcgcct atgccaaccg cacggccctc 660

ttcccggaac tgctggcaca aggcaatgca tcctgaggc tgcagcgcgt gcgtgtggcg 720

gacgagggca gcttcacctg cttcgtgagc atccgggatt tcggcagcgc tgccgtcagc 780

ctgcaggtgg ccgctcccta ctgaagccc agcatgacct tggagcccaa caaggacctg 840

cggccagggg acacggtgac catcacgtgc tccagctacc ggggctacct tgaggctgag 900

gtgttctggc aggatgggca ggggtgtgcc ctgactggca acgtgaccac gtcgcagatg 960

gccaacgagc agggcttgtt tgatgtgcac agcgtcctgc gggtggtgct gggtgccaat 1020

ggcacctaca gctgcctggt gcgcaacccc gtgctgcagc aggatgcgca cggctctgtc 1080

accatcacag ggcagcctat gacattcccc ccagaggccc tgtgggtgac cgtggggctc 1140

tctgtctgtc tcattgcact gctgggtggc ctggctttcg tgtgctggag aaagatcaaa 1200

cagagctgtg aggaggagaa tgcaggagcc gaggaccagg atggggaggg agaaggctcc 1260







gcctctggcc agctcccggc ctctggtaga gtgagacttc agacgttctg atgccttccg 1440

gatgtcatct ctccctgccc caggaatgga agatgtgagg acttctaatt taaatgtggg 1500

actcggaggg attttgtaaa ctgggggtat attttgggga aaataaatgt ctttgtaaaa 1560

a 1561

<210> 11

<211> 1602

<212> DNA

<213> Homo sapiens

<400> 11

atgctgcgtc ggcggggcag ccctggcatg ggtgtgcatg tgggtgcagc cctgggagca 60

ctgtggttct gcctcacagg agccctggag gtccaggctc ctgaagacc agtggtggca 120

ctgggtggga ccgatgccac cctgtgctgc tctttctccc ctgagcctgg cttcagcctg 180

gcacagctca acctcatctg gcagctgaca gataccaaac agctggtgca cagctttgct 240

gagggccagg accagggcag cgcctatgcc aaccgcacgg ccctcttccc ggacctgctg 300

gcacaggga acgcattcct gaggtgcag cgcgtgcgtg tggcggacga gggcagcttc 360

acctgcttcg tgagcatccg ggatttcggc agcgtgccc tcagcctgca ggtggccgct 420

ccctactcga agcccagcat gaccctggag cccaacaagg acctgcggcc aggggacacg 480

gtgaccatca cgtgctccag ctaccagggc taccctgagg ctgaggtgtt ctggcaggat 540

gggcagggtg tgcccctgac tggcaacgtg accacgtcgc agatggccaa cgagcagggc 600

ttgtttgatg tgcacagcat cctgcgggtg gtgctgggtg caaatggcac ctacagctgc 660

ctggtgcgca acccctgct gcagcaggat gcgcacagct ctgtcaccat cacacccag 720

agaagcccca caggagccgt ggaggtccag gtccctgagg acccgtggt ggccctagt 780

ggcacgatg ccaccctgcg ctgctccttc tccccgagc ctggcttcag cctggcacag 840

ctcaacctca tctggcagct gacagacacc aaacagctgg tgcacagttt caccgaaggc 900

cgggaccagg gcagcgccta tgccaaccgc acggccctct tcccggacct gctggcacia 960

ggcaatgcat ccctgaggct gcagcgcgtg cgtgtggcgg acgagggcag cttcacctgc 1020

ttcgtgagca tccgggattt cggcagcgt gccgtcagcc tgcaggtggc cgctccctac 1080

tcgaagccca gcatgaccct ggagcccaac aaggacctgc ggccagggga cacggtgacc 1140

atcacgtgct ccagctaccg gggctaccct gaggctgagg tgttctggca ggatgggcag 1200

ggtgtgcccc tgactggcaa cgtgaccacg tgcagatgg ccaacgagca gggcttgttt 1260

gatgtgcaca gcgtcctgcg ggtggtgctg ggtgcgaatg gcacctacag ctgcctgggtg 1320

cgcaaccccg tgctgcagca ggatgcgcac ggctctgtca ccatcacagg gcagcctatg 1380

acattcccc cagagggcct gtgggtgacc gtggggctgt ctgtctgtct cattgcactg 1440

ctggtggccc tggctttcgt gtgctggaga aagatcaaac agagctgtga ggaggagaat 1500

gcaggagctg aggaccagga tggggaggga gaaggctcca agacagccct gcagcctctg 1560

aaacactctg acagcaaaga agatgatgga caagaaatag cc 1602

<210> 12

<211> 568

<212> DNA

<213> Homo sapiens

<400> 12

tgaccatgag gaccagggag ctgctacccc tccctacagc tcctaccctc tggctgcaat 60

ggggctgcac tgtgagccct gcccacaaca gatgcatcct gctctgacag gtgggctcct 120

tctccaaagg atgcgataca cagaccactg tgcagcctta tttctccaat ggacatgatt 180

cccaagtcat cctgctgcct tttttcttat agacacaatg aacagaccac ccacaacctt 240



11069626 4740000000

Ser Cys Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile

50

60

Tyr Trp Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp

65

75

80

Met Asn Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr

85

95

Asn Asn Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly

100

110

Thr Tyr Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg

115

125

Glu His Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr

130

140

Pro Ser Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile

145

155

160

Ile Cys Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu

165

175

Glu Asn Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp

180

190

Pro Glu Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met

195

200

205

Thr Thr Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg

210

215

220

Val Asn Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro

225

230

235

240

Asp Asn Leu Leu Pro Ser Trp Ala Ile Thr Leu Ile Ser Val Asn Gly

245

250

255

Ile Phe Val Ile Cys Cys Leu Thr Tyr Cys Phe Ala Pro Arg Cys Arg

260

265

270

Glu Arg Arg Arg Asn Glu Arg Leu Arg Arg Glu Ser Val Arg Pro Val

275

280

285

<210> 14

<211> 288

<212> PRT

<213> Macaca mulatta

<400> 14

2025 RELEASE UNDER E.O. 14176

Met Gly His Thr Arg Arg Gln Glu Ile Ser Pro Ser Lys Cys Pro Tyr

1                      5                      10                      15

Leu Lys Phe Phe Gln Leu Leu Val Leu Ala Cys Leu Ser His Phe Cys

20                      25                      30

Ser Gly Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu

35                      40                      45

Ser Cys Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile

50                      55                      60

Tyr Trp Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp

65                      70                      75                      80

Met Asn Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr

85                      90                      95

Asn Asn Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly

100                      105                      110

Thr Tyr Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg

115                      120                      125

Glu His Leu Ala Glu Val Met Leu Ser Val Lys Ala Asp Phe Pro Thr

130                      135                      140

Pro Ser Ile Thr Asp Ser Glu Ile Pro Pro Ser Asn Ile Arg Arg Ile







Tyr Thr Cys Val Val Gln Lys Asn Glu Asn Gly Ser Phe Arg Arg Glu  
115 120 125

His Leu Thr Ser Val Thr Leu Ser Ile Arg Ala Asp Phe Pro Val Pro  
130 135 140

Ser Ile Thr Asp Ile Gly His Pro Asp Pro Asn Val Lys Arg Ile Arg  
145 150 155 160

Cys Ser Ala Ser Gly Gly Phe Pro Glu Pro Arg Leu Ala Trp Met Glu  
165 170 175

Asp Gly Glu Glu Leu Asn Ala Val Asn Thr Thr Val Asp Gln Asp Leu  
180 185 190

Asp Thr Glu Leu Tyr Ser Val Ser Ser Glu Leu Asp Phe Asn Val Thr  
195 200 205

Asn Asn His Ser Ile Val Cys Leu Ile Lys Tyr Gly Glu Leu Ser Val  
210 215 220

Ser Gln Ile Phe Pro Trp Ser Lys Pro Lys Gln Glu Pro Pro Ile Asp  
225 230 235 240

Gln Leu Pro Phe Trp Val Ile Ile Pro Val Ser Gly Ala Leu Val Leu  
245 250 255

Thr Ala Val Val Leu Tyr Cys Leu Ala Cys Arg His Val Ala Arg Trp

260

265

270

Lys Arg Thr Arg Arg Asn Glu Glu Thr Val Gly Thr Glu Arg Leu Ser

275

280

285

Pro Ile Tyr Leu Gly Ser Ala Gln Ser Ser Gly

290

295

<210> 16

<211> 292

&lt;212&gt; PRT

<213> Felis catus

<400> 16

Met Gly His Ala Ala Lys Trp Lys Thr Pro Leu Leu Lys His Pro Tyr

1

5

10

15

Pro Lys Leu Phe Pro Leu Leu Met Leu Ala Ser Leu Phe Tyr Phe Cys

20

25

30

Ser Gly Ile Ile Gln Val Asn Lys Thr Val Glu Glu Val Ala Val Leu

35

40

45

Ser Cys Asp Tyr Asn Ile Ser Thr Lys Glu Leu Thr Glu Ile Arg Ile

50

55

60

Tyr Trp Gln Lys Asp Asp Glu Met Val Leu Ala Val Met Ser Gly Lys

65 70 75 80

Val Gln Val Trp Pro Lys Tyr Lys Asn Arg Thr Phe Thr Asp Val Thr

85 90 95

Asp Asn His Ser Ile Val Ile Met Ala Leu Arg Leu Ser Asp Asn Gly

100 105 110

Lys Tyr Thr Cys Ile Ile Gln Lys Ile Glu Lys Gly Ser Tyr Lys Val

115 120 125

Lys His Leu Thr Ser Val Met Leu Leu Val Arg Ala Asp Phe Pro Val

130 135 140

Pro Ser Ile Thr Asp Leu Gly Asn Pro Ser His Asn Ile Lys Arg Ile

145 150 155 160

Met Cys Leu Thr Ser Gly Gly Phe Pro Lys Pro His Leu Ser Trp Leu

165 170 175

Glu Asn Glu Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp

180 185 190

Pro Glu Thr Glu Leu Tyr Thr Ile Ser Ser Glu Leu Asp Phe Asn Met

195 200 205

Thr Asn Asn His Ser Phe Leu Cys Leu Val Lys Tyr Gly Asn Leu Leu

ALL INFORMATION CONTAINED HEREIN IS UNCLASSIFIED

210	215	220
Val Ser Gln Ile Phe Asn Trp Gln Lys Ser Glu Pro Gln Pro Ser Asn		
225	230	235
240		
Asn Gln Leu Trp Ile Ile Ile Leu Ser Ser Val Val Ser Gly Ile Val		
245	250	255
Val Ile Thr Ala Leu Thr Leu Arg Cys Leu Val His Arg Pro Ala Ala		
260	265	270
Arg Trp Arg Gln Arg Glu Met Gly Arg Ala Arg Lys Trp Lys Arg Ser		
275	280	285
290		
His Leu Ser Thr		

<210> 17

<211> 306

<212> PRT

<213> mus sp.

<400> 17

Met Ala Cys Asn Cys Gln Leu Met Gln Asp Thr Pro Leu Leu Lys Phe  
1 5 10 15

Pro Cys Pro Arg Leu Ile Leu Leu Phe Val Leu Leu Ile Arg Leu Ser

20

25

30

Gln Val Ser Ser Asp Val Asp Glu Gln Leu Ser Lys Ser Val Lys Asp

35

40

45

Lys Val Leu Leu Pro Cys Arg Tyr Asn Ser Pro His Glu Asp Glu Ser

50

55

60

Glu Asp Arg Ile Tyr Trp Gln Lys His Asp Lys Val Val Leu Ser Val

65

70

75

80

Ile Ala Gly Lys Leu Lys Val Trp Pro Glu Tyr Lys Asn Arg Thr Leu

85

90

95

Tyr Asp Asn Thr Thr Tyr Ser Leu Ile Ile Leu Gly Leu Val Leu Ser

100

105

110

Asp Arg Gly Thr Tyr Ser Cys Val Val Gln Lys Lys Glu Arg Gly Thr

115

120

125

Tyr Glu Val Lys His Leu Ala Leu Val Lys Leu Ser Ile Lys Ala Asp

130

135

140

Phe Ser Thr Pro Asn Ile Thr Glu Ser Gly Asn Pro Ser Ala Asp Thr

145

150

155

160

Lys Arg Ile Thr Cys Phe Ala Ser Gly Gly Phe Pro Lys Pro Arg Phe

165

170

175

Ser Trp Leu Glu Asn Gly Arg Glu Leu Pro Gly Ile Asn Thr Thr Ile  
180 185 190

Ser Gln Asp Pro Glu Ser Glu Leu Tyr Thr Ile Ser Ser Gln Leu Asp  
195 200 205

Phe Asn Thr Thr Arg Asn His Thr Ile Lys Cys Leu Ile Lys Tyr Gly  
210 215 220

Asp Ala His Val Ser Glu Asp Phe Thr Trp Glu Lys Pro Pro Glu Asp  
225 230 235 240

Pro Pro Asp Ser Lys Asn Thr Leu Val Leu Phe Gly Ala Gly Phe Gly  
245 250 255

Ala Val Ile Thr Val Val Val Ile Val Val Ile Ile Lys Cys Phe Cys  
260 265 270

Lys His Arg Ser Cys Phe Arg Arg Asn Glu Ala Ser Arg Glu Thr Asn  
 , 275 280 285

Asn Ser Leu Thr Phe Gly Pro Glu Glu Ala Leu Ala Glu Gln Thr Val  
290 295 300

Phe Leu  
305





**SECRET**

Ile His Tyr Lys Gly Pro Lys Gly Leu Val Pro Met His Gln Met Ser  
115 120 125

Ser Asp Leu Ser Val Leu Ala Asn Phe Ser Gln Pro Glu Ile Thr Val  
130 135 140

Thr Ser Asn Arg Thr Glu Asn Ser Gly Ile Ile Asn Leu Thr Cys Ser  
145 150 155 160

Ser Ile Gln Gly Tyr Pro Glu Pro Lys Glu Met Tyr Phe Gln Leu Asn  
165 170 175

Thr Glu Asn Ser Thr Thr Lys Tyr Asp Thr Val Met Lys Lys Ser Gln  
180 185 190

Asn Asn Val Thr Glu Leu Tyr Asn Val Ser Ile Ser Leu Pro Phe Ser  
195 200 205

Val Pro Glu Ala His Asn Val Ser Val Phe Cys Ala Leu Lys Leu Glu  
210 215 220

Thr Leu Glu Met Leu Leu Ser Leu Pro Phe Asn Ile Asp Ala Gln Pro  
225 230 235 240

Lys Asp Lys Asp Pro Glu Gln Gly His Phe Leu Trp Ile Ala Ala Val  
245 250 255

Leu Val Met Phe Val Val Phe Cys Gly Met Val Ser Phe Lys Thr Leu

260 265 270

Arg Lys Arg Lys Lys Lys Gln Pro Gly Pro Ser His Glu Cys Glu Thr

275 280 285

Ile Lys Arg Glu Arg Lys Glu Ser Lys Gln Thr Asn Glu Arg Val Pro

290 295 300

Tyr His Val Pro Glu Arg Ser Asp Glu Ala Gln Cys Val Asn Ile Leu

305 310 315 320

Lys Thr Ala Ser Gly Asp Lys Asn Gln

325

<210> 19

<211> 329

<212> PRT

<213> Canis familiaris

<400> 19

Met Tyr Leu Arg Cys Thr Met Glu Leu Asn Asn Ile Leu Phe Val Met

1 5 10 15

Thr Leu Leu Leu Tyr Gly Ala Ala Ser Met Lys Ser Gln Ala Tyr Phe

20 25 30

Asn Lys Thr Gly Glu Leu Pro Cys His Phe Thr Asn Ser Gln Asn Ile

35	40	45
Ser Leu Asp Glu Leu Val Val Phe Trp Gln Asp Gln Asp Lys Leu Val		
50	55	60
Leu Tyr Glu Leu Tyr Arg Gly Lys Glu Asn Pro Gln Asn Val His Arg		
65	70	75 80
Lys Tyr Lys Gly Arg Thr Ser Phe Asp Lys Asp Asn Trp Thr Leu Arg		
85	90	95
Leu His Asn Ile Gln Ile Lys Asp Lys Gly Leu Tyr Gln Cys Phe Val		
100	105	110
His His Lys Gly Pro Lys Gly Leu Val Pro Met His Gln Met Asn Ser		
115	120	125
Asp Leu Ser Val Leu Ala Asn Phe Ser Gln Pro Glu Ile Met Val Thr		
130	135	140
Ser Asn Arg Thr Glu Asn Ser Gly Ile Ile Asn Leu Thr Cys Ser Ser		
145	150	155 160
Ile Gln Gly Tyr Pro Glu Pro Lys Glu Met Tyr Phe Leu Val Lys Thr		
165	170	175
Glu Asn Ser Ser Thr Lys Tyr Asp Thr Val Met Lys Lys Ser Gln Asn		
180	185	190





Gly Leu Val Pro Ile His Gln Met Ser Ser Asp Leu Ser Leu Leu Ala

115

120

125

Asn Phe Ser Gln Pro Glu Ile Asn Leu Leu Thr Asn His Thr Glu Asn

130

135

140

Ser Val Ile Asn Leu Thr Cys Ser Ser Thr Gln Gly Tyr Pro Glu Pro

145

150

155

160

Gln Arg Met Tyr Met Leu Leu Asn Thr Lys Asn Ser Thr Thr Glu His

165

170

175

Asp Ala Asp Met Lys Lys Ser Gln Asn Asn Ile Thr Glu Leu Tyr Asn

180

185

190

Val Ser Ile Arg Val Ser Leu Pro Ile Pro Pro Glu Thr Asn Val Ser

195

200

205

Ile Val Cys Val Leu Gln Leu Glu Pro Ser Lys Thr Leu Leu Phe Ser

210

215

220

Leu Pro Cys Asn Ile Asp Ala Lys Pro Pro Val Gln Pro Pro Val Pro

225

230

235

240

Asp His Ile Leu Trp Ile Ala Ala Leu Leu Val Thr Val Val Val Val

245

250

255

Cys Gly Met Val Ser Phe Val Thr Leu Arg Lys Arg Lys Lys Lys Gln





35	40	45
Val Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu		
50	55	60
Gly Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Gly Arg Thr		
65	70	75 80
Ser Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile		
85	90	95
Lys Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr		
100	105	110
Gly Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu Ala		
115	120	125
Asn Phe Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn		
130	135	140
Val Tyr Ile Asn Leu Thr Cys Ser Ser Ile His Gly Tyr Pro Glu Pro		
145	150	155 160
Lys Lys Met Ser Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr		
165	170	175
Asp Gly Ile Met Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp		
180	185	190

The musical score for 'The Rose Tree' is presented in two systems. The first system consists of a vocal line (Soprano) and a piano accompaniment. The vocal line begins with a treble clef and a key signature of one flat (B-flat). The piano accompaniment begins with a bass clef and a key signature of one flat. The second system continues the vocal line and piano accompaniment. The vocal line ends with a double bar line. The piano accompaniment ends with a double bar line. The score is written in a standard musical notation style, with notes, rests, and bar lines clearly visible.

Val Ser Ile Ser Leu Ser Val Ser Phe Pro Asp Val Thr Ser Asn Met  
195 200 205

Thr Ile Phe Cys Ile Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser  
210 215 220

Pro Phe Ser Ile Glu Leu Glu Asp Pro Gln Pro Pro Pro Asp His Ile  
225 230 235 240

Pro Trp Ile Thr Ala Val Leu Pro Thr Val Ile Ile Cys Val Met Val  
245 250 255

Phe Cys Leu Ile Leu Trp Lys Trp Lys Lys Lys Lys Arg Pro Arg Asn  
260 265 270

Ser Tyr Lys Cys Gly Thr Asn Thr Met Glu Arg Glu Glu Ser Glu Gln  
275 280 285

Thr Lys Lys Arg Glu Lys Ile His Ile Pro Glu Arg Ser Asp Glu Ala  
290 295 300

Gln Arg Val Phe Lys Ser Ser Lys Thr Ser Ser Cys Asp Lys Ser Asp  
305 310 315 320

Thr Cys Phe

<210> 22

<211> 309

<212> PRT

<213> Mus musculus

<400> 22

Met Asp Pro Arg Cys Thr Met Gly Leu Ala Ile Leu Ile Phe Val Thr

1 5 10 15

Val Leu Leu Ile Ser Asp Ala Val Ser Val Glu Thr Gln Ala Tyr Phe

20 25 30

Asn Gly Thr Ala Tyr Leu Pro Cys Pro Phe Thr Lys Ala Gln Asn Ile

35 40 45

Ser Leu Ser Glu Leu Val Val Phe Trp Gln Asp Gln Gln Lys Leu Val

50 55 60

Leu Tyr Glu His Tyr Leu Gly Thr Glu Lys Leu Asp Ser Val Asn Ala

65 70 75 80

Lys Tyr Leu Gly Arg Thr Ser Phe Asp Arg Asn Asn Trp Thr Leu Arg

85 90 95

Leu His Asn Val Gln Ile Lys Asp Met Gly Ser Tyr Asp Cys Phe Ile

100 105 110

Gln Lys Lys Pro Pro Thr Gly Ser Ile Ile Leu Gln Gln Thr Leu Thr

115

120

125

Glu Leu Ser Val Ile Ala Asn Phe Ser Glu Pro Glu Ile Lys Leu Ala

130

135

140

Gln Asn Val Thr Gly Asn Ser Gly Ile Asn Leu Thr Cys Thr Ser Lys

145

150

155

160

Gln Gly His Pro Lys Pro Lys Lys Met Tyr Phe Leu Ile Thr Asn Ser

165

170

175

Thr Asn Glu Tyr Gly Asp Asn Met Gln Ile Ser Gln Asp Asn Val Thr

180

185

190

Glu Leu Phe Ser Ile Ser Asn Ser Leu Ser Leu Ser Phe Pro Asp Gly

195

200

205

Val Trp His Met Thr Val Val Cys Val Leu Glu Thr Glu Ser Met Lys

210

215

220

Ile Ser Ser Lys Pro Leu Asn Phe Thr Gln Glu Phe Pro Ser Pro Gln

225

230

235

240

Thr Tyr Trp Lys Glu Ile Thr Ala Ser Val Thr Val Ala Leu Leu Leu

245

250

255

Val Met Leu Leu Ile Ile Val Cys His Lys Lys Pro Asn Gln Pro Ser

1. The first part of the document is a list of names and titles, including "The Hon. Mr. Justice" and "The Hon. Mr. Justice".

265

270

Arg Pro Ser Asn Thr Ala Ser Lys Leu Glu Arg Asp Ser Asn Ala Asp

280

285

Arg Glu Thr Ile Asn Leu Lys Glu Leu Glu Pro Gln Ile Ala Ser Ala

295

300

Lys Pro Asn Ala Glu

305

<210> 23

<211> 303

<212> PRT

<213> Mus musculus

<400> 23

Met Gly Leu Ala Ile Leu Ile Phe Val Thr Val Leu Leu Ile Ser Asp

5

10

15

Ala Val Ser Val Glu Thr Gln Ala Tyr Phe Asn Gly Thr Ala Tyr Leu

25

30

Pro Cys Pro Phe Thr Lys Ala Gln Asn Ile Ser Leu Ser Glu Leu Val

40

45

Val Phe Trp Gln Asp Gln Gln Lys Leu Val Leu Tyr Glu His Tyr Leu

50

55

60

Gly Thr Glu Lys Leu Asp Ser Val Asn Ala Lys Tyr Leu Gly Arg Thr

65

70

75

80

Ser Phe Asp Arg Asn Asn Trp Thr Leu Arg Leu His Asn Val Gln Ile

85

90

95

Lys Asp Met Gly Ser Tyr Asp Cys Phe Ile Gln Lys Lys Pro Pro Thr

100

105

110

Gly Ser Ile Ile Leu Gln Gln Thr Leu Thr Glu Leu Ser Val Ile Ala

115

120

125

Asn Phe Ser Glu Pro Glu Ile Lys Leu Ala Gln Asn Val Thr Gly Asn

130

135

140

Ser Gly Ile Asn Leu Thr Cys Thr Ser Lys Gln Gly His Pro Lys Pro

145

150

155

160

Lys Lys Met Tyr Phe Leu Ile Thr Asn Ser Thr Asn Glu Tyr Gly Asp

165

170

175

Asn Met Gln Ile Ser Gln Asp Asn Val Thr Glu Leu Phe Ser Ile Ser

180

185

190

Asn Ser Leu Ser Leu Ser Phe Pro Asp Gly Val Trp His Met Thr Val

195

200

205

Val Cys Val Leu Glu Thr Glu Ser Met Lys Ile Ser Ser Lys Pro Leu

210 215 220

Asn Phe Thr Gln Glu Phe Pro Ser Pro Gln Thr Tyr Trp Lys Glu Ile

225 230 235 240

Thr Ala Ser Val Thr Val Ala Leu Leu Leu Val Met Leu Leu Ile Ile

245 250 255

Val Cys His Lys Lys Pro Asn Gln Pro Ser Arg Pro Ser Asn Thr Ala

260 265 270

Ser Lys Leu Glu Arg Asp Ser Asn Ala Asp Arg Glu Thr Ile Asn Leu

275 280 285

Lys Glu Leu Glu Pro Gln Ile Ala Ser Ala Lys Pro Asn Ala Glu

290 295 300

<210> 24

<211> 534

<212> PRT

<213> Unknown

<220>

<223> Description of Unknown Organism: Sequence

mz5020.protein from Figure 4.

[illegible]

<400> 24

Met Leu Arg Arg Arg Gly Ser Pro Gly Met Gly Val His Val Gly Ala

1                      5                      10                      15

Ala Leu Gly Ala Leu Trp Phe Cys Leu Thr Gly Ala Leu Glu Val Gln

20                      25                      30

Val Pro Glu Asp Pro Val Val Ala Leu Val Gly Thr Asp Ala Thr Leu

35                      40                      45

Cys Cys Ser Phe Ser Pro Glu Pro Gly Phe Ser Leu Ala Gln Leu Asn

50                      55                      60

Leu Ile Trp Gln Leu Thr Asp Thr Lys Gln Leu Val His Ser Phe Ala

65                      70                      75                      80

Glu Gly Gln Asp Gln Gly Ser Ala Tyr Ala Asn Arg Thr Ala Leu Phe

85                      90                      95

Pro Asp Leu Leu Ala Gln Gly Asn Ala Ser Leu Arg Leu Gln Arg Val

100                      105                      110

Arg Val Ala Asp Glu Gly Ser Phe Thr Cys Phe Val Ser Ile Arg Asp

115                      120                      125

Phe Gly Ser Ala Ala Val Ser Leu Gln Val Ala Ala Pro Tyr Ser Lys

130                      135                      140



Pro Ser Met Thr Leu Glu Pro Asn Lys Asp Leu Arg Pro Gly Asp Thr  
 145 150 155 160

Val Thr Ile Thr Cys Ser Ser Tyr Gln Gly Tyr Pro Glu Ala Glu Val  
 165 170 175

Phe Trp Gln Asp Gly Gln Gly Val Pro Leu Thr Gly Asn Val Thr Thr  
 180 185 190

Ser Gln Met Ala Asn Glu Gln Gly Leu Phe Asp Val His Ser Ile Leu  
 195 200 205

Arg Val Val Leu Gly Ala Asn Gly Thr Tyr Ser Cys Leu Val Arg Asn  
 210 215 220

Pro Val Leu Gln Gln Asp Ala His Ser Ser Val Thr Ile Thr Pro Gln  
 225 230 235 240

Arg Ser Pro Thr Gly Ala Val Glu Val Gln Val Pro Glu Asp Pro Val  
 245 250 255

Val Ala Leu Val Gly Thr Asp Ala Thr Leu Arg Cys Ser Phe Ser Pro  
 260 265 270

Glu Pro Gly Phe Ser Leu Ala Gln Leu Asn Leu Ile Trp Gln Leu Thr  
 275 280 285

Asp Thr Lys Gln Leu Val His Ser Phe Thr Glu Gly Arg Asp Gln Gly

290 295 300

Ser Ala Tyr Ala Asn Arg Thr Ala Leu Phe Pro Asp Leu Leu Ala Gln

305 310 315 320

Gly Asn Ala Ser Leu Arg Leu Gln Arg Val Arg Val Ala Asp Glu Gly

325 330 335

Ser Phe Thr Cys Phe Val Ser Ile Arg Asp Phe Gly Ser Ala Ala Val

340 345 350

Ser Leu Gln Val Ala Ala Pro Tyr Ser Lys Pro Ser Met Thr Leu Glu

355 360 365

Pro Asn Lys Asp Leu Arg Pro Gly Asp Thr Val Thr Ile Thr Cys Ser

370 375 380

Ser Tyr Arg Gly Tyr Pro Glu Ala Glu Val Phe Trp Gln Asp Gly Gln

385 390 395 400

Gly Val Pro Leu Thr Gly Asn Val Thr Thr Ser Gln Met Ala Asn Glu

405 410 415

Gln Gly Leu Phe Asp Val His Ser Val Leu Arg Val Val Leu Gly Ala

420 425 430

Asn Gly Thr Tyr Ser Cys Leu Val Arg Asn Pro Val Leu Gln Gln Asp

435 440 445

Ala His Gly Ser Val Thr Ile Thr Gly Gln Pro Met Thr Phe Pro Pro

450 455 460

Leu Val Ala Leu Ala Phe Val Cys Trp Arg Lys Ile Lys Gln Ser Cys  
485 490 495

Ser Lys Thr Ala Leu Gln Pro Leu Lys His Ser Asp Ser Lys Glu Asp  
515 520 525

<210> 25

<211> 350

<212> PRT

<213> Homo sapiens

<400> 25

Met Ala Ser Phe Leu Ala Phe Leu Leu Leu Asn Phe Arg Val Cys Leu

1	5	10	15
Leu Leu Leu Gln Leu Leu Met Pro His Ser Ala Gln Phe Ser Val Leu			
20	25	30	
Gly Pro Ser Gly Pro Ile Leu Ala Met Val Gly Glu Asp Ala Asp Leu			
35	40	45	
Pro Cys His Leu Phe Pro Thr Met Ser Ala Glu Thr Met Glu Leu Lys			
50	55	60	
Trp Val Ser Ser Ser Leu Arg Gln Val Val Asn Val Tyr Ala Asp Gly			
65	70	75	80
Lys Glu Val Glu Asp Arg Gln Ser Ala Pro Tyr Arg Gly Arg Thr Ser			
85	90	95	
Ile Leu Arg Asp Gly Ile Thr Ala Gly Lys Ala Ala Phe Arg Ile His			
100	105	110	
Asn Val Thr Gly Ser Asp Arg Trp Lys Tyr Leu Cys Tyr Phe Gln Asp			
115	120	125	
Gly Asp Phe Tyr Glu Lys Ala Leu Val Glu Leu Lys Val Ala Ala Leu			
130	135	140	
Gly Ser Asp Leu His Val Asp Val Lys Gly Tyr Lys Asp Gly Gly Ile			
145	150	155	160

His Leu Glu Cys Arg Ser Thr Gly Trp Tyr Pro Gln Pro Gln Ile Gln

170

175

Trp Ser Asn Asn Lys Gly Glu Asn Ile Pro Thr Val Glu Ala Pro Val

180

185

190

Val Ala Asp Gly Val Gly Leu Tyr Ala Val Ala Ala Ser Val Ile Met

195

200

205

Arg Gly Ser Ser Gly Glu Gly Val Ser Cys Thr Ile Arg Asn Ser Leu

210

215

220

Leu Gly Leu Glu Lys Thr Ala Ser Ile Ser Ile Ala Arg Pro Phe Phe

225

230

235

240

Arg Ser Ala Gln Arg Trp Ile Ala Ala Leu Ala Gly Thr Leu Pro Val

245

250

255

Leu Leu Leu Leu Leu Gly Gly Ala Gly Tyr Phe Leu Trp Gln Gln Gln

260

265

270

Glu Glu Lys Lys Thr Gln Phe Arg Lys Lys Lys Arg Glu Gln Glu Leu

275

280

285

Arg Glu Met Ala Trp Ser Thr Met Lys Gln Glu Gln Ser Thr Arg Val

290

295

300

Lys Leu Leu Glu Glu Leu Arg Trp Arg Ser Ile Gln Tyr Ala Ser Arg

305 310 315 320

Gly Glu Arg His Ser Ala Tyr Asn Glu Trp Lys Lys Ala Leu Phe Lys

325 330 335

Pro Gly Glu Glu Met Leu Gln Met Arg Leu His Phe Val Lys

340 345 350